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The hypothalamus is the principle integrating centre between 
central neurotransmitter circuits involved in affective pro-
cessing and the peripherally situated pituitary and adrenal 
glands (de Kloet et al., 2005; Holsboer and Ising, 2008). Stim-
uli from the environment activate affective neurotransmitter 
circuits in the medial prefrontal cortex (MPFC), the limbic 
system and the autonomic brainstem (Gratton and Sullivan, 
2005; Reul and Droste, 2009). Afferent neurotransmitter pro-
jections originating from these circuits ultimately terminate 
in the hypothalamus (Aguilera and Rabadan-Diehl, 2000; de 
Kloet et al., 2005; Dinan and Scott, 2005; Holsboer and Ising, 
2008). There, rapid gene transcription products modulate  
the production of the neuropeptides corticotrophin-releasing 
hormone (crh) and arginine-vasopressin (avp) (DeBold et al., 
1984; Favrod-Coune et al., 1993; Scott and Dinan, 1998). crh 
and avp in turn induce the production and release of acth 
from the anterior pituitary (Holsboer and Barden, 1996). acth 
is the main stimulatory hpa axis neuroendocrine hormone 
and is responsible for the increased synthesis and release of 
the endogenous glucocorticoid cortisol (cort) from the adre-
nal cortices (de Kloet et al., 2005; Dinan and Scott, 2005; Pari-
ante and Lightman, 2008). cort facilitates systemic behav-
ioural- and metabolic adaptation to environmental stimuli. 
At the same time it inhibits the neuroendocrine response via 
negative feedback that ultimately shuts down the affective 
neuroendocrine response (de Kloet et al., 2005; Keck, 2006). 
Together, these organs and their respective effectors form a 
functional-anatomical system known as the hypothalamus-
pituitary-adrenal (hpa) axis.
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hpa axis activation in health
The paraventricular nucleus (pvn) of the hypothalamus is inti-
mately involved in the coordination of hpa axis function. It main-
tains the physiological tone of the hpa axis and plays a crucial role 
in the integration and translation of stress signals (Herman et al., 
2005). Following affective stimuli, the pvn is activated by serotonin 
(5-hydroxytryptamine – 5-ht) and noradrenaline (na) that projects 
from distinct nuclei situated in the brainstem (Ulrich-Lai and Her-
man, 2009; Herman et al., 2005) and by stimulatory pathways from 
the (medial nuclei) of the amygdala (Ulrich-Lai and Herman, 2009). 
Conversely, the pvn is inhibited by γ-aminobutyric acid (GABA)-
producing cells in the peri-paraventricular region of the hypothala-
mus and by a relatively specific population of neurons in the subic-
ulum of the hippocampus (Ulrich-Lai and Herman, 2009). The 
(central) hypothalamic pvn induces (peripheral) endocrine activa-
tion by releasing the neuropeptides crh and avp into the pituitary 
portal circulation. crh is considered the major hpa axis secreta-
gogue under physiological conditions, while avp co-activates the 
hpa axis together with crh under conditions of acute stress (Agu-
ilera and Rabadan-Diehl, 2000; Dinan and Scott, 2005; Holsboer et 
al., 1984a; Pariante and Lightman, 2008; Keck, 2006). crh is primar-
ily produced by the parvocellular neurons of the hypothalamic pvn 
and acts specifically at the crha receptors on the anterior pituitary 
to release acth into the systemic circulation (corticotrophinergic 
activation) (Holsboer et al., 1984a; von Bardeleben and Holsboer, 
1988; Dinan and Scott, 2005). avp, otherwise known as antidiuretic 
hormone (adh), is produced in both the magnocellular- and parvo-
cellular neurons of the pvn and the supraoptic nucleus (son) of the 
hypothalamus (Ring, 2005). avp secreted by the magnocellular cells 
is transported via the medial eminence to the posterior pituitary 
where it is stored and released systemically in response to (physio-
logical) stimuli such as hypotension, hypoglycemia, hypovolemia 
and hyperosmolality (Dinan and Scott, 2005; Keck, 2006; Pariante 
and Lightman, 2008; Ring, 2005). On the other hand, avp originat-
ing from the hypothalamic parvocellular neurosecretory cells is 
released into the pituitary portal system following acute (affective) 
stress, enabling avp to stimulate the vasopressin 3 receptor (vc or 
vab) on the anterior pituitary (Ring, 2005; Ryckmans, 2010). There, 
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avp transiently mobilizes calcium into the cytoplasm and subse-
quently potentiates crha-associated acth release by enhancing its 
production via proteolysis of the acth precursor pro-opiomelano-
cortin (pomc).(DeBold et al., 1984; Dinan and Scott, 2005; Favrod-
Coune et al., 1993). avp synergizes acth release in the presence of 
increased crh, culminating in the enhanced release of cort from 
the adrenal cortices into the systemic circulation (vasopressinergic 
co-activation) (Dinan and Scott, 2005; Holsboer and Barden, 1996; 
Pariante and Lightman, 2008; Scott and Dinan, 1998; Tichomirowa 
et al., 2005). In turn, cort induces concentration-dependent affec-
tive-, cognitive- and metabolic effects that facilitate adequate 
adaptive behavioural responses to (stressful) environmental stim-
uli. In parallel, cort inhibits the neuroendocrine response via a 
complex feedback mechanism that involves the glucocorticoid 
receptors (gr) and mineralocorticoid receptors (mr) in the pitu-
itary, hypothalamus and hippocampus (Figure 1) (Ulrich-Lai and 
Herman, 2009; de Kloet et al., 2005). Thus, physiological hpa axis 
activity is the consequence of a dynamic balance between cortico-
trophinergic activation and cort feedback, while a stress-induced 
increase of this neuroendocrine activity is determined by both cor-
ticotrophinergic activation and vasopressinergic co-activation on 
the one hand and cort feedback on the other hand (Pariante and 
Lightman, 2008; Tichomirowa et al., 2005; Aguilera and Rabadan-
Diehl, 2000; de Kloet et al., 2005). 
Pathological hpa axis function
Abnormal hpa axis function is associated with different forms of 
stress-related psychopathology, which include chronic fatigue syn-
drome, post-traumatic stress disorder (PTsd) and major depressive 
disorder (mdd) (Bao et al., 2008; Dinan and Scott, 2005; Holsboer et 
al., 1984a; Holsboer and Ising, 2008; von Bardeleben and Holsboer, 
1988). Specifically, hyperactivity of the hpa axis is the most consis-
tently reported finding in mdd and is especially present in individ-
uals that develop more severe forms of the disease (Bao et al., 
2008; Dinan and Scott, 2005; Pariante and Lightman, 2008; Ticho-
mirowa et al., 2005). Untreated depressed patients with melan-
cholic and/or psychotic features are likely to display increased  
crh levels in the cerebrospinal fluid (Nemeroff et al., 1984), adrenal 
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gland enlargement (Nemeroff et al., 1992; Rubin et al., 1995), dis-
turbed acth- and cort secretory bursts (Tichomirowa et al., 2005; 
Carroll et al., 2007), increased basal cort levels and urinary free 
cort excretion (Carroll et al., 2007; Pariante and Miller, 2001), and 
increased cort release after the administration of exogenous acth 
(Dinan et al., 1999; Dinan et al., 2004; Amsterdam et al., 1983). 
Mechanistically, both disturbed neurotransmitter/neuropeptide 
function (leading to increased activation) and dysfunctional gr/
mr feedback (leading to decreased inhibition) have been impli-
cated in mdd-associated hpa axis hyperactivity (Carroll et al., 2007; 
Pariante and Miller, 2001; Pariante and Lightman, 2008; Carroll, 
1982b). Increased hpa axis activation in mdd has traditionally been 
ascribed to increased crh production or increased sensitivity of 
the crha receptors (Nemeroff et al., 1984; Nemeroff et al., 1988). 
However, recent observations have also implicated avp in mdd-
associated hpa hyperactivity. In mdd, crha receptors undergo 
downregulation in response to the chronically elevated cort lev-
els, peripheral avp levels seem to be elevated (Dinan et al., 1999; 
Dinan et al., 2004; van Londen et al., 1997) and an increased expres-
sion of hypothalamic vasopressinergic-secreting neurons has been 
found in suicide victims (Meynen et al., 2006; Purba et al., 1996). 
Also, chronically elevated cort levels in rats enforce the avp sys-
tem by increasing the expression of avp-receptor mrna and the 
avp: crh mrna ratio in the pvn (Aguilera and Rabadan-Diehl, 
2000). Taken together, these findings suggest that either increased 
vc receptor expression, increased central avp levels or a combina-
tion of these factors leads to sustained vasopressinergic co-activa-
tion and subsequent hpa axis hyperactivity in severe mdd (Figure 
2). The individual contributions of corticotrophinergic activation 
and vasopressinergic co-activation to hpa axis pathology have not 
been clearly defined. This is not surprising considering that hpa 
activation and -inhibition are dynamically intertwined. Also, avp is 
a co-activator of the hpa axis, and is therefore expected to interact 
significantly with crh in hpa axis disturbances. Although these 
corticotrophinergic and vasopressinergic factors are difficult to 
disentangle in observational studies, they may play distinct roles 
in the pathophysiology of different forms of mdd and other psy-
chiatric disorders (Pariante and Lightman, 2008; Swaab et al., 
2005). This distinction may also have an impact on prognosis and 
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treatment, particularly for new therapies that are specifically 
designed to correct one essential step in the various abnormal 
feedback loops of the dysregulated hpa axis. Reliable clinical labo-
ratory tools that functionally dissect corticotrophinergic and vaso-
pressinergic aspects of hpa axis activation and/or feedback would 
clearly be advantageous. 
Clinical laboratory tools for the hpa axis: 
pharmacological function tests 
Function tests are clinical laboratory tools that are applied to char-
acterize physiological systems or - functions that are not readily 
subject to examination, due to their anatomical location and/or 
complex interconnectivity with other systems. Typically, function 
tests are developed and technically perfected in healthy individuals 
after which validation is undertaken in (different) patient groups. 
Function tests have been in use for decades in both clinical practice 
and research settings and are still widely applied across different 
medical specialties. These vary from the oral glucose tolerance test 
(ogtt) to the exertional electrocardiogram and various allergen 
provocation tests. In psychiatry, function tests are frequently 
applied in the research setting to examine the functionality of neu-
rotransmitter systems and/or hpa axis function (Gijsman, 2002; 
Gijsman et al., 2004). Often, the stimuli are psychological as in the 
case of the Trier social stress test (tsst) (Kirschbaum et al., 1993) or 
physiological with measurement of the early morning cort awak-
ening response (car) (Clow et al., 2004). However, research on the 
pharmacology of neurotransmitter- and neuropeptide systems has 
enabled the development of pharmacological function tests to 
characterize and quantify the functionality of the neurotransmit-
ters and neuropeptides involved in hpa axis function. A pharmaco-
logical function test consists of an oral (p.o.) or intravenous (i.v.) 
dose of a drug with a relevant and well-characterized pharmaco-
logical mechanism (Gijsman et al., 2004; van Gerven, 2005). The 
administered drug leads to quantifiable pharmacodynamic (pd) 
responses that reflect the function of the stimulated neurotrans-
mitter system and its associated central nervous system (cns) 
functions. Most pharmacological cns function tests rely on the 
principle of pharmacological stimulation and are the result of 
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either (1) agonism at excitatory (mainly postsynaptic) receptors, (2) 
increase of a (direct) precursor to a neurotransmitter or neuropep-
tide (3), antagonism at inhibitory (mainly presynaptic axodendritic) 
receptors, (4) release stimulation of a neurotransmitter or neuro-
peptide, or (5) reuptake inhibition of a neurotransmitter (Gijsman 
et al., 2004). Pharmacological cns function tests induce a wide 
range of pd effects that vary from (neuro)physiological or -psycho-
logical effects such as changes in cognition or in subjective mood 
or anxiety, to neuroendocrine hpa activation and the release of 
acth, prolactin, cort and/or growth hormone. 
Pharmacological function tests: application in hpa axis 
function assessment 
Many different pharmacological systems are involved in hpa axis 
activation, which reflects its central role in the stress system that  
is essential for survival. Consequently, a number of different drugs 
have been used as pharmacological function tests of the hpa axis 
in the past (Table 1) (Gijsman et al., 1998; Gijsman et al., 2002b;  
Gijsman et al., 2002a; Gijsman, 2002). A range of serotonergic 
drugs have been used to study the links between the hpa axis and 
psychiatric disorders like depression and anxiety, in which both 
serotonergic and stress systems are involved (Gijsman, 2002; Van 
der Does, 2001). The most direct way of investigating the cortico-
trophinergic and vasopressinergic aspects of hpa axis activation is 
by administration of (synthetic forms of) the  neuropeptides avp 
and crh. Exogenous i.v. administration of corticotrophin-releasing 
hormone (corticorelin - hcrh) alone induces corticotrophinergic 
activation by directly stimulating the peripheral pituitary crha 
receptors. Similarly, direct stimulation of the pituitary vc receptors 
with i.v. administration of desmopressin (ddavp) allows for the 
examination of vasopressinergic co-activation. The integrity of hpa 
axis feedback can be assessed with the synthetic glucocorticoid 
dexamethasone (dex), which is administered p.o. either alone (dex 
suppression test) or in combination with i.v hcrh (dex/crh test).
In this chapter, a short (non-exhaustive) overview of some of  
the most frequently applied pharmacological function tests in  
hpa axis research will be provided. Conceptually, these tests are 
best approached by artificially classifying them in tests that  
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assess hpa axis feedback integrity and those addressing hpa axis 
activation (major corticotrophinergic activation and vasopressin-
ergic co-activation) (Figure 3). 
Assessment of hpa axis feedback
oral dexamethasone (dex) test
The oral dex test consists of measuring early morning cort con-
centrations after the oral administration of a single dose of dex 
(usually 1.5 mg) on the preceding evening (Carroll, 1982c; Carroll, 
1982a). dex is a synthetic glucocorticoid with relatively specific 
affinity for the gr. Contrary to cort, dex does not cross the blood-
brain-barrier (bbb) and hence does not mimic the endogenous 
hypothalamic cort feedback. The dex excess however does cause 
feedback inhibition of acth production on the level of the pitu-
itary, which suppresses the physiological morning acth - and cort 
surge in healthy individuals. In depressive illness this so-called 
“dex suppression” is decreased, meaning that cort levels are ele-
vated after dex administration compared to healthy controls (Heu-
ser et al., 1994; Holsboer, 1983). This phenomenon is interpreted as  
a sign of reduced feedback inhibition of the hpa axis in depression, 
probably by an abnormality at the level of gr/mr-receptor function 
(Carroll et al., 2007; Holsboer, 1983). However, the dex suppression 
test typically consists of a fixed dose of dex and two cort mea-
surements, which is a relatively simple way to measure a complex 
regulatory process. Hence, the variability is quite large and the sen-
sitivity of this test to distinguish patients with mood disorder from 
the healthy population is too low to be of much clinical value (Ising 
et al., 2005). In most cases, the dex suppression test is also too 
imprecise for a more detailed evaluation of hpa axis dysregulation.
dex/hcrh test
In an attempt to enhance the dex test’s reliability, hcrh was 
administered after dex which resulted in the combined dex/hcrh 
test. The dex/hcrh test consists of the administration of an eve-
ning dose of a fixed dex dose (1.5mg), followed by the administra-
tion of hcrh (usually 100µg i.v.) the following afternoon (Heuser  
et al., 1994; Ising et al., 2005). hcrh is a synthetic polypeptide with 
selective affinity for the crha receptor. In healthy individuals, the 
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administration of dex reduces the release of acth and cort by 
hcrh, much as it suppresses the early morning activation of the 
hpa axis without exogenous hcrh. In depressed patients however, 
the dex/hcrh test is associated with an enhanced release of acth 
and cort compared to both healthy individuals and depressed 
patients receiving 100µg hcrh alone, again similar to non-suppre-
sion following the dex-suppression test and another sign of 
reduced negative feedback sensitivity (Heuser et al., 1994; Ising et 
al., 2007; Watson et al., 2006). A possible explanation is that the fall 
in brain cort levels after dex reduces the occupation of limbic mr- 
and gr-receptors, which are usually occupied due to increased 
cort production in depression. The disoccupation of mr- and gr-
receptors disinhibits the blunting of the hpa axis after hcrh 
administration without prior dex treatment in depression. Such 
exaggerated response may involve avp release since the decrease in 
cort levels due to dex pretreatment leads to a compensatory 
increase in avp release which in turn enhances the effect of hcrh 
administered i.v. (Aguilera and Rabadan-Diehl, 2000). Thus, the 
next afternoon these changes culminate in an increased sensitivity 
to crh, which is reflected by the enhanced cort response to hcrh 
in depressed patients, the so-called “dex/hcrh non-suppression”.
Assessment of hpa axis activation
corticotrophinergic activation using hcrh 
100µg hcrh i.v. induces a blunted acth response in patients with 
depression compared to healthy volunteers (Holsboer et al., 1984b; 
Holsboer et al., 1984a; von Bardeleben and Holsboer, 1988). This 
phenomenon is assumed to be due to the downregulation and/or 
desensitization of crha receptors secondary to chronic hypercorti-
solism (Pariante and Lightman, 2008; von Bardeleben and Hols-
boer, 1988). Such an assumption is supported by the fact that cort 
(but not acth) release is similar between patients and healthy indi-
viduals after the administration of 100µg hcrh (Holsboer et al., 
1984b; Holsboer et al., 1984a; von Bardeleben and Holsboer, 1988). 
Taken together, these findings indicate that more crh is needed in 
patients to induce cort release similar to that in healthy individu-
als. Thus, the hcrh function test is able to demonstrate that the 
setpoint of the hpa axis in depression is increased, as it were. 
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vasopressinergic activation using ddavp
Vasopressinergic hpa axis activation can be quantified dose-
dependently by the administration of 5µg and 10µg ddavp i.v.  
and the subsequent measurement of acth and cort (Scott et al., 
1999). ddavp is a partially specific vasopressin receptor agonist 
exhibiting pharmacological activity at the vc as well as the vaso-
pressin 2 receptors (vb) (Lethagen, 1994). Since endogenous crh 
concentrations are low under non-pathological situations and avp 
acts as co-activator of the hpa together with crh, hpa axis activa-
tion associated with ddavp administration in healthy individuals 
is small. In depressed patients, 10µg ddavp i.v induces an exagger-
ated acth response compared to that in healthy volunteers, indi-
cating vasopressinergic (receptor) hyperactivity in depression 
(Dinan et al., 2004; Dinan and Scott, 2005; Scott and Dinan, 1998). 
This has been confirmed by an experiment combining both ddavp 
and hcrh in patients. As alluded to earlier, 100µg hcrh i.v. induces 
a “blunted” acth response in depressed patients compared to 
healthy individuals. However, when 100µg hcrh and 10µg ddavp 
are administered concomitantly, the blunting associated with 
hcrh in the depressed patients is abolished and the acth 
response of depressed individuals is identical to that of healthy 
volunteers (Dinan et al., 1999). These findings are strongly indica-
tive of avp acting as principle hpa axis activator in depression as 
opposed to crh in health. 
alternative function tests to hcrh and ddavp
hcrh and ddavp modulate hpa axis activation on the level of the 
pituitary. By focusing on the pituitary, the crucial role of the more 
“proximal” structures such as the hypothalamus and important 
central neurotransmitter contributions originating from the mpfc 
and limbic circuits are not addressed. hpa axis dysregulation in 
depression is more likely to be associated with central than pitu-
itary or adrenal mechanisms. Although changes in any part of the 
different release chains and feedback loops of the hpa axis will 
inevitably also change the other parts, such an “exogenous” 
approach clearly has its limitations. In contrast, “endogenous” 
function tests targeting the hypothalamus or limbic neurotrans-
mitters would have the advantage of relying on rate-limiting 
physiological processes such as central neuropeptide/transmitter 
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release or enzymatic conversion rather than direct pituitary 
receptor stimulation. Such an approach might therefore reflect 
hpa axis functionality in depression more accurately and may 
have less potentially (indirect) confounding effects than the tradi-
tional “exogenous” function tests. In this context, the release of 
endogenous crh and/or avp instead of directly stimulating crha 
receptors with hcrh and vc receptors with ddavp has been pro-
posed. Acute increases of serotonin (5-ht) stimulate the release  
of crh via 5-htba and/or 5-htbc receptors in the pvn to induce cor-
ticotrophinergic activation of the hpa axis (Gartside and Cowen, 
1990; Lowry, 2002; Zhang et al., 2002). Central 5-ht concentra-
tions can be increased by the administration of the direct 5-ht 
precursor 5-hydroxytryptophan (5-htp). Similarly, an agent that 
releases endogenous avp from the hypothalamus or pituitary 
would be able to induce vasopressinergic co-activation without 
directly interacting with vc receptors. In this context, the anti-
emetic db receptor antagonist metoclopramide has been reported 
to activate the hpa axis by releasing avp. 5-htp might therefore  
be an alternative to hcrh to quantify corticotrophinergic hpa 
activation, and metoclopramide to ddavp in assessing vasopress-
inergic co-activation. 
corticotrophinergic activation using 5-htp
The role of the neurotransmitter serotonin/5-hydroxytryptamine 
(5-ht) in the regulation of affective circuits of the brain is widely 
accepted. Moreover, dysfunction in the serotonergic circuits is 
implicated in the pathophysiology of depression according to its 
monoamine hypothesis (Pariante and Lightman, 2008). 5-ht is pro-
duced in the serotonergic dorsal raphé nuclei which are located in 
the brain stem. From its source in the brain stem, 5-ht is projected 
into several different functional brain circuits, including the limbic 
system and the hypothalamus (Dinan, 1996; Leonard, 2005; Sotty et 
al., 2009). A pharmacological function test that enhances seroto-
nergic neurotransmission would therefore also activate the hpa 
axis and induce a neuroendocrine response. In the past, several 
serotonergic agents such as the direct 5-ht precursor L-5-hydroxy-
tryptophan (5-htp), subtype selective 5-ht agonists and 5-ht reup-
take inhibitors have been applied as function test models for this 
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purpose (Gijsman, 2002; Gijsman et al., 2004). Notably, orally 
administered 5-htp activates the hpa axis as a precursor drug for 
endogenous 5-ht, which stimulates the postsynaptic 5-htba and 
5-htbc receptors in the hypothalamic pvn (Lowry, 2002; Zhang et 
al., 2002; Gartside and Cowen, 1990). Corticotrophinergic hpa axis 
activation with 5-htp therefore reflects (central) hypothalamic hpa 
activation as opposed to (peripheral) pituitary activation with 
administration of hcrh. Although such an approach is attractive, 
the use of oral 5-htp has been associated with technical problems. 
Variable kinetics, little standardization and a narrow window 
between pd effects and side-effects have hampered its application 
in hpa axis research (Gijsman et al., 2002a). Further development 
and fine tuning of the 5-htp test was therefore needed. In this con-
text, the addition of the peripheral monoamine decarboxylase 
inhibitor carbidopa to 5-htp increased the availability of 5-htp for 
central conversion to 5-ht and rendered 5-htp pharmacokinetics 
(pk) more predictable. However, the frequent occurrence nausea 
and vomiting with 5-htp remains an obstacle to its further devel-
opment and validation.
vasopressinergic activation using metoclopramide
The anti-emetic metoclopramide has previously been shown to 
activate the hpa axis (Chiodera et al., 1986; Seki et al., 1997; Walsh 
et al., 2005). Metoclopramide is a substituted benzamide and acts 
as db- and 5-htc receptor antagonist on the one hand and 5-htd 
receptor agonist on the other hand. It is hypothesized to release 
endogenous avp from the hypothalamus and/or the pituitary, 
leading to vasopressinergic co-activation through pharmacolo-
gical mechanisms that have not been clearly identified. However, 
it is an unknown test and has not been applied frequently as func-
tion test for vasopressinergic hpa axis activation. Also, method-
ological issues in previous trials examining its effects limit inter-
pretation of the results (Chiodera et al., 1986; Seki et al., 1997; 
Walsh et al., 2005). avp release from the hypothalamus by meto-
clopramide would be confirmed by a reliable avp assay detecting 
avp in peripheral blood and/or most importantly, would demon-
strate co-activation of the hpa axis in the presence of increased 
endogenous crh.
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Shortcomings of pharmacological function tests for  
hpa axis activation
In the context of the pharmacological function test paradigm, the 
neurotransmitter system or cns function under investigation can 
be conceived of as a “black box” (van Gerven, 2005; Gijsman, 2002). 
A pharmacological agent with a known pharmacological profile is 
applied to induce a pharmacological effect via specific receptors 
within the “black box”, which leads to different objectively quanti-
fiable pd effects. Reliable quantification of such effects and char-
acterization of the agent’s pharmacokinetic (pk) properties can 
thus be used to describe the process inside the “black box” in terms 
of the relationship between the pk properties and pd effects. An 
important assumption in this model is that differences between 
groups of healthy individuals or patients are not due to inherent 
variation in the test itself, but to functional differences in the sys-
tem under investigation. However, inherent variability is often 
introduced unintentionally when applying pharmacological func-
tion tests. For instance, the administration of different doses of 
function agent and little or no attention for the pharmacological 
agent’s pk characteristics is an important source of variability. 
Also, pharmacological characteristics and pd endpoints are not 
always unequivocal and potential confounding pd effects are often 
disregarded. Usually, the pd effects are dependent on the dose of 
function agent and exhibit changes over time, which makes it 
essential to correct the pd effects for different concentrations of 
the function agent over a certain time period. Therefore, too infre-
quent or once-off sampling of pd parameters does not allow for 
adequate assessment of effects over time and prevents the clarifi-
cation of pk-pd relationships. Clearly, such issues add confusion to 
an already complex research field and at the same time hamper the 
further development and wider application of the function test 
paradigm. Investigating and minimizing inherent variability 
should ideally be an important step in the development of any 
given pharmacological function test. In this context, certain princi-
ples have been proposed to minimize variability including (1) a well-
known and -characterized pharmacological mechanisms; (2) little 
or no confounding pharmacological effects; (3) inducing pd effects 
that are easily and reliably measurable; (4) a robust physiological 
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model of the investigated system, based on the pk/pd-characteris-
tics of the function test; (5) limited and acceptable adverse effects; 
(6) a wide window between pd effects and undesirable effects; (7) pd 
effects that can be plausibly linked to the system or function under 
investigation; (8) practical to administer and (9) an ethical balance 
between the information obtained with the function test and the 
discomfort it causes for patients or healthy volunteers (van Gerven, 
2005). The application of these principles to pharmacological func-
tion tests is expected to reduce their inherent variability and in- 
crease their reliability. However, most existing function tests have 
not been exposed to such systematic scrutiny. Consequently, many 
questions regarding the interpretation of hpa axis function in mdd 
and other stress-related disorders still remain. It is expected that the 
systematic application of these principles to existing function tests 
will address such issues and contribute to their wider application in 
cns research. The main objective of this thesis was to address some 
of the major shortcomings of several different corticotrophinergic 
and vasopressinergic hpa axis function tests (Table 2, Chapters 2 - 6). 
The (functional) characteristics of the hpa axis are almost always 
derived from changes in acth and cort levels. The pharmacokinetic 
properties of these hormones vary considerably between subjects, 
and release rates change with time due to feedback inhibition. 
Therefore, it is very difficult to construct a quantitative physiologi-
cal model of the hpa axis based on these instable parameters, and 
hence to comply with criterion number four mentioned above. It 
would be helpful to directly quantify the activation of the hypothal-
amus, which drives the hpa axis after central stimulation. To this 
end, a neuroimaging technique was applied to investigate pharma-
cologically-induced hypothalamic changes in Chapter 7. 
shortcomings of hcrh and ddavp
The pharmacological characteristics of hcrh and ddavp are well-
characterized and fairly specific, which makes them suitable as 
function tests for the hpa axis. However, their interpretation  
is often thwarted by variable responses due to a lack of standardi-
zation and variable pk properties, and there are confounding phar-
macodynamic (pd) effects that may cause safety concerns in vulner-
able patients. Previous studies with ddavp have focused on the 
magnitude of vc modulated neuroendocrine pd effects with 
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minimal attention for systemic effects that may cause secondary 
hpa axis activation. Specifically, ddavp may cause blood pressure 
reduction that may lead to acth release by activation of the auto-
nomic nervous system (ans). Also, ddavp enhances the coagula-
tion cascade, which is particularly relevant if the ddavp function 
test is to be applied in patient populations with comorbid cardio-
vascular disease. We therefore investigated the relation between 
neuroendocrine, cardiovascular, pro-coagulatory, anti-diuretic and 
non-specific stress effects of ddavp applied as pharmacological 
function test for assessing vasopressinergic co-activation of the 
hpa in healthy volunteers (Chapter 2). 
The individual effects of corticotrophinergic activation (with 
hcrh) and vasopressinergic co-activation (with ddavp) and their 
interactions are required for a proper understanding of hpa axis 
activation. Although it is possible to induce hpa axis activation 
with ddavp, it is difficult to derive quantitative measures of co-
activation from this response without knowing the prevailing  
level of crh activity. Therefore, we examined whether concomitant 
administration of ddavp and hcrh could provide more informative 
vasopressinergic co-activation of the hpa axis than ddavp alone in 
healthy volunteers (Chapter 3). In the literature, corticotrophinergic 
activation and vasopressinergic co-activation of the hpa axis have 
been determined on different study days, which gives rise to inter-
session variability and is unpractical for patient studies. So far, 
there was no practical function test that is able to examine both 
activation routes on a single short study occasion. Independent 
evaluations of each route would logically require an adequate 
washout period, to ensure that vc stimulation does not affect  
subsequent crha stimulation (or vice versa), but it is unknown  
how long the carry-over effects remain. Since the plasma half-life 
of ddavp is only 90 to 180 minutes, we determined the feasibility  
of a practical function test of both corticotrophinergic activation 
and vasopressinergic co-activation of the hpa axis on a single short 
laboratory visit, with a washout period of two hours (Chapter 3).
5-htp 
5-htp is a direct 5-ht precursor used to assess central serotonergic 
function. In the past, its use has been limited by a narrow window 
between neuroendocrine changes and side effects, and variable 
kinetics related to inconsistent administration modes (Gijsman  
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et al., 2002a). The addition of the peripheral monoamine decarbox-
ylase inhibitor carbidopa to 5-htp increased the availability of 
5-htp for central conversion to 5-ht and rendered 5-htp pk more 
predictable (Gijsman et al., 2002a). However, the dose-response 
relationship and the pharmacokinetic properties of various oral 
doses of 5-htp, their tolerability and subjective (adverse) effects, 
and their secondary impact on hpa axis activation are still unclear. 
We investigated the feasibility of the combined 5-htp/cbd func-
tion test as candidate test for examining endogenous hpa activa-
tion. To this end, we examined the dose- and concentration effect 
relationship of different doses of orally administered 5-htp in  
combination with cbd in healthy volunteers (Chapter 4) and we 
attempted to suppress the most confounding systematic seroto-
nergic side-effects (nausea and vomiting) without influencing the 
neuroendocrine response, using a subtype selective serotonin 
receptor antagonist (Chapter 5). 
metoclopramide
Metoclopramide is hypothesized to lead to vasopressinergic co-
activation of the hpa axis. It would have the advantages of releas-
ing endogenous avp from the hypothalamus or pituitary and of 
inducing minimal confounding effects. However, there is a paucity 
of data regarding its potency to co-activate the hpa axis, and meth-
odological issues in previous trials preclude adequate interpreta-
tion of metoclopramide’s effects on hpa axis activation. Therefore, 
endogenous vasopressinergic co-activation using metoclopramide 
was investigated under conditions of low and enhanced endoge-
nous crh-release in healthy volunteers (Chapter 6).
hypothalamic neuroimaging 
In the studies described in Chapters 2-6, activity of the hpa axis  
is derived from neuroendocrine changes measured in peripheral 
blood. These hormonal responses are the product of complex inter-
acting phenomena, such as central and peripheral amplification 
and co-activation, negative feedback mechanisms, and pharma-
cokinetic clearance. More direct measurements of drug-induced 
neuronal activity in the brain using neuroimaging techniques 
could lead to a better understanding of the cns processes involved 
in the stimulation of neurotransmitter systems. Functional neuro-
imaging of pharmacological cns-processes often use functional 
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magnetic resonance imaging (fmri) to demonstrate regional shifts 
in blood oxygen level dependent (bold) signals. However, the appli-
cation of bold-mri is limited by factors such  
as drift of the mri signal with time, changes due to nonspecific  
confounding factors such as (drug-induced) vascular reactivity,  
and substantial intersession variance in cross-over designs. These 
factors limit the application of fmri in the quantification of drug-
induced neuronal activity. Alternatively, functional proton reso-
nance magnetic spectroscopy (mrs) could be a candidate neuro-
imaging technique to directly quantify drug-induced neurotrans - 
mission. In vivo proton magnetic resonance spectroscopy (mrs)  
of the brain determines relative and absolute concentrations of  
protons from tissue chemicals other than water, such as glutamate-
glutamine (Glx), n-acetyl-aspartate (naa), myo-inositol, lactate, 
choline and creatine. In this context, naa and Glx are generally 
regarded as surrogate mrs markers for neuronal activity, and Chol is 
considered a metabolic marker of membrane density and integrity. 
Although mrs is typically applied in neurodegenerative disease and 
malignant brain tumours, recent findings suggests that mrs might 
also be able to demonstrate and quantify changes in neuronal bio-
chemistry during (prolonged) pharmacological treatment with cns-
active drugs (Taylor et al., 2008). We studied the effects of a com-
bined 5-htp/cbd/granisetron function test on hypothalamic levels 
of glutamate/glutamine (Glx), choline, n-acetyl-aspartate (naa) 
and creatine using 7-Tesla (7T) mrs, and related these effects to 
5-htp-induced acth and cort in peripheral blood in healthy volun-
teers (Chapter 7).
This thesis focuses on the most important pharmacological short-
coming of hcrh and 5-htp (for corticotrophinergic activation) and 
ddavp and metoclopramide (for vasopressinergic co-activation), in 
an attempt to contribute to the validation of these drugs as clinical 
laboratory tools in hpa axis research. At the same time, these func-
tion tests are expected to contribute to a better understanding of 
hpa axis function and to further clarify the respective contributions 
of crh and avp in its activation. Hopefully, such information will be 
helpful in the future application of these function tests to investi-
gate aberrant hpa axis activation in different patient groups and as 
clinical tools in the development of novel drugs targeting the major 
hpa axis neuropeptide systems. 
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Table 1 Drugs that have been used as function tests to assess hpa axis activation:  
a summary of their respective characteristics and shortcomings (adapted  
from Gijsman 2002).




5-htbc receptor agonist; 5-htbb receptor 
antagonist; strongly binds to alpha-2 
receptors
Autonomic shortcomings and emotional 
disturbance; large interinidivudal 
variability in pk; cyp p450 inhibitors; 
limited test-retest variability.
Dexfenfluramine Stimulates 5-ht release from axons in the 
frontal cortex, hippocampus and striatum; 
5-htba and 5-htbc receptor agonist.
Reproducibility not investigated; few side-




Direct precursor of the neurotransmitter 
serotonin (5-ht); decarboxylated into 5-ht 
by 5-ht decarboxylase; available for non-
specific actions at pre- and postsynaptic 
serotonergic receptors.
Test-retest variability not investigated;  
pk characteristics unclear; potentially 
confounding and bothersome side-effects
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Table 2 Summary of the corticotrophinergic (hcrh and 5-htp/carbidopa) and vasopress-
inergic (ddavp and metclopramide) function tests to assess hpa axis activation 
and their correspondence to the proposed principles of reliable pharmacological 
function tests 
Corticotrophinergic activation Vasopressinergic co-activation




Agonism at the crha 
receptor in the 
anterior pituitary
Conversion of 5-htp to 
5-ht in the raphé 
nuclei followed by 
agonism at 5-htba or 
5-htbc receptors in the 
pvn
Agonism at the vc 
(vab) receptor of the 
anterior pituitary





reduction leading to 
autonomic nervous 
system activation
Nausea and vomiting 































Few effects Few effects, nausea 
and vomiting 
potentially the most 
disturbing
Few effects Few effects
Wide window 
between  
pd – and 
undesirable 
effects
Probably Narrow window 





Plausibility Abnormalities in the 
crh system have 
been associated with 
mdd
Abnormalities in the 
5-ht system are 
implicated according 
to the monoamine 
hypothesis of 
depression
Abnormalities in the 
avp system have been 
associated with mdd
Unclear






Easy to administer (i.v.) Easy to administer (i.v.)
Ethical Yes Yes Yes Yes
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Figure 1  Graphic representation of hpa axis function in health: light gray arrows signify 
activation and dark gray arrows signify inhibition via negative feedback (crh: 
corticotrophin-releasing hormone; avp: vasopressin; acth: adrenocorticotrophic 

















Figure 2  Graphic representation of hpa axis function in severe major depressive disorder 
(mdd): thick arrows signify hyperactivation and dotted arrows signify decreased 
inhibition via negative feedback (crh: corticotrophin-releasing hormone; avp: 
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Figure 3 Graphic representation of the characterization of hpa axis function: proposed 
classification of pharmacological function tests (crh: corticotrophin-releasing 
hormone; avp: vasopressin; hcrh: corticorelin; 5-htp: 5-hydroxytryptophane; 
ddavp: desmopressin; MCP: metoclopramide; dex: dexamethasone).
Characterization of hpa axis function 
pharmacological function tests
Characterization



















31 chapter 1 • introduction
reference list
Aguilera G, Rabadan-Diehl C (2000) Vasopressinergic 
regulation of the hypothalamic-pituitary-adrenal 
axis: implications for stress adaptation. Regul Pept 
96: 23-29.
Amsterdam JD, Winokur A, Abelman E, Lucki I, Rickels K 
(1983) Cosyntropin (acth alpha 1-24) stimulation 
test in depressed patients and healthy subjects. 
Am J Psychiatry 140: 907-909.
Bao AM, Meynen G, Swaab DF (2008) The stress system 
in depression and neurodegeneration: focus on the 
human hypothalamus. Brain Res Rev 57: 531-553.
Carroll BJ (1982a) Clinical applications of the 
dexamethasone suppression test for endogenous 
depression. Pharmacopsychiatria 15: 19-25.
Carroll BJ (1982b) The dexamethasone suppression test 
for melancholia. Br J Psychiatry 140: 292-304.
Carroll BJ (1982c) Use of the dexamethasone 
suppression test in depression. J Clin Psychiatry 43: 
44-50.
Carroll BJ, Cassidy F, Naftolowitz D, Tatham NE, Wilson 
WH, Iranmanesh A, Liu PY, Veldhuis JD (2007) 
Pathophysiology of hypercortisolism in 
depression. Acta Psychiatr Scand Suppl90-103.
Chiodera P, Volpi R, Delsignore R, Marchesi C, Salati G, 
Camellini L, Rossi G, Coiro V (1986) Different effects 
of metoclopramide and domperidone on arginine-
vasopressin secretion in man. Br J Clin Pharmacol 
22: 479-482.
Clow A, Thorn L, Evans P, Hucklebridge F (2004) The 
awakening cortisol response: methodological 
issues and significance. Stress 7: 29-37.
de Kloet ER, Joels M, Holsboer F (2005) Stress and the 
brain: from adaptation to disease. Nat Rev 
Neurosci 6: 463-475.
DeBold CR, Sheldon WR, DeCherney GS, Jackson RV, 
Alexander AN, Vale W, Rivier J, Orth DN (1984) 
Arginine vasopressin potentiates 
adrenocorticotropin release induced by ovine 
corticotropin-releasing factor. J Clin Invest 73: 
533-538.
Dinan TG (1996) Serotonin and the regulation of 
hypothalamic-pituitary-adrenal axis function. Life 
Sci 58: 1683-1694.
Dinan TG, Lavelle E, Scott LV, Newell-Price J, Medbak S, 
Grossman AB (1999) Desmopressin normalizes the 
blunted adrenocorticotropin response to 
corticotropin-releasing hormone in melancholic 
depression: evidence of enhanced vasopressinergic 
responsivity. J Clin Endocrinol Metab 84: 
2238-2240.
Dinan TG, O’Brien S, Lavelle E, Scott LV (2004) Further 
neuroendocrine evidence of enhanced vasopressin 
vc receptor responses in melancholic depression. 
Psychol Med 34: 169-172.
Dinan TG, Scott LV (2005) Anatomy of melancholia: 
focus on hypothalamic-pituitary-adrenal axis 
overactivity and the role of vasopressin. J Anat 207: 
259-264.
Favrod-Coune C, Raux-Demay MC, Proeschel MF, 
Bertagna X, Girard F, Luton JP (1993) Potentiation of 
the classic ovine corticotrophin releasing hormone 
stimulation test by the combined administration 
of small doses of lysine vasopressin. Clin 
Endocrinol (Oxf) 38: 405-410.
Gartside SE, Cowen PJ (1990) Mediation of acth and 
prolactin responses to 5-htp by 5-ht2 receptors. 
Eur J Pharmacol 179: 103-109.
Gijsman HJ (2002) Pharmacological aspects of challenge 
tests of the serotonergic system of the brain.
Gijsman HJ, Cohen AF, van Gerven JM (2004) The 
application of the principles of clinical drug 
development to pharmacological challenge tests 
of the serotonergic system. J Psychopharmacol 18: 
7-13.
Gijsman HJ, van Gerven JM, de Kam ML, Schoemaker RC, 
Pieters MS, Weemaes M, de Rijk R, van der PJ, Cohen 
AF (2002a) Placebo-controlled comparison of three 
dose-regimens of 5-hydroxytryptophan challenge 
test in healthy volunteers. J Clin Psychopharmacol 
22: 183-189.
Gijsman HJ, van Gerven JM, Tieleman MC, Schoemaker 
RC, Pieters MS, Ferrari md, Cohen AF, van Kempen 
GM (1998) Pharmacokinetic and pharmacodynamic 
profile of oral and intravenous meta-
chlorophenylpiperazine in healthy volunteers. J 
Clin Psychopharmacol 18: 289-295.
Gijsman HJ, van Gerven JM, Verkes RJ, Schoemaker RC, 
Pieters MS, Pennings EJ, Hessing TJ, Cohen AF 
(2002b) Saccadic peak velocity and EEG as end-
points for a serotonergic challenge test. Hum 
Psychopharmacol 17: 83-89.
Gratton A, Sullivan RM (2005) Role of prefrontal cortex 
in stress responsivity. In: Handbook of stress and 
the brain (Steckler T, Kalin NH, Reul JMHM, eds), pp 
807-817. Elsevier.
Herman JP, Ostrander MM, Mueller NK, Figueiredo H 
(2005) Limbic system mechanisms of stress 
regulation: hypothalamo-pituitary-adrenocortical 
axis. Prog Neuropsychopharmacol Biol Psychiatry 
29: 1201-1213.
Heuser I, Yassouridis A, Holsboer F (1994) The combined 
dexamethasone/crh test: a refined laboratory test 
for psychiatric disorders. J Psychiatr Res 28: 
341-356.
32 pharmacological aspects of corticotrophinergic and vasopressinergic function
  tests for hpa axis activation
Holsboer F (1983) The dexamethasone suppression test 
in depressed patients: clinical and biochemical 
aspects. J Steroid Biochem 19: 251-257.
Holsboer F, Barden N (1996) Antidepressants and 
hypothalamic-pituitary-adrenocortical regulation. 
Endocr Rev 17: 187-205.
Holsboer F, Gerken A, Steiger A, Benkert O, Muller OA, 
Stalla GK (1984a) Corticotropin-releasing-factor 
induced pituitary-adrenal response in depression. 
Lancet 1: 55.
Holsboer F, Ising M (2008) Central crh system in 
depression and anxiety--evidence from clinical 
studies with crha receptor antagonists. Eur J 
Pharmacol 583: 350-357.
Holsboer F, von Bardeleben U, Gerken A, Stalla GK, 
Muller OA (1984b) Blunted corticotropin and 
normal cortisol response to human corticotropin-
releasing factor in depression. N Engl J Med 311:  
1127.
Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, 
Kern N, Kunzel HE, Pfennig A, Uhr M, Holsboer F 
(2007) Combined dexamethasone/corticotropin 
releasing hormone test predicts treatment 
response in major depression - a potential 
biomarker? Biol Psychiatry 62: 47-54.
Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, 
Holsboer F (2005) The combined dexamethasone/
crh test as a potential surrogate marker in 
depression. Prog Neuropsychopharmacol Biol 
Psychiatry 29: 1085-1093.
Keck ME (2006) Corticotropin-releasing factor, 
vasopressin and receptor systems in depression 
and anxiety. Amino Acids 31: 241-250.
Kirschbaum C, Pirke KM, Hellhammer DH (1993) The 
‘Trier Social Stress Test’--a tool for investigating 
psychobiological stress responses in a laboratory 
setting. Neuropsychobiology 28: 76-81.
Leonard BE (2005) The hpa and immune axes in stress: 
the involvement of the serotonergic system. Eur 
Psychiatry 20 Suppl 3: S302-S306.
Lethagen S (1994) Desmopressin (ddavp) and 
hemostasis. Ann Hematol 69: 173-180.
Lowry CA (2002) Functional subsets of serotonergic 
neurones: implications for control of the 
hypothalamic-pituitary-adrenal axis. J 
Neuroendocrinol 14: 911-923.
Meynen G, Unmehopa UA, van Heerikhuize JJ, Hofman 
MA, Swaab DF, Hoogendijk WJ (2006) Increased 
arginine vasopressin mrna expression in the 
human hypothalamus in depression: A preliminary 
report. Biol Psychiatry 60: 892-895.
Nemeroff CB, Krishnan KR, Reed D, Leder R, Beam C, 
Dunnick NR (1992) Adrenal gland enlargement in 
major depression. A computed tomographic study. 
Arch Gen Psychiatry 49: 384-387.
Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley 
M (1988) Reduced corticotropin releasing factor 
binding sites in the frontal cortex of suicide 
victims. Arch Gen Psychiatry 45: 577-579.
Nemeroff CB, Widerlov E, Bissette G, Walleus H, 
Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W 
(1984) Elevated concentrations of CSF 
corticotropin-releasing factor-like 
immunoreactivity in depressed patients. Science 
226: 1342-1344.
Pariante CM, Lightman SL (2008) The hpa axis in major 
depression: classical theories and new 
developments. Trends Neurosci 31: 464-468.
Pariante CM, Miller AH (2001) Glucocorticoid receptors 
in major depression: relevance to pathophysiology 
and treatment. Biol Psychiatry 49: 391-404.
Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF (1996) 
Increased number of vasopressin- and oxytocin-
expressing neurons in the paraventricular nucleus 
of the hypothalamus in depression. Arch Gen 
Psychiatry 53: 137-143.
Reul JMHM, Droste SK (2009) The hypothalamic-
pituitary-adrenal axis as a dynamically organized 
sysrtem: lessons from exercising mice. In: 
Handbook of stress and the brain (Steckler T, Kalin 
NHRJMHH, eds), pp 95-112. Elsevier.
Ring RH (2005) The central vasopressinergic system: 
examining the opportunities for psychiatric drug 
development. Curr Pharm Des 11: 205-225.
Rubin RT, Phillips JJ, Sadow TF, McCracken JT (1995) 
Adrenal gland volume in major depression. 
Increase during the depressive episode and 
decrease with successful treatment. Arch Gen 
Psychiatry 52: 213-218.
Ryckmans T (2010) Modulation of the vasopressin 
system for the treatment of cns diseases. Curr 
Opin Drug Discov Devel 13: 538-547.
Scott LV, Dinan TG (1998) Vasopressin and the regulation 
of hypothalamic-pituitary-adrenal axis function: 
implications for the pathophysiology of 
depression. Life Sci 62: 1985-1998.
Scott LV, Medbak S, Dinan TG (1999) acth and cortisol 
release following intravenous desmopressin: a 
dose-response study. Clin Endocrinol (Oxf) 51: 
653-658.
Seki K, Kato T, Sekiya S (1997) Corticotrophin and 
vasopressin responses to metoclopramide in 
patients with hypothalamic amenorrhoea. Clin 
Endocrinol (Oxf) 46: 203-207.
Sotty F, Folgering JH, Brennum LT, Hogg S, Mork A, 
Hertel P, Cremers TI (2009) Relevance of dorsal 
33 chapter 1 • introduction
raphe nucleus firing in serotonin 5-ht(2C) receptor 
blockade-induced augmentation of ssris effects. 
Neuropharmacology 57: 18-24.
Swaab DF, Bao AM, Lucassen PJ (2005) The stress system 
in the human brain in depression and 
neurodegeneration. Ageing Res Rev 4: 141-194.
Tichomirowa MA, Keck ME, Schneider HJ, Paez-Pereda 
M, Renner U, Holsboer F, Stalla GK (2005) Endocrine 
disturbances in depression. J Endocrinol Invest 28: 
89-99.
Ulrich-Lai YM, Herman JP (2009) Neural regulation of 
endocrine and autonomic stress responses. Nat 
Rev Neurosci 10: 397-409.
Van der Does AJ (2001) The effects of tryptophan 
depletion on mood and psychiatric symptoms. J 
Affect Disord 64: 107-119.
van Gerven JM (2005) Het benevelde brein: de Delyside-
challenge-test van Sandoz.
van Londen L, Goekoop JG, van Kempen GM, 
Frankhuijzen-Sierevogel AC, Wiegant VM, van der 
Velde EA, De Wied D (1997) Plasma levels of arginine 
vasopressin elevated in patients with major 
depression. Neuropsychopharmacology 17: 
284-292.
von Bardeleben U, Holsboer F (1988) Human 
corticotropin releasing hormone: clinical studies in 
patients with affective disorders, alcoholism, panic 
disorder and in normal controls. Prog 
Neuropsychopharmacol Biol Psychiatry 12 Suppl: 
S165-S187.
Walsh P, Spelman L, Sharifi N, Thakore JH (2005) Male 
patients with paranoid schizophrenia have greater 
acth and cortisol secretion in response to 
metoclopramide-induced avp release. 
Psychoneuroendocrinology 30: 431-437.
Watson S, Gallagher P, Smith MS, Ferrier IN, Young AH 
(2006) The dex/crh test--is it better than the DST? 
Psychoneuroendocrinology 31: 889-894.
Zhang Y, Damjanoska KJ, Carrasco GA, Dudas B, D’Souza 
DN, Tetzlaff J, Garcia F, Hanley NR, Scripathirathan 
K, Petersen BR, Gray TS, Battaglia G, Muma na, Van 
de Kar LD (2002) Evidence that 5-ht2A receptors in 
the hypothalamic paraventricular nucleus mediate 
neuroendocrine responses to (-)DOI. J Neurosci 22: 
9635-9642.
34 pharmacological aspects of corticotrophinergic and vasopressinergic function
  tests for hpa axis activation
35 chapter 1 • introduction
chapter 2 
Desmopressin as a pharmaco-
logical tool in vasopressinergic 
hypothalamus–pituitary– .
adrenal (hpa) axis modulation: 
neuroendocrine, cardiovascu-
lar and coagulatory effects
J Psychopharmacol. 2010 Mar 23. [Epub ahead of print]
G.E. Jacobs mdA, E.G.J. Hulskotte PhDB, J.M.A. van GervenA md 
PhD, L. Zuurman md PhDA, M.L. de Kam MScA, 
J Elassaiss-Schaap PhDB, G. Ruigt PhDB, J. van Pelt PhDC, 
B.W.M.M. Peeters PhDB, P.A.M. Peeters PhDB, J. Burggraaf md PhDA
1 Centre for Human Drug Research, Leiden, The Netherlands
2 NV Organon, part of Schering-Plough Corporation, Department 
of Clinical Pharmacology and Kinetics, Oss, the Netherlands
3 Department of Clinical Chemistry, Leiden University Medical
 Centre, Leiden, The Netherlands 
36 pharmacological aspects of corticotrophinergic and vasopressinergic function
  tests for hpa axis activation
Abstract
background Arginine-vasopressin(avp) is a physiological co-activator of the 
hypothalamus-pituitary-adrenal-axis(hpa), together with cortico-
trophin-releasing hormone (crh). A synthetic analogue of avp, 
desmopressin(ddavp) is often used as pharmacological tool to 
assess co-activation in health and disease. The relation between 
ddavp’s neuroendocrine, cardiovascular, pro-coagulatory, anti-
diuretic and non-specific stress effects has not been studied.
objectives A randomized, double-blind, placebo-controlled, three-way cross-
over study was performed in 12 healthy male and female volun-
teers(6: 6). ddavp was administered intravenously as a 10µg bolus 
(over one minute) or a 30µg incremental infusion (over 60 min-
utes). Neuroendocrine, cardiovascular, pro-coagulatory, anti-
diuretic effects and adverse events (ae’s) were recorded, and auto-
nomic nervous system (ans) activation evaluated.
results The incremental infusion reached 1.8 fold higher ddavp concentra-
tions than the bolus. Neuroendocrine effects were similar for the 
10µg ddavp bolus and the 30µg incremental infusion, while cardio-
vascular- and coagulatory effects were greater with the 30µg dose. 
Osmolality and ans activity remained uninfluenced. ae’s corre-
sponded to ddavp’s side-effect profile. 
conclusions The neuroendocrine effects of a 10µg ddavp bolus administered 
over one minute are similar to those of a 30µg incremental infusion 
administered over one hour, despite higher ddavp concentrations 
after the infusion. Cardiovascular and coagulatory effects showed 
clear dose-related responses. A 10µg ddavp bolus is considered a 
safe vasopressinergic function test at which no confounding 
effects of systemic or autonomic stress were seen.
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Introduction
Arginine-vasopressin (avp) is the nonapeptide modulator of the 
human vasopressinergic system. It acts as neurotransmitter within 
the central nervous system (cns) and as neuroendocrine hor-
mone in the peripheral circulation (Ring, 2005). avp produced by 
hypothalamic parvocellular neurones of the medial paraventricular 
nucleus (pvn) is not only released into the cns but also secreted 
into the pituitary portal circulation (Aguilera and Rabadan-Diehl, 
2000; Scott and Dinan, 2002). Centrally acting avp is believed to 
play a role in the regulation of learning and memory, social behav-
iours, circadian rhythmicity and thermoregulation (Ring, 2005). 
Furthermore, following acute psychological and/or physical stress, 
it acts as co-activator of the hypothalamus-pituitary-adrenal (hpa) 
axis by inducing acth release via the vc receptor (vc or Vab) on the 
anterior pituitary (Dinan and Scott, 2005; Scott and Dinan, 1998). 
Co-activation is believed to occur in the presence of the main hpa 
axis activator corticotrophin-releasing hormone (crh) (Scott and 
Dinan, 2002). Subsequently, the stress hormone cortisol is released 
into the circulation from the adrenal cortices, causing various 
systemic and metabolic effects in peripheral tissues, and differ-
ent behavioural and cognitive effects in the cns. In addition to 
these actions on the hpa-axis, avp originating from magnocellular 
neurons of the supraoptic nucleus and pvn of the hypothalamus 
is secreted peripherally via the posterior pituitary (Ring, 2005). 
Peripheral release is triggered by hypo-osmolality, hypovolemia, 
reduced blood pressure, hemorrhage, hypoglycemia, fever and 
pain. After release, it acts principally at Vaa receptors of the renal 
tubular cells restoring plasma volume and osmolality (Ring, 2005). 
 Hyperactivity of the avp system of the anterior pituitary has 
been implicated in hpa axis dysregulation during chronic stress-
related psychopathology (Pariante and Lightman, 2008; Scott and 
Dinan, 2002). Preclinical data indicate that avp sustains hpa axis 
hyperactivity under conditions of chronic stress (Spiga et al., 2008). 
Humans with (subtypes of) depressive disorder display hyper-
cortisolism, indicating chronic hpa axis hyperactivation. Also, 
these patients have an enhanced neuroendocrine response to the 
combined dexamethasone-corticotrophin release hormone (dex/
hcrh) function test, This potentiation of the response to hcrh is 
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predominantly ascribed to pre-existing hypersensitivity of the avp 
system (Holsboer, 1983; Holsboer, 2000). However, the exact role of 
avp in the pathophysiology of different (sub)types of affective dis-
orders or other psychiatric conditions has not been clearly defined. 
 The lack of a better understanding of the role of avp in psycho-
pathology is in part related to the lack of validated function tests 
of vasopressinergic hpa axis regulation. A reliable pharmacological 
vasopressinergic function test would not only be useful to examine 
avp in hpa axis regulation in health and (psychiatric) disease in 
more detail, but it would also be helpful to investigate innovative 
drugs targeting this system. Modulation of the avp system by vc 
antagonists could for instance be clearly demonstrated in an early 
stage of drug development by suppression of the hpa-effects 
induced by a validated avp function test. Such a function test can 
also be used as functional diagnostic and/or prognostic tool in 
patients suffering from hpa axis associated psychiatric disorders. 
Previously, intravenous (i.v.) administration of desmopressin 
(ddavp), a synthetic analogue of avp, has been proposed as phar-
macological function test of vasopressinergic hpa axis function 
(Dinan and Scott, 2005; Scott and Dinan, 1998). ddavp is a partially 
specific vasopressin receptor agonist exhibiting pharmacological 
activity at the vc as well as the vasopressin 2 receptors (vb) (Craig-
head et al., 2008). It has an elimination half-life of 0.9 to 3.8 hours 
and is excreted unchanged by the kidneys (Rembratt et al., 2004). 
In the past, a number of important studies have utilized ddavp  
to help understand avp’s role in the (patho)physiology of hpa axis 
regulation (Dinan et al., 1999; Dinan et al., 2004; Scott et al., 1999a; 
Scott et al., 1999b). However, to a large extent these studies have 
focussed on the magnitude of vc modulated neuroendocrine  
pharmacodynamic (pd) effects with minimal attention for system-
ic effects that may confound hpa axis activation by non-specific 
stress, or affect the safety of this test. Specifically, the influence  
of blood pressure reduction induced by ddavp via the vb and its 
potential subsequent influence on acth release via the autono- 
mic nervous system (ans) remains unclear. There is also very little 
information on the procoagulant and anti-diuretic adverse effects 
of i.v. administered 10µg ddavp via the vb. These effects are par-
ticularly relevant if the ddavp function test is to be applied in 
depressed patient populations, who have an increased risk for 
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comorbid cardiovascular disease or (components of) the metabolic 
syndrome (Evans et al., 2005; Musselman et al., 2003; Ramasubbu, 
2002). 
 We performed a study that simultaneously investigated the 
neuroendocrine-, cardiovascular-, anti-diuretic-, pro-coagulant- 
and (indirect) ans effects of ddavp, and their concentration- and 
infusion rate-dependence. Two different doses of ddavp were 
administered i.v. using two different administration modes: (1) 
10µg ddavp was administered as a bolus over 60 seconds and (2) 
30µg ddavp was administered incrementally over a period of 60 
minutes. The 10µg dose was previously shown to be the minimum 
dose able to induce vasopressinergic hpa axis activation, whereas 
an incremental dose of 30µg was expected to produce comparable 
peak ddavp plasma levels (cmax) (Agerso et al., 2004). In this regard, 
it is important to note that the predictability of this approach is 
limited since previous pharmacokinetic analyses have reported 
more than 2-fold differences in clearance and 100-fold differences 
in cmax of i.v. administered ddavp (Callreus et al., 1999; Fjellestad-
Paulsen et al., 1996; Odeberg et al., 2004; Rembratt et al., 2004). 
At any rate, the use of two different infusion paradigms was to 
provide an impression on how the different peripheral and central 




A randomized, double-blind, double-dummy infusion, placebo-
controlled, three-way crossover study was performed in 12 healthy 
volunteers. The study protocol was approved by the Medical Ethics 
Committee of Leiden University Medical Centre (lumc) and per-
formed according to Good Clinical Practice and International  
Conference on Harmonisation guidelines. 
Main outcome measures
The main pharmacodynamic (pd) outcome measures were  
ddavp’s (1) neuroendocrine effects (serum acth, cortisol)  
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and (2) cardiovascular effects (systolic blood pressure (sbp), diasto-
lic blood pressure (dbp) and heart rate (hr)). Furthermore, ddavp’s 
effect on coagulation was assessed by measuring plasma Von  
Willebrand factor (vwf) and its antidiuretic effects were investi-
gated by measuring serum osmolality. ddavp-modulated ans acti-
vation was assessed indirectly by measuring serum prolactin and 
saliva alpha amylase. Adverse events (ae’s) were recorded through-
out the trial.
Drug administration
The incremental infusion consisted of cumulative i.v. doses of 
ddavp 30µg over 60 minutes (0min to 60min). The infusion rate 
was increased every five minutes for the first 30 minutes up an 
infusion rate of 40µg/h, after which the infusion rate remained 
constant at 40µg/h for the remaining 30 minutes. At 50min 
an intravenous bolus of 10µg ddavp was administered over 60 
seconds.
Volunteers
Twelve healthy volunteers (six male and six female) participated  
in the study. After obtaining written informed consent, the sub-
jects underwent a full medical screening to assess eligibility. Vol-
unteers were excluded from study participation if (1) using more 
than 4 units alcohol on average per day, (2) smoking more than 5 
cigarettes per day, (3) using any drug (except oral contraceptives for 
females) or substance within one week before the first dosing, (4) 
using any drug or substance known to influence the metabolism  
of ddavp in the month preceding the trial (5) demonstrating an 
adamts-13 deficiency or presenting with a personal or family his-
tory of hypercoagulability as reflected by a diagnosis of coagula-
tion factor deficiency (eg. Factor V Leiden mutation, apc resist-
ance) or previous pulmonary embolism, deep venous thrombosis 
or other (arterial) cardiovascular disease, (6) presenting with a per-
sonal or family history of renal disease including diabetes insipidus 
and symptoms such as polydypsia, (7) presenting with a personal 
or a first degree family history of a clinical significant psychiatric 
disorder according to dsm-iv. Xanthine containing foods or 
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beverages, tobacco or alcohol were not allowed during the stay on 
the research unit. Concomitant medication other than paraceta-
mol was not permitted during the study period. 
ddavp
Ddavp (Octostim ®) and placebo (0.9% NaCl) were prepared for 
administration by Profil GmbH, Neuss, Germany and were identical 
in appearance. 
Study days
Volunteers arrived at the Centre for Human Drug Research (chdr) 
on the evening before the study day. On admission urinary screen-
ing was performed for drugs of abuse using the OnCalltm Test, 
ACON laboratories, Inc. Rapid Assays for Drug Abuse (Instruchemie 
Hilversum B.V. the Netherlands) and qualitative color immunochro-
matografic urinary hCG was performed in all female subjects using 
the ‘On Call’ test device (Acon Laboratories Inc, San Diego, CA 92121, 
usa). Volunteers went to bed at 23.00 and were woken up around 
8.00 the next morning after which a standardized breakfast was 
served. Two cannulas were inserted into the antecubital vein of 
each arm for blood sampling and intravenous administration of 
ddavp. This occurred at least 1 hour preceding the first pd blood 
sampling to allow any potential procedure-related hpa axis activa-
tion to return to baseline. Fluid intake was restricted to 900 ml 
water administered at fixed time points and subjects remained 
supine on bed for the first four hours after start of the incremental 
infusion At 0min either 30µg ddavp or placebo was infused incre-
mentally for 30 minutes followed by a constant infusion rate for  
30 minutes. At 0min and 50min ddavp or placebo was adminis-
tered as described above. Administration of the i.v. infusions was 
performed under hospital conditions and a research physician 
attended all study occasions. At the end of the study day, volun-
teers were discharged from the research unit only after having  
produced urine. Adverse events were registered from spontaneous 
reports and hourly inquiries.
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Biochemical measurements
Venous blood (1.2ml; prechilled edta tubes) was collected for 
the determination of plasma acth on -20, -10 before and 5, 10, 
15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 110, 
120, 140, 160, 180, 210, 240, 270 and 480 minutes after start of the 
incremental infusion. Samples were immediately placed on ice, 
processed within 30 minutes and stored at -80°C. Samples were 
analyzed within six weeks using the Immulite 2500 Analyzer Assay 
(euro/dcp, United Kingdom) at the Central Laboratories of lumc. 
Venous blood (1.2ml; serum tubes) for the assay of serum cortisol 
and prolactin was taken at -20, -10 before and 10, 20, 25, 30, 35, 40, 
45, 55, 60, 65, 70, 75, 80, 90, 100, 120, 140, 160, 180, 210, 240, 270 
and 480 minutes after start of the incremental infusion. Samples 
were stored for 30 – 45 minutes at ambient temperature to allow 
coagulation, subsequently centrifuged for 15 minutes at 2000 x 
g and stored at -20 °C. Samples were analyzed using Perkin Elmer 
AutoDelfia Testkits at Organon Development GmbH, Department 
of Bioanalytics, Waltrop, Germany. Venous blood (2 ml; edta tubes) 
was obtained for plasma ddavp on -10 before and 10, 20, 25, 30, 35, 
40, 45, 55, 60, 65, 70, 75, 80, 90, 120,180, 240, and 480 after start of 
the incremental infusion. Samples were inverted, centrifuged with-
in 15 min after collection for 15 minutes between 2000 – 3000 x g 
and stored at -20 °C. ddavp was analyzed using lc-ms/ms at Xendo 
Drug Development BV, Groningen, The Netherlands. It appeared 
that the stability of ddavp in human plasma, under the storage 
conditions used, was not demonstrated to cover the length of time 
from sample collection to analysis (accuracy against value at 0min 
was >15%). Therefore, only relative and no absolute ddavp concen-
trations are reported. 1.2ml venous blood was collected in citrate-
0.106mol/l collection tubes for von Willebrand Factor (vwf) on -10 
before and 30, 60, 90, 120 and 240 min after start of the incremen-
tal infusion. Samples were centrifuged within 30 minutes for 20 
minutes at 2000xg and 4°C, frozen according to the “snap freeze” 
method and stored at - 40°C. Samples were analyzed at the Labora-
tory of tno Pharma, Leiden, the Netherlands. 1.2ml blood was col-
lected in serum clotting activator tubes for serum osmolality on 
-10, 30, 60, 90, 120, 150, 180, 240 min after start of the incremental 
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infusion. Samples were stored for 30 – 45 minutes at ambient 
temperature to allow coagulation, subsequently centrifuged for 10 
minutes at 2000xg and 4°C and stored refrigerated until analysis at 
the end of the collection day. Samples were analyzed by molecular 
freezing-point depression with a Osmometer OM-6050 of Arkry 
(Japan) at the Central Laboratories of lumc. 
Vital signs
Blood pressure and pulse rate were measured continuously from 
15 minutes prior until 4 h after start infusion using the Finapres 
methodology (Finapres Medical Systems BV, Amsterdam The 
Netherlands) and Nihon-Kohden (bsm-1100) or Colin (Pressmate 
BP-8800) blood pressure apparatus. Electrocardiogram (ecg) 
recordings were made at -30min and 180 min.
Data analysis
Neuroendocrine parameters (acth, cortisol), cardiovascular 
parameters (systolic blood pressure (sbp), diastolic blood pres-
sure (dbp), heart rate (hr)), serum osmolality, vwf and indirect 
ans effects (prolactin, saliva alpha amylase) were analyzed by 
mixed model analyses of variance (using sas proc mixed) with 
treatment, time, gender, gender-by-treatment and treatment-
by-time as fixed effects, with subject and subject-by-time as ran-
dom effect, and with the average baseline value as covariate. The 
neuroendocrine parameters, prolactin and serum osmolality were 
log-transformed prior to analysis. The contrasts between placebo 
and the bolus and between placebo and the incremental infusion 
were calculated over different time periods: for the incremental 
infusion over the period 0 to 180min, and for the bolus infusion 
over 50 to 180min since it was administered from 50min to 51min. 
Contrasts were reported as placebo vs. bolus infusion; placebo vs. 
incremental infusion and bolus infusion vs. incremental infusion. 
Results were presented as average differences compared to placebo 
(in percentages when back transformed from log-transformed vari-
ables) with 95% confidence intervals. The pharmacokinetic analy-
sis of ddavp consisted of determining the maximal mean plasma 
concentration (cmax).
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Results 
Subject disposition and demographic data
Eighteen volunteers were screened after having provided informed 
consent. Four subjects did not comply with the in- and exclusion 
criteria and were excluded from participation. Twelve volunteers 
received study medication of which one dropped out due an ae not 
related to study medication. The mean age of the volunteers was 
21 years (range 18-27 years) and was similar for males and females. 
Females had a mean weight of 65kg (60-67kg) and mean height of 
1.73m (range 1.68-1.84m). Males had a mean weight of 80kg (range 
63-99kg) and mean height of 1.88 (range 1.83-1.90m).
Adverse events 
All ae’s were of mild to moderate intensity, transitory in nature and 
had mostly dissipated within 12 hours after drug administration. 
ae’s were predictable based on the side-effect profile of ddavp 
and no subjects discontinued participation directly due to related 
adverse effects. The most commonly occurring ae’s were light-
headedness (2/12 subjects), headache (2/12 subjects) and fatigue 
(2/12 subjects) for placebo; facial flushing(5/12 subjects), headache 
(5/12 subjects), fatigue (3/12 subjects) and dizziness (2/12 subjects) 
for the incremental infusion and facial flushing (8/11 subjects),  
dizziness (4/11 subjects) and headache (4/11 subjects) for the bolus 
infusion respectively.
Pharmacokinetics 
In contrast to the expectation, a 1.8-fold higher maximal ddavp 
concentration was reached during the incremental infusion com-
pared to the bolus infusion. The maximal ddavp concentration was 
reached 55 minutes after start of the incremental infusion and 5 
minutes after the start of the bolus infusion, ie. at 55 minutes for 
both administration modes.
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Neuroendocrine pharmacodynamic effects
Mean acth release was statistically significant for both the bolus 
+26.1 (5.8, 50.3)% and incremental +30.9 (11.1, 54.2)% infusions com-
pared to placebo, but the difference between the two infusion regi-
mens was not significant (Table 1). Maximal mean acth concentra-
tions were also comparable with 15.85 ng/l and 15.02 ng/l for the 
bolus and incremental infusions respectively. The maximal mean 
acth concentration was attained at 55 min, 5 minutes after the 
cmax of ddavp for both the bolus and incremental infusions. Mean 
cortisol levels increased with +18.9 (4.1, 35.8)% for the bolus and 
+17.7 (3.5, 33.8)% for the incremental infusion compared to placebo 
(Table 1). The maximal mean concentrations of cortisol, attained 15 
minutes after those of acth, were very similar at 160.22 ng/ml and 
158.25 ng/ml for the bolus and incremental infusions respectively. 
The effects on acth and cortisol are illustrated in figures 1 and 2. 
Pro-coagulant – and anti-diuretic effects 
vwf was released after ddavp administration, with higher lev-
els attained with the 30µg incremental infusion. Compared to 
placebo, the incremental infusion led to an increase of +104% 
(84,124). A smaller increase of +64.0% (41,86) was observed with 
the bolus infusion (Table 2). Although the levels of vwf-Ag tended 
to decrease from 120min onwards, they had not returned to base-
line at the end of the measurement period (480min). Furthermore, 
serum osmolality was not altered by either the bolus or the incre-
mental infusion. 
Cardiovascular pharmacodynamic effects 
The incremental infusion had larger blood pressure lowering 
effects than the bolus infusion. Heart rate increased compensa-
tory with both infusions. These effects are illustrated best for dbp 
and hr in figures 3 and 4. After the bolus, rapid but short lasting 
circulatory effects were recorded. Similar maximum cardiovascu-
lar changes occurred during the incremental infusion, but these 
effects appeared and disappeared more gradually than after the 
bolus. Compared to placebo, the bolus infusion decreased average 
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sbp by -3.2 (-6.7, 0.3) mmHg and dbp by -7.2 (-10.2, -4.3) mmHg, and 
increased hr by +6.0 (1.2, 10.7) bpm. These effects were somewhat 
smaller than after the incremental infusion, which decreased aver-
age sbp by -5.3 (-8.6, -2.0) mmHg and dbp by -8.5 (-11.2,-5.8) mmHg, 
and increased hr by +9.7 (5.1, 14.4) bpm (Table 2).
Measures of ddavp-induced ans activation
Serum prolactin was not consistently affected by either ddavp 
infusion. The incremental infusion decreased prolactin significant-
ly by -15.4 (-23.5,-6.4) % while the bolus infusion increased prolac-
tin non-significantly by +6.1 (-5.2, 18.8)% compared to placebo. Sali-
va alpha-amylase increased non-significantly by +11.4 (-14.5,45.2)% 
following the incremental infusion and by +13.6 (-13.9,50.0)% after 
the bolus infusion. 
Discussion
This study aimed to concomitantly investigate neuroendocrine-, 
cardiovascular-, antidiuretic-, procoagulatory- and (indirect) ans 
effects of i.v. ddavp, administered using two different dosing regi-
mens. ddavp could be a useful pharmacological function tests of 
vasopressinergic activation of the hpa axis to study the involve-
ment of this system in normal or abnormal (psycho)physiology 
and during treatment. The study showed differences in neuroen-
docrine, coagulatory and cardiovascular effects between a slow 
incremental infusion of 30µg and a rapid intravenous bolus of 10µg 
in healthy volunteers. 
 avp is a physiological co-activator of the hpa-axis, mediated by 
vc-receptors on anterior pituitary corticotrophes and requiring the 
presence of endogenously available crh to release acth (Dinan 
and Scott, 2005; Ring, 2005). We found small but statistically sig-
nificant increases in acth and cortisol release after administering 
either 10µg ddavp over one minute or 30µg ddavp over 60 minutes. 
Both administration modes induced comparable elevations of 
acth and cortisol, despite an almost two-fold higher maximum 
ddavp concentration reached with the incremental infusion com-
pared to the bolus. The maximum serum cortisol concentrations 
of roughly 160 ng/ml after ddavp were only 50 to 70% of the levels 
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attained previously with serotonergic and corticotrophinergic 
function tests. Meta-chlorophenylpiperazine (mcpp) 0.5 mg/kg 
administered i.v. lead to a cortisol cmax 228.4ng/ml (Gijsman et 
al., 1998), 5-hydroxytryptophan (5-htp) 300mg administered orally 
induced a cortisol cmax of 218.9ng/ml (Smarius et al., 2008) and 
100µg human crh (hcrh) i.v. produced maximal serum cortisol 
concentrations of 210ng/ml (Dinan et al., 1999; Scott et al., 1999b). 
This indicates a higher maximum release of acth and cortisol fol-
lowing corticotrophinergic stimulation than after vasopressinergic 
co-activation. This is also illustrated in trials where ddavp induced 
a dose-dependent acth release for 5µg and 10µg but not for 15µg 
ddavp (Scott et al., 1999a) and crh augmented the vasopressin-
induced vc effects when administered concomitantly with ddavp 
(Favrod-Coune et al., 1993). Such limited vasopressinergic co-acti-
vation may be determined by low levels of endogenous crh, since 
this study was performed late in the morning and early afternoon, 
when circadian activity of the hpa-axis is relatively low.
 The hpa-axis can also be activated by homeostatic perturba-
tions, like hypotension causing an indirect stress responses via 
the sympatho-medullary route. ddavp-induced blood pressure 
reduction seems to be dependent on vb stimulation, causing pros-
taglandin release from vascular endothelium (Aldasoro et al., 1997; 
Medina et al., 1999). A reduction in peripheral resistance can acti-
vate sympathetic outflow via fibres descending from the vasocon-
strictor regions of the medulla oblongata. Concomitantly, direct 
stimulation of sympathetic outflow fibres terminating on the 
adrenal cortex can release adrenaline, which in turn might induce 
acth release via avp neurons (Aldasoro et al., 1997; Scott and 
Dinan, 2002). On average, 10µg ddavp reduced diastolic blood pres-
sure (dbp) by 7.2 mmHg, and the incremental 30µg infusion by 8.5 
mmHg in the current study. Heart rate showed average compen-
satory increases of 6.0 bpm after the bolus and 9.7 bpm with the 
infusion. It could be argued that even these small cardiovascular 
changes signify an activation of the autonomous nervous system 
(ans), inducing acth release via alternative routes. However, indi-
rect stress measures (saliva alpha amylase and serum prolactin) 
that indicate catecholamine-mediated ans activity via the sym-
pathoadrenal medullary route (Aldasoro et al., 1997; Rohleder et al., 
2004) remained unaffected by either ddavp administration mode. 
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Thus, ddavp’s effects on the hpa-axis do not seem to be mediated 
by peripheral stress effects, at least if subjects are kept supine dur-
ing the test to minimize blood pressure lowering effects of ddavp. 
 ddavp displayed a differential concentration-effect relationship 
for the neuroendocrine parameters on the one hand and cardiovas-
cular and coagulatory parameters on the other. ddavp’s vb-mediat-
ed effects (hr and vwf) were concentration dependent, which was 
not the case for its vc-mediated effects (acth and cortisol release). 
The maximal plasma concentrations (cmax) attained with 30µg 
ddavp were nearly twice (1.8-fold) as large as those reached with 
10µg ddavp. This difference was reflected by the concentration-
dependence of the cardiovascular and coagulatory effects, but not 
of the neuroendocrine responses, which were similar for the two 
doses. 
 The results suggest that 10µg ddavp is a safe pharmacological 
function test in healthy volunteers and patients, at least if some 
potential restrictions are considered. Neither 10µg ddavp nor 
30µg ddavp affected serum osmolality with fluid restriction, but 
ddavp can cause a reduced osmolality if liberal water consump-
tion is allowed. ddavp clearly induced von Willebrand factor (vwf) 
release, but this is unlikely to produce coagulatory complications. 
The intravenous administration of ddavp stimulates the release 
of vwf and factor viii from the vascular endothelium via vb recep-
tors (Lethagen, 1994). At the same time, ddavp releases tissue 
plasminogen activator (tpa), which mitigates the prothrombotic 
effects of vwf (Burggraaf et al., 1994). vwf itself is degraded by 
the vwf cleaving protease adamts13. Also, a twice higher dose of 
ddavp compared to the present trial (0,3µg/kg vs. 0,13µg/kg) lead 
to (maximal) vwf release (Lethagen, 1994) without the occurrence 
of coagulation–related ae’s in healthy volunteers. The prothrom-
botic effects of 10µg ddavp thus appear to be self-limiting, at 
least in healthy volunteers. Susceptible patients however may be 
at an increased risk of thrombo-embolic events following ddavp-
induced vwf-elevations, although this is only suggested by rare 
case reports of patients who developed an acute myocardial inf-
arction after administration of ddavp for their hemophilia or Von 
Willebrand’s disease (Follenius et al., 1982). Therefore, it is probably 
sensible to avoid higher doses of ddavp, and to exclude patients 
with multiple cardiovascular risk factors or a (past) history of 
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ischemic heart disease or a (congenital) adamts13 deficiency. In 
this study, ddavp had its maximum neuroendocrine effects at a 
dose of 10µg, with limited coagulatory and cardiovascular manifes-
tations. At this dose, the risk of thrombotic complications seems 
very small in patients who suffer from depression but have no 
clearly elevated cardiovascular risk. 
 In conclusion, administering 10µg ddavp intravenously over one 
minute is an effective pharmacological tool to induce vasopress-
inergic hpa axis activation in healthy volunteers. Under low corti-
cotrophinergic conditions, this function test produces a clear but 
limited co-activation of pituitary acth-release via the vc. A 10µg 
ddavp bolus does not cause much systemic effects, and avoids 
non-specific stress responses. The effects on serum osmolality 
and coagulation are limited, although the safety in specific risk 
populations remains to be established. Higher doses of ddavp are 
not expected to produce much more informative vasopressinergic 
co-activation, and could induce adverse and confounding vb-medi-
ated effects. 
this work was supported by the schering-plough research institute
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Table 2  Cardiovascular, coagulatory and anti-diuretic parameters for the period 50 min to 
3 hours for the bolus infusion and over 3 hours for the incremental infusion: Esti-
mated difference (%) with 95% confidence interval from placebo for 10μg ddavp 
bolus infusion and 30μg ddavp incremental infusion and the estimated differ-
ence (%) with 95% confidence interval between 10μg ddavp bolus infusion and 
30μg ddavp incremental infusion for systolic blood pressure (sbp), diastolic 
blood pressure (dbp), heart rate (hr), von Willebrand factor (vwf) and serum 
osmolality (mOsmol/kg)




50 – 180 min
Incremental infusion
vs placebo 
0 -180 min Bolus vs incremental
sbp (mmHg) -3.2 (-6.7,0.3) p=0.0715 -5.3 (-8.6,-2.0) p=0.0036 -2.3 (-5.7,1.1) p=0.1722
dbp (mmHg) -7.2 (-10.2,-4.3) p<.0001 -8.5 (-11.2,-5.8) p=<.0001 -2.1 (-5.0,.08) p=0.1473
hr (bpm) +6.0 (1.2, 10.7) p=0.016 +9.7 (5.1, 14.4) p=0.000 +5.7 (1.0, 10.4) p=0.020
vwf (%) +64.0 (41, 86)p<0.000 +104.0 (84, 124) p<0.000 +58.0 (36, 80) p<0.000
Serum osmolality (mOsmol/kg) -0.2 (-0.6, 0.3) p=0.446 -0.2 (-0.6, 0.1) p=0.199 -0.1 (-0.6, 0.4) p=0.644
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Figure 1 Average concentration time profile of plasma adrenocorticotrophic hormone 
(acth) with sd error bars (closed circle: Placebo; open circle: Incremental infu-
sion; open square: Bolus infusion)
 


























30µg ddavp incremental infusion
10µg ddavp bolus infusion
Time (min)
Figure 2 Average concentration time profile of serum cortisol with sd error bars (closed 
circle: Placebo; open circle: Incremental infusion; open square: Bolus infusion)



















30µg ddavp incremental infusion
10µg ddavp bolus infusion
Time (min)
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Figure 3 Average concentration time profile of diastolic blood pressure (dbp) with sd error 
bars (closed circle: Placebo; open circle: Incremental infusion; open square: Bolus 
infusion)
 












30µg dDAVP incremental infusion
10µg dDAVP bolus infusion
Time (min)
Figure 4 Average concentration time profile of heart rate (hr) with sd error bars (closed 
circle: Placebo; open circle: Incremental infusion; open square: Bolus infusion)
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10µg ddavp bolus infusion
Time (min)
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Abstract
background Pharmacological function tests consisting of 100µg hcrh (corti-
corelin) and 10µg ddavp (desmopressin) mimic endogenous hpa-
axis activation. However, physiological crh concentrations pre-
clude informative vasopressinergic co-activation (using ddavp) 
and independent quantification of both corticotrophinergic (using 
hcrh) and vasopressinergic (using ddavp) activation is limited due 
to administration on separate occasions. 
objectives This randomized, double-blind, placebo-controlled, partial five-
way crossover study in healthy males and females (six: six) exam-
ined whether (1) concomitant administration of ddavp and hcrh 
provides more informative vasopressinergic co-activation than 
ddavp alone and (2) whether the administration of ddavp followed 
two hours later by hcrh can quantify both vasopressinergic and 
corticotrophinergic activation on a single test day.
results 10µg ddavp combined with 10µg and 30µg hcrh caused dose-
related acth- and cortisol-release which was larger than with 10µg 
ddavp alone and respectively comparable to and greater than that 
induced by 100µg hcrh. 10µg ddavp alone demonstrated limited 
acth-release while the effects of 100µg hcrh two hours later were 
three times as large. acth and cortisol released by 10µg ddavp 
returned to baseline prior to 100µg hcrh administration and ddavp 
did not influence the response to subsequent hcrh 
administration. 
conclusions Dose-related vasopressinergic co-activation of the hpa-axis was 
induced by combining 10µg ddavp with 10µg and 30µg hcrh. 10µg 
ddavp combined with 10µg hcrh induced the potentially most 
informative vasopressinergic co-activation since it is not restricted 
by ceiling- or flooring-effects. The hcrh-response was not affected 
by prior ddavp, allowing for a practical function test examining 
both hpa-activation routes on the same day. 
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Introduction
The hypothalamic neuropeptides corticotrophic release hormone 
(crh) and vasopressin (avp) modulate activation of the hypothala-
mus-pituitary-adrenal axis (hpa), releasing adrenocorticotrophic 
hormone (acth) from pituitary corticotrophes and subsequently 
cortisol from the adrenal cortices. Under physiological circum-
stances, crh acts as major neuroendocrine secretagogue via pitui-
tary crha receptors (crha) (inducing corticotrophinergic activa-
tion) while avp has weak neuroendocrine properties at pituitary 
vasopressin 3 receptors (vc) (inducing vasopressinergic co-activa-
tion) (Ring, 2005; Scott and Dinan, 1998). However, following acute 
psychological and/or physical stress, avp synergistically releases 
acth in the presence of increased levels of crh, inducing an up to 
30 times higher acth release compared to the effects of crh alone 
(vasopressinergic co-activation) (DeBold et al., 1984; Favrod-Coune 
et al., 1993; Lamberts et al., 1984). After disappearance of a stressful 
insult, the hpa axis returns to basal activity via cortisol feedback 
and avp again resumes its role as minor activator (de Kloet et al., 
2005; Holsboer, 2000). In some stress-related psychiatric disorders, 
failure of the hpa axis to “reset” after stress has been attributed to 
chronic vasopressinergic hyperactivity or sustained vasopressiner-
gic co-activation (Ring, 2005; Scott and Dinan, 1998; Holsboer et al., 
1984; Holsboer and Ising, 2008; Scott et al., 1999b). A pharmacologi-
cal function test quantifying vasopressinergic co-activation would 
therefore be useful to examine functional vasopressinergic distur-
bances of the hpa axis. 
 The synthetic analogue of avp, desmopressin (ddavp), is fre-
quently used as a pharmacological function test for vasopressiner-
gic functionality (Craighead et al., 2008). Infusing 10 µg ddavp over 
60 seconds induces a neuroendocrine response at the vc receptor, 
without causing clinically relevant confounding effects via other 
avp receptors (Jacobs et al., 2009). However, acth and cortisol 
release induced by ddavp alone is small and (frequently) variable 
(Dinan and Scott, 2005; Scott et al., 1999b; Jacobs et al., 2009). 
Without addition of hcrh, 10 µg ddavp administered as a bolus 
over one minute induces a maximal vc-mediated acth release of 
16 ng/l, which is virtually equal to the increase (15 ng/l) induced by 
30 µg ddavp administered incrementally over one hour (Jacobs et 
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al., 2009). These increases are small compared to corticotrophiner-
gic hpa activation with intravenous (i.v.) human corticotrophic 
release hormone (hcrh) or oral administration of the serotonergic 
precursor agent 5-hydroxtrypthophan (5-htp) (Dinan et al., 1999; 
Scott et al., 1999b) (Smarius et al., 2008). At maximally tolerated 
doses, these interventions induce maximal serum cortisol concen-
trations (cmax) that are roughly 90 – 100% higher than those 
induced by 10 µg ddavp alone. In these experiments, the effects  
of ddavp alone seem to be limited by the low levels of endogenous 
crh. Thus, since avp is a crh-dependent co-activator of the hpa 
axis, it might be better to study vasopressinergic co-activation by 
administration of ddavp in combination with hcrh.
 Corticotrophinergic (via crha) and vasopressinergic (via vc) hpa 
axis activation have been quantified previously, most frequently by 
investigating the effects of ddavp and hcrh separately on three (in-
cluding placebo) different study days (Dinan et al., 1999; von Barde-
leben and Holsboer, 1988). Since such an approach would be unfeasi-
ble in most studies in (depressed) patients, the current study 
examined whether it would be possible to address the most impor-
tant aspects of pituitary acth-release (vasopressinergic co-activa-
tion and corticotrophic responsiveness alone) in a single short study 
occasion. Independent evaluations of each route would require an 
adequate washout period, to ensure that vc stimulation does not 
affect subsequent crha stimulation (or vice versa). A minimal wash-
out period after a ddavp challenge would at least require a full re-
turn of acth levels to baseline, which according to previous studies 
occurs after 90 minutes (Jacobs et al., 2009; Scott et al., 1999a).
 To examine these issues, we performed a single trial consisting  
of two separate experiments divided by two hours. In experiment  
A we examined whether vasopressinergic co-activation could be 
quantified by simultaneously adding small amounts of hcrh 
(either 10 µg or 30 µg hcrh) to a vasopressinergic function test  
consisting of 10 µg ddavp in healthy volunteers. Experiment B 
examined the effects of hcrh alone, and potential interaction 
effects of prior ddavp administration on corticotrophinergic activa-
tion by administration of 100 µg hcrh two hours later. To compare 
the two routes of acth-activation, the acth-release by 100 µg hcrh 
alone in experiment B was used as benchmark for the effects of the 
combinations in experiment A. This dose was chosen since 100 µg 
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hcrh has often been used in the literature, whereas the effects  
of lower doses (such as those used in experiment A in combination 
with ddavp) were unknown. This attempt to characterize both 
routes of acth-stimulation on the same day had several practical 
reasons. The design restricted the burden for subjects and the 
amount of blood sampling, and is anticipated to be more accepta-
ble than separate study days for patients in future clinical trials. 
Methods 
Study design
The study protocol was approved by the Medical Ethics Committee 
of Leiden University Medical Centre and performed according to 
Good Clinical Practice and International Conference on Harmonisa-
tion guidelines. A randomized, double blind, placebo-controlled, 
partial five-way crossover trial was performed in 12 healthy volun-
teers. Study medication was administered intravenously over 30 
seconds, at two time points separated by two hours (t=0min and 
t=120min). In this way, two different experiments could be per-
formed on the same day (Figure 1). Experiment A examined modula-
tion of vasopressinergic co-activation by concomitant administra-
tion of different doses of hcrh with ddavp at t=0min. Experiment 
B examined the effect of corticotrophinergic activation alone, and 
any carry-over effects of vasopressinergic co-activation after two 
hours, by first administering ddavp or placebo followed by hcrh  
at t=120min. The main pharmacodynamic (pd) outcome measures 
for both experiments were changes in the concentrations of serum 
acth, cortisol and prolactin. Also, adverse events (ae’s) were 
recorded to assess the safety and tolerability of concomitantly 
administering ddavp and hcrh.
Volunteers
Twelve healthy volunteers (six male and six female) participated  
in the study. After providing their written informed consent volun-
teers received a full medical examination during a pre-study 
screening. Volunteers were excluded from study participation if (1) 
using more than 4 units alcohol on average per day, (2) smoking 
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more than 5 cigarettes per day, (3) using any drug or substance 
within one week before the first dosing, (4) using any drug or sub-
stance known to influence the metabolism of ddavp in the month 
preceding the trial (5) demonstrating an adamts-13 deficiency or 
presenting with a personal or family history of hypercoagulability 
as reflected by a diagnosis of coagulation factor deficiency (eg. Fac-
tor V Leiden mutation, apc resistance) or previous pulmonary 
embolism, deep venous thrombosis or other (arterial) cardiovascu-
lar disease, (6) presenting with a personal or family history of renal 
disease including diabetes insipidus and symptoms such as poly-
dypsia, (7) presenting with a personal or a first degree family history 
of a clinical significant psychiatric disorder according to dsm-iv.  
No xanthine containing foods or beverages, tobacco or alcohol were 
allowed during the stay on the research unit. Concomitant medica-
tion other than paracetamol was not permitted during the study 
period. 
ddavp and hcrh
Identical syringes containing either ddavp (Octostim®) or 0.9% 
NaCl as placebo were prepared for administration by the Depart-
ment of Clinical Pharmacy and Toxicology of the Leiden University 
Medical Centre (lumc). hcrh (Ferring crh®) was provided by the 
Department of Clinical Pharmacy and Toxicology of the lumc and 
identical syringes containing either hcrh or hcrh solvent as pla-
cebo were prepared for administration on-site at chdr by trained 
staff not directly involved in the trial. Due to hcrh’s rapid degra-
dation after preparation, a maximal limit of 6 minutes was allowed 
between its preparation and administration to the volunteers. If any 
delay caused transgression of this limit, hcrh was prepared again 
and administered within 6 minutes.
Study days
Volunteers arrived at the Centre for Human Drug Research (chdr) 
on the evening preceding each study day. On admission urinary 
screening was performed for drug use on all volunteers (tetrahydro-
cannabinol (thc), cocaine, morphine,benzodiazepines, 3,4-methyl-
enedioxymethamphetamine (mdma)/metamphetamine and 
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amphetamines) using the OnCall™ Test, acon laboratories, Inc. 
Rapid Assays for Drug Abuse (Instruchemie Hilversum B.V. the 
Netherlands). In all females hCG was qualitatively measured in 
urine using the ‘On Call’ test device (Acon Laboratories Inc, San 
Diego, CA 92121, usa). Volunteers went to bed at 23.00 and were 
woken up around 8.00 the next morning after which a standardized 
breakfast was served. Two cannulas were inserted into the antecu-
bital vein of each arm for blood sampling and intravenous adminis-
tration of study medication. This occurred at least 1 hour preceding 
the first pd blood sampling to allow any puncture-induced hpa axis 
activation to return to baseline. Fluid intake was restricted to a 
total of 900 ml until the first urination infusion and only water was 
administered on fixed time points during the study day. Adminis-
tration of the intravenous infusions was performed under hospital 
conditions and a research physician attended all study days. At the 
end of a study day, volunteers were discharged from the research 
unit only after having produced urine.
Biochemical measurements and vital signs on study days
1.2ml venous blood was collected in prechilled edta collection 
tubes for the determination of plasma acth on -60, -10 before and 
5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 75, 90, 120, 125, 130, 135, 140, 145, 
150, 155, 160, 170, 180, 195, 210, 240, 270, 300, 360, 390, 420 and 510 
minutes after the administration of the infusion at t=0h. Samples 
were immediately placed on ice, processed within 30 minutes and 
stored at -80°C. Samples were analyzed within six weeks using  
the Immulite 2500 Analyzer (Siemens, Germany) at the Laboratory 
for Clinical Chemistry, Leiden University Medical Centre (lumc), 
Leiden, the Netherlands. 1.2ml venous blood was collected in serum 
collection tubes for the determination of serum cortisol and prol-
actin on -60, -10 before and 10, 20, 30, 40, 50, 60, 75, 90, 120, 130, 
140, 150, 160, 180, 195, 210,240, 300, 360, 390, 420 and 510 minutes 
after start of the incremental infusion. Samples were stored for 30 
– 45 minutes at ambient temperature to allow coagulation, subse-
quently centrifuged for 15 minutes at 2000 x g and stored at -20 °C. 
Samples were analyzed using Perkin Elmer AutoDelfia at Organon 
Development GmbH, Department of Bioanalytics, Waltrop, Ger-
many. Blood pressure and pulse rate were measured at fixed 
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timepoints using the Nihon-Kohden (bsm-1100) or Colin (Pressmate 
bp-8800) blood pressure apparatus. Electrocardiogram (ecg) 
recordings were made at -30 and 180 min after infusion.
Pharmacodynamic (pd) analysis
The pd endpoints (acth, cortisol, prolactin) for 12 volunteers were 
log-transformed and analyzed by mixed model analyses of variance 
(using sas proc mixed) with treatment, time, gender, gender-by-
treatment and treatment-by-time as fixed effects, with subject 
and subject-by-time as random effect, and with the average base-
line value as covariate. Since the trial consisted of two experi-
ments, the pd effects were analyzed over two different time peri-
ods. To examine the effects of 10 µg and 30 µg hcrh on 10 µg 
ddavp-induced vasopressinergic hpa axis activation (experiment 
A), pd effects were analyzed over the period 0 to 90 min. This analy-
sis period was based on a previous investigation of the pd effects 
of 10 µg ddavp, showing that acth and cortisol had returned to 
placebo levels within 90 minutes after its administration. To exam-
ine the effect of 100 µg hcrh on corticotrophinergic hpa axis acti-
vation and the effect of vasopressinergic hpa axis activation using 
10 µg ddavp two hours earlier (experiment B), pd effects were ana-
lyzed over the period 120 to 510 min since 100 µg hcrh was admin-
istered at t=120min. To put the vasopressinergic-corticotrophiner-
gic co-activation in perspective, the mean maximal concentrations 
(cmax) of acth and cortisol of 100 µg hcrh in experiment B were 
compared to those of 10 µg and 30 µg hcrh with 10 µg ddavp in 
experiment A. Neuroendocrine results were presented as estimates 
of percentual difference from placebo, with 95% confidence inter-
vals and mean maximal concentrations (cmax). Adverse events were 
registered from spontaneous reports and hourly inquiries. 
Results 
Subject disposition and demographic data
Thirteen volunteers were screened after having provided informed 
consent. Twelve volunteers received study medication of which one 
dropped out due an ae not related to study medication. The mean 
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age of the volunteers was 21 years (range 18-27 years), which was 
similar for males and females. Females had a mean weight of 65kg 
(60-67kg) and mean height of 1.73m (range 1.68-1.84m). Males had 
a mean weight of 80kg (range 63-99kg) and mean height of 1.88 
(range 1.83-1.90m).
Adverse events 
All ae’s were of mild to moderate intensity, transitory in nature 
and had dissipated within 12 hours after drug administration.  
ae’s were predictable based on the side-effect profiles of hcrh 
and ddavp and no subjects discontinued participation directly 
due to related adverse effects. Since the side-effects of both drugs 
are very much alike, it was not possible to readily identify the 
causating agent when ddavp and hcrh were administered simul-
taneously. At any rate, the administration of ddavp and hcrh 
together, either simultaneously or sequentially did not influence 
the intensity or occurrence of ae’s. The most commonly occurring 
ae’s were headache (2/12 subjects) for placebo; facial flushing 
(10/12 subjects), palpitations (4/12 subjects), dizziness (2/12 sub-
jects) and headache (1/12 subjects) for 100 µg hcrh; facial flushing 
(8/12 subjects), palpitations (3/12 subjects), dizziness (2/12 sub-
jects) and headache (2/12 subjects) for 100 µg hcrh preceded by  
10 µg ddavp; facial flushing (6/12 subjects), palpitations (1/12 sub-
jects) and headache (1/12 subjects) for 10 µg ddavp combined with 
10 µg hcrh and facial flushing (8/12 subjects), headache (3/12 sub-
jects), palpitations (2/12 subjects) and dizziness (1/12 subjects) for 
10 µg ddavp combined with 30 µg hcrh.
Neuroendocrine effects 
In experiment A, acth increased by +34.6(8.7, 66.7,p=0.0075)%, 
(cmax19.3ng/l) with 10 µg ddavp; by +154 (105, 213,p<0.0001)%, 
(cmax56.7ng/l) after 10 µg ddavp combined with 10µg crh; and  
by +242(177, 322,p<0.0001)%, (cmax75.2ng/l) following 10 µg  
ddavp combined with 30µg hcrh (Table 1; Figures 2 and 3).  
Cortisol increased similarly by +18.2(-2.4, 42.9)%, (cmax114.2 ng/
ml) with 10 µg ddavp; by +76.7(46.1, 114)%, (cmax172 ng/ml) after  
10 µg ddavp combined with 10µg hcrh; and by +113(76.5, 158)%, 
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(cmax192 ng/ml) following 10 µg ddavp combined with 30µg hcrh. 
(Table 1; Figure 4). 
In experiment B, acth increased by +88.0(58.4, 145),p<0.0001)% 
(cmax59.2 ng/l) after 100µg hcrh, and by +104(70.5, 145.,p<0.0001)% 
(cmax70.4 ng/l) with 100 µg hcrh preceded by 10 µg ddavp. The dif-
ference between these two responses was not statistically signifi-
cant [+8.7(-9.0, 29.9)% p=0.340)%] (Table 2; Figures 2 and 5). Cortisol 
increased similarly by +40.0(25.5, 56.1),p<0.0001)% (cmax196 ng/ml) 
following 100 µg hcrh and by +45.7 (30.2, 63.1),p<0.0001)% (cmax209 
ng/ml) after 100 µg hcrh preceded by 10 µg ddavp. This difference 
was also not statistically significant [+4.1 (-6.7, 16.1),p=0.425)%]. 
(Table 2; Figure 6).
The acth increases after 10 µg or 30 µg hcrh combined with 10 
µg ddavp of respectively 154% and 242%, were larger than the 
increases of 88.0% and 104% following 100 µg hcrh. 
Discussion
avp is believed to enhance crha-associated camp production in 
pituitary corticotrophes by stimulating vc, potentiating the effect 
of crh and leading to a synergistic release in acth and subse-
quently cortisol (Scott and Dinan, 1998; DeBold et al., 1984; Favrod-
Coune et al., 1993). A full pharmacological characterisation of this 
co-activation, including a quantitative description of the individual 
and (supra)additive components of the system, would have 
required a complete assessment of all interactions between ddavp 
and hcrh, including different doses. Although undoubtedly useful, 
such a study would be very difficult to perform, even in healthy vol-
unteers and much more so in patients. The current study was not 
designed for these purposes, but it provided clear indications for  
a dose-related co-activation, and showed that the effects of low 
doses of hcrh are boosted by ddavp to the levels of a much higher 
dose of hcrh alone. Administration of 10 µg ddavp alone induced  
a maximal acth concentration of 19.3 ng/l. The addition of 10 µg 
hcrh produced an acth-peak of 56.7 ng/l, which did not differ 
much from the effect of a ten-fold higher dose of 100 µg hcrh alone 
(59.2 ng/l). The combination with 30 µg hcrh caused a cmax of 
75.2 ng/l, which was on average even larger than with 100 µg hcrh. 
Very similar results were found for cortisol, where the maximal 
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levels induced by ddavp alone or combined with 10 µg and 30 µg 
hcrh were 60%, 90% and 98% of those produced by 100 µg hcrh 
alone. This clearly shows that ddavp potentiates the pituitary 
release of acth caused by exogenous hcrh in a dose-related man-
ner. The results also show that the effects of 10 µg ddavp alone are 
limited to a cmax of 19.3 ng/l, possibly reflecting the relatively low 
endogenous hcrh levels in healthy volunteers during the morning.
 Instead of administering 100 µg hcrh in a separate treatment 
arm, it was given two hours later than 10 µg ddavp. This relatively 
short washout period was mainly chosen to investigate whether  
a vasopressinergic and corticotrophinergic function test could be 
combined in half a day, in order to reduce the burden for patients  
in future clinical trials. Previous studies showed that acth-release 
following ddavp alone return to baseline within 90 min (Jacobs et 
al., 2009; Scott et al., 1999a), and this was confirmed in the current 
study for ddavp combined with hcrh. A longer washout duration 
could also have introduced differences related to diurnal fluctua-
tions, which were probably less important within this late mor- 
ning two-hour period. The results show that the vasopressinergic 
effects of a single dose of 10 µg ddavp are small and have disap-
peared after two hours. Such a dose does not have a significant 
interaction with 100 µg hcrh administered 120min later in healthy 
volunteers. This allows for a fairly independent assessment of the 
corticotrophic component of acth-stimulation, after determina-
tion of the vasopressinergic co-activation using a ddavp-challenge 
earlier the same day. The difference in acth- and cortisol release  
induced by hcrh with or without preceding ddavp was on average 
less than 10%. Although this difference is statistically non-signifi-
cant, a small augmentation of the hcrh effect by administering 
ddavp two hours earlier is not fully precluded. However, this poten-
tial carry-over effect is no more than a fraction of the effects of  
the concomitant administration of ddavp and hcrh.  It should  
be realized however that the optimal challenge interval to avoid 
confounding carry-over effects still needs to be confirmed in 
patients. In patients with vasopressinergic hyperactivity the 
effects of ddavp alone will be determined by both vc receptor 
hypersensitivity and (increased) endogenous crh-levels. Under 
these circumstances, the carry-over effects may be larger and 
therefore might require a longer wash-out period between 
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subsequent administrations. On the other hand, co-administration 
of ddavp and hcrh in the present trial pharmacologically mim-
icked  
a vasopressinergic hypersensitivity analogous to that expected in 
patients. Despite a clear augmentation of the maximal acth and 
cortisol responses in experiment A, their return to baseline levels 
remained unaffected and there was no detectable influence on  
the effects of hcrh in part B. In practice therefore, 10 µg ddavp 
with 10 µg or 30 µg hcrh followed by hcrh alone after two hours,  
is also expected to provide useful information both on vasopressin-
ergic and corticotrophinergic activity of the hpa-axis in patients. 
Moreover, the application of a function test in this form in patients 
could be used to detect unexpected interactions between vc and 
crha by comparing baseline values and normative responses. 
 An important goal of this study programme is to develop a relia-
ble and practical pharmacological function test to quantify vaso-
pressinergic co-activation. Such a function test could be used to 
demonstrate treatment effects of novel pharmacological agents 
modulating the vc receptor (Spiga et al., 2008b; Spiga et al., 2008a), 
and ultimately it can be used to detect functional differences 
betweens (patient) groups. In this regard, it is important to induce 
co-activation that is neither too small nor too large (Gijsman et al., 
2004). If a function test would produce suboptimal stimulation,  
it would be difficult to detect differences between patient groups 
or treatment effects. On the other hand, maximal or supramaximal 
stimulation may obscure changes or differences in vasopressiner-
gic sensitivity by means of ceiling effects. The ideal dose combina-
tion to quantify vasopressinergic/corticotrophinergic co-activation 
can only be determined from the full dose-response curves of hcrh 
and ddavp and their combinations. Although such data are not 
available, our studies provide indications that 10 µg ddavp with  
10 µg hcrh may actually constitute a reasonable combination.  
We showed that the 10 µg ddavp function test (in the presence of 
physiological crh concentrations) induces small maximal cortisol 
concentrations of 120 ng/ml in the present study and 140 ng/ml in 
a previous study (Jacobs et al., 2009). A dose of 30 µg hcrh admin-
istered alone has previously been reported to induce maximal cor-
tisol concentrations of 134 ng/ml (Oelkers et al., 1988). Considering 
the cmax of 196 ng/ml after the 100 µg dose in the current study,  
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50 µg hcrh should produce a readily detectable hpa-activation 
above baseline, but clearly lower than that caused by 100 µg.  
Addition of 10 µg hcrh to 10 µg ddavp increases cortisol levels to 
172 ng/ml, which is still below emax-values in healthy volunteers 
found with other pharmacological function tests. For example, the 
administration of 100 µg hcrh previously demonstrated maximal 
serum cortisol concentrations around 210 ng/ml (Dinan et al., 1999; 
Scott et al., 1999b). Also, the non-specific serotonin agonist meta-
chlorophenylpiperazine (mcpp) 0.5 mg/kg administered i.v. lead to 
a cortisol cmax 228.4 ng/ml (Gijsman et al., 1998) and the direct 
serotonin precursor agent 5-hydroxytryptophan (5-htp) 300mg 
administered orally induced a cortisol cmax of 219 ng/ml (Smarius  
et al., 2008). Higher doses of hcrh have not been administered due 
to undesirable aspecific stress effects, while mcpp and 5-htp are 
not tolerated at higher doses due to serotonergic side-effects.  
Cortisol release (at least via the crha receptor) therefore appears  
to be limited to approximately 210 - 230 ng/ml in this setting. Thus, 
a combination of 10µg ddavp with 10 µg hcrh is expected to con-
stitute a good function test to assess co-activation. The vasopress-
inergic contribution to the hpa-response can be determined by 
comparing the acth- and cortisol-effects of the combination of  
10 µg ddavp and 10 µg hcrh to those of 50 µg hcrh alone, adminis-
tered two hours later. This being said, it should be borne in mind 
that our recommendation is putative and the application of phar-
macokinetic-pharmacodynamic (pk-pd) modelling techniques in 
future will have to point out the validity of this approach. 
 In conclusion, we demonstrated dose-dependent vasopressiner-
gic co-activation when combining hcrh with ddavp. These find-
ings form a basis for the further development of a pharmacological 
function test to assess vasopressinergic co-activation of the hpa-
axis. This tool should be able to establish functional differences 
between different patient groups, and to demonstrate modulatory 
effects of innovative drug such as vc-antagonists. Furthermore, 
administering ddavp followed by hcrh at least two hours later 
presents a practical procedure to independently examine vaso-
pressinergic co-activation and corticotrophinergic activation of  
the hpa axis. 
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Table 2  Average plasma acth (ng/l) and serum cortisol (ng/ml) for the period 120 to 510 
min for 100 μg hcrh and for 100 μg hcrh preceded by 10 μg ddavp: Estimated 
means (back transformed least Square Means) for placebo, 100μg hcrh and 100 
μg hcrh preceded by 10μg ddavp. Estimated difference (%) with 95% confidence 
interval from placebo for 100μg hcrh and 100μg hcrh preceded by 10 μg ddavp; 
and estimated difference (%) with 95% confidence interval from 100 μg hcrh for 
100μg hcrh preceded by 10 μg ddavp.
Back transformed least 
Square Means (lsm)
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Figure 1 Schematic representation of the study design: a five-way crossover study  
consisting of two different experiments.
 
100µg hcrhplacebo + placebo5
100µg hcrh10µg ddavp +  placebo4
placeboplacebo + placebo3
placebo10µg ddavp + 30µg hCRH2
placebo10µg ddavp + 10 µg hCRH1
t = 120 mint = 0 minTreatment
10µg ddavp + 10µg hcrh
10µg ddavp + 30µg hcrh
10µg ddavp +  placebo
placebo + placebo
t = 0 min
Experiment A
100µg hcrh10 µg ddavp + placebo
100µg hcrhplacebo + placebo
placeboplacebo + placebo
t = 120 mint = 0 min
Experiment B
Figure 2 Average concentration time profile of plasma adrenocorticotropic hormone 
(acth) with sd error bars (ng/l) for experiments A and B combined (closed circle: 
placebo followed by placebo; open triangle: placebo followed by 100 mg hcrh; 
open circle: 10 mg ddavp followed by 100 mg hcrh; closed square: 10 mg ddavp 
combined with 10 mg hcrh followed by placebo; open square: 10 mg ddavp com-
bined with 30 mg hcrh followed by placebo). 
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10µg dDAVP+30µg hCRH (t=0min) followed by placebo 
(t=120min)
Time (min)
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Figure 3 Average concentration time profile of plasma adrenocorticotropic hormone 
(acth) with sd error (ng/l) bars for experiment A (closed circle: placebo; open cir-
cle: 10 mg ddavp; closed square: 10 mg ddavp combined with 10 mg hcrh; open 
square: 10 mg ddavp combined with 30 mg hcrh; grey open triangle: 100 mg 
hcrh superimposed from administration point at t = 120 min in experiment B). 
 





























10µg ddavp + 10µg hcrh
10µg ddavp + 30µg hcrh
100µg hcrh
Figure 4 Average concentration time profile of serum cortisol with sd error (ng/ml) bars 
for experiment A (closed circle: placebo; open circle: 10 mg ddavp; closed square: 
10 mg ddavp combined with 10 mg hcrh; open square: 10 mg ddavp combined 
with 30 mg hcrh; grey open triangle: 100 mg hcrh superimposed from adminis-
tration point at t = 120 min in experiment B).
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Figure 5 Average concentration time profile of plasma adrenocorticotropic hormone 
(acth) with sd error (ng/l) bars for experiment B (closed circle: placebo followed 
by placebo; open triangle: placebo followed by 100 mg hcrh; open circle: 10 mg 
ddavp followed by 100 mg hcrh). 
 

























) placebo ( t=0min) followed 
by placebo (t=120min)
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Time (min)
Figure 6 Average concentration time profile of serum cortisol with sd error (ng/ml) bars 
for experiment B (closed circle: placebo followed by placebo; open triangle: pla-
cebo followed by 100 mg hcrh; open circle: 10 mg ddavp followed by 100 mg 
hcrh). 
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Abstract
background  5-hydroxytryptophan (5-htp) is a direct 5-hydroxytryptamine (5-ht) 
precursor used to assess central serotonergic function. Its use has 
been limited by a narrow window between neuroendocrine 
changes and side effects, and variable kinetics related to inconsis-
tent administration modes. By combining 5-htp with carbidopa 
(cbd), increased bioavailability for brain penetration, and 
decreased peripheral side effects would be expected, due to 
reduced peripheral decarboxylation of 5-htp to 5-ht. 
objectives  A double blind, placebo-controlled, single rising dose, four-way 
crossover trial with placebo randomization was performed in fif-
teen healthy male volunteers to investigate the neuroendocrine 
dose-response relationship at various 5-htp levels, the tolerability 
and subjective effects of oral 5-htp at 100, 200 and 300 mg com-
bined with cbd and the pharmacokinetic properties of the 5-htp/
cbd-challenge.
results  Dose-dependent increases in average cortisol concentrations were 
observed. Mean response (auc) over the first 4 hours (sd): 172.0 
nmol/l (22.3) for placebo; 258.3 nmol/l (72.6) for 100 mg; 328.47 
nmol/l (84.6) for 200 mg; and 387.3 nmol/l (82.4) for 300 mg 5-htp. 
Similar dose-dependent increases for prolactin were seen while 
acth-response was more variable. 5-htp kinetics were adequately 
described using a one-compartment model with first order absorp-
tion and a lag time (mean oral clearance 28L/hr ± inter-individual 
coefficient of variation 31%). Nausea and vomiting occurred dose-
dependently as most frequent side effects, resulting in dose-
related dropout of 6.6% at 100 mg and 45.5% at 300 mg 5-htp.
conclusions  Orally administered 5-htp combined with cbd is an effective sero-
tonergic challenge test, exhibiting dose-related plasma concentra-
tions and neuroendocrine responsiveness. Frequent occurrence of 
nausea and vomiting limits the applicability of this challenge at 
5-htp doses above 100 mg.
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Introduction
Pharmacological stimulation tests, using challenges with receptor 
agonists, release stimulators or re-uptake inhibitors, are used to 
quantify the integrity and function of serotonergic pathways in  
the central nervous system (cns) (Gijsman et al., 2002b). These 
challenges may provide a tool for understanding the mechanisms 
underlying psychiatric disorders, or to predict the efficacy of novel 
therapies with a direct or indirect effect on serotonergic systems 
(Meibohm and Derendorf, 1997). One of the more frequently used 
serotonergic challenge tests consists of a single dose of L-5-Hy-
droxytryptophane (5-htp), the immediate precursor of serotonin. 
Its decarboxylation into serotonin in raphé neurons with hypotha-
lamic projections induces increases in cortisol and prolactin in 
peripheral blood, which are frequently used neuroendocrine end-
points of serotonergic challenges. However, there is little standard-
isation of 5-htp-challenge tests, and their use has been hampered 
by a narrow window between neuroendocrine responses and side 
effects, mainly nausea and vomiting. The doses used in 5-htp chal-
lenge tests vary extensively, and include oral doses of 10, 20 and 40 
mg (den Boer and Westenberg, 1990), 60 mg (van Vliet et al., 1996), 
100 mg (Vlasses et al., 1989), 200 mg (Maron et al., 2004; Schruers 
et al., 2002b; Schruers et al., 2002a), and intravenous doses of 0.8 
mg/kg (Birmaher et al., 1997; Ryan et al., 1992) . These doses were 
established by trial and error. In some studies, oral 5-htp has been 
administered together with the peripheral L-aromatic decarbox-
ylase inhibitor carbidopa (cbd). The rationale of cbd co-admin-
istration is that it prevents peripheral decarboxylation of 5-htp, 
leading to more 5-htp being available to enter the brain, and less 
peripheral serotonin being formed to cause systemic side effects. 
In practice, different doses of cbd have been used, varying from 
one single dose to three daily doses for one week before the chal-
lenge test (Birmaher et al., 1997; Magnussen and Nielsen-Kudsk, 
1979; Magnussen and Engbaek, 1978; van Vliet et al., 1996; Vlasses et 
al., 1989). Recently, the pharmacokinetics and pharmacodynamics 
of a 5-htp challenge test, consisting of two different doses of 5-htp 
with or without pre-treatment with cbd, were studied (Gijsman et 
al., 2002a). A dose of 100 mg 5-htp plus cbd (100 mg before and  
50 mg after 5-htp administration) induced a significant cortisol 
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and prolactin response, and the elimination half-life of 5-htp  
was doubled compared to 5-htp 100 mg without cbd. However,  
the neuroendocrine effects, which are known to be relatively sen-
sitive to serotonergic challenges, were smaller after 5-htp 100 mg 
with cbd than with usual challenge doses of dexfenfluramine or 
mcpp. 5-htp 100 mg with cbd produced few clinically significant 
adverse events in this study (3 out of 12 cases of nausea of which  
1 vomited) compared to mcpp. This suggests that the 100 mg dose 
of 5-htp may be too low to exert a full serotonergic response, 
despite its combination with cbd. The optimal dosing regimen  
of 5-htp that leads to a simple, reliable and tolerable challenge  
test of pre-synaptic serotonergic transmission thus remains to  
be established. Therefore, the current study was aimed at examin-
ing the neuroendocrine effects and the tolerability of single doses 
of 5-htp with cbd co treatment, in a rising dose design. A second 
aim was to reproduce some of the findings of the previous 5-htp-
study, to develop an impression of the intersubject variability and 
to establish the pharmacokinetic properties of the 5-htp/cbd-
challenge test.
Methods 
This study was a double blind, placebo controlled, four-way cross-
over, single rising dose investigation of oral 5-htp with co-admi-
nistration of carbidopa (cbd) with interspersed placebo random-
ization. The study protocol was approved by the Medical Ethics 
Committee of Leiden University Medical Centre (lumc) and all  
subjects gave written informed consent. The four dose regimens 
were placebo (including cbd placebo); 5-htp 100 mg; 5-htp 200 
mg; and 5-htp 300 mg, the last three with co-administration of  
100 mg cbd 3 hours before and 50 mg cbd 3 hours after admini-
stration of 5-htp. Based on the pharmacokinetic characteristics  
of cbd, we expected this regimen to result in a relatively constant 
level of cbd during the first hours after administration of 5-htp. 
Subjects
Twelve healthy, male volunteers were recruited from the chdr 
database and from the local student population by means of 
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advertisements. Dropouts were to be replaced with subjects 
assigned to the same treatment randomisation order. A Dutch 
translation of the Structured Clinical Interview for dsm-iv axis I 
(scid i), was used to exclude any subject with a past or present  
psychiatric disorder, including substance abuse (Groenestijn mac 
and Akkerhuis GW, 1999). Other exclusion criteria were abnormali-
ties on physical or laboratory examination or ecg; participation  
in a clinical study within three months prior to the study, or in 
(more than) two studies in the past year; blood donation within 
three months before the study period; a self-admitted chance of  
a HIV positive state; the use of medication other than occasional 
paracetamol in the last months; smoking of more than 5 cigarettes 
per day; an average intake of xanthene containing fluids of more 
than 3 units per day; current average use of alcohol of more than  
3 units per day; or an irregular day-night-rhythm. 
Study days
Volunteers arrived at the Centre for Human Drug Research (chdr) 
at 8.00 in a fasted state, and remained on site for the following 12 
hours. On arrival a urine drug screen (morphine, benzodiazepines, 
cocaine, amphetamine, thc, methamphetamines including 
mdma) was performed. Subjects with a negative drug screen 
received the first oral dose of cbd or placebo (t=-3 hr). This was fol-
lowed by a standardized breakfast, which, like all other supplied 
meals and snacks during their stay, did not contain tryptophan rich 
foods. Subsequently, a cannula was inserted into the antecubital 
vein of one arm to allow withdrawal of blood, an ecg was mounted 
and all baseline measurements were made. At 11.00 hours (t=0 hr), 
5-htp or its placebo was administered and the second dose of cbd 
was given at t=3 hr. At t= 2 hr the volunteers received a glucose 
drink, after cbd administration (t=3hr) a light lunch and at t=7 hr  
a dinner. All challenges were performed under hospital conditions. 
A research physician attended all study occasions. Vital signs were 
monitored at 1 hour before and at t=1, 2, 3, 4, 5 and 6 hours after 
5-htp administration. Blood pressure was measured using a non-
invasive oscillometric system, the Nihon Kohden Lifescoop EC bsm-
1101J/K (Nihon Kohden Co., Oss). For Electrocardiography (12 lead) a 
Nihon Kohden Cardiofax with ECaps 12 software (Nihon Kohden Co., 
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Japan) was used. Oral temperature was measured with a digital 
thermometer (Terumo Corporation, Tokyo, Japan. Occasions were 
separated by a washout period of at least 6 days.
5-htp and cbd
5-htp and cbd were obtained from bufa b.v. (Uitgeest, The Nether-
lands) and prepared by the Department of Clinical Pharmacy of the 
Leiden University Medical Centre. Capsules containing 100 mg 
5-htp and capsules containing 50 mg cbd were made with match-
ing placebos. 
Biochemical measurements
On every challenge day at 1 hour before and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 
5, 6 and 8 hours after 5-htp administration, 9 ml whole blood was 
drawn in a Greiner Vacuette edta-tube, tilted, and immediately 
stored on ice water (4°C). Within one hour blood was centrifuged  
at 4°C for 10 minutes at 2000G. Plasma was divided into four por-
tions, with two portions of at least 1,0 ml for the 5-htp assay, at 
least 1.0 ml for cortisol and prolactin and 0.5 ml for acth. Plasma 
was stored directly at -20°C. The 5-htp assay was performed at the 
Biochemical Laboratory of the Rijngeestgroep, Oegstgeest, The 
Netherlands. After addition of buffer and internal standard, a solu-
tion with 1.55 mol/l trichloroacetic acid, 13.4 mmol/l edta, and 50
mmol/l sodium bisulphite (Na2S2O5) was added to remove pro-
teins. After centrifuging at 3,000 g for 32 minutes, the supernatant 
was assayed by high-pressure liquid chromatography (HPLC) with 
electrochemical detection using 650 millivolts. The HPLC contained 
a Merck LiChroSpher 60, RP Select B5 _m, 125 _4 mm internal diam-
eter plus 1 cm guard column. For the mobile phase, we used a solu-
tion (pH 3,60) with 50 mmol/l sodium acetate (NaAc), 50 mmol/l 
citric acid, 0,27 mmol/l edta, 1,17 mmol/l 1-octanesulfonic acid 
sodium salt, and 1.5% volume- to-volume ratio acetonitrile. The 
lower limits of detection and quantification were 0.5 ng/ml and  
1.7 ng/ml, respectively. The coefficients of variability for precision 
and reliability were 2.6% and 7.9%, respectively. Cortisol and prol-
actin were analysed by an electrochemiluminescention immu-
noassay (eclia) on the Roche Elecsys 1010, and analysis of acth 
84 pharmacological aspects of corticotrophinergic and vasopressinergic function
  tests for hpa axis activation
was performed by radio-immuno-assay, according to methods 
described previously (Gijsman et al., 2002a).
Side-effects
Adverse events were registered from spontaneous reports and 
hourly inquiries. For each symptom, the relationship (definite, 
probable, possible, unknown, definitely not) with the treatment 
was assessed by the research physician. Only side effects judged 
definitely, probably or possibly related to the treatment were con-
sidered in the analyses. Side effects did not necessarily lead to 
dropout from the study. If deemed safe by the research physician, 
subjects who experienced side effects were allowed to participate 
in the following occasion.
Self report questionnaires
The volunteers scored self report questionnaires at 1 hour before 
and 1, 2, 3, 4, 5, 6 and 8 hours after 5-htp administration. The short 
version of the Dutch translation of the Profile of Mood States 
(poms) (McNair DM et al., 1971; Wald FDM and Mellenbergh GJ, 
1990), the Dutch version of the State scale of the Spielberger State-
Trait Anxiety Inventory (stai-dy-1) (Spielberger CD et al., 1983; Wald 
FDM and Mellenbergh GJ, 1990), the somatization-subscale of the 
Dutch Translation and adaptation of the Symptom Check List (scl-
90) (Arrindell WA, 1986; Derogatis et al., 1973) and Visual Analogue 
Scales (as originally described by Norris, for the three factors corre-
sponding to alertness, mood and calmness (Bond A and Lader M, 
1974; Norris, 1971) were used for follow up of subjective effects.  
All Visual Analogue Scales were practised three times during the 
pre-study screening.
Pharmacodynamic analysis
Occasions on which subjects vomited were excluded from pharma-
codynamic analysis, since this would have interfered with the neu-
roendocrine treatment effects. Analyses were performed on sub-
jects of whom the data of at least two non-vomiting occasions 
were available. For each individual, the auc over 4 hour and 8-hour 
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periods were calculated and divided by the corresponding time-
span for all parameters. The resulting time-weighted average effect 
was analyzed using anova with factors subject, treatment and 
occasion. Contrasts of all treatments with placebo were estimated 
within the anova design and presented with 95% confidence 
intervals. The 4 hour period was chosen based on the results of a 
previous study, indicating that most of the effects of 5-htp 100 mg 
with cbd had dissipated after 4 hours (Gijsman et al., 2002a).  
All variables were analyzed untransformed. 
Pharmacokinetic analysis
The 5-htp data were analysed using nonlinear mixed effect model-
ling as implemented in the nonmem program (Version 5, Glo-
bomax LLC, Hanover, md, usa). This ‘population approach’ allows 
the description of the entire data set using a common structural 
model, with allowance for interindividual kinetic variability. Based 
on the population estimates, individual empirical Bayes estimates 
can be generated by nonmem that can be used to generate individ-
ual concentration time profiles. First order conditional estimation 
was used throughout. Data were described using a one-compart-
ment model with first order absorption and a lag-time. Various 
models and parameterisations were attempted. In the final model 
absorption half-life, elimination half-life, oral clearance (Cl/F) and 
lag-time were estimated. Inter-individual variability was modelled 
using a multiplicative model with a correlation between absorp-
tion and elimination half-life. An additive residual error model best 
described the data. 
 Occasions on which subjects vomited were excluded from pri-
mary pharmacokinetic analysis. Analysis was performed on sub-




Twenty-three volunteers were recruited originally, eight of whom 
were excluded at screening. To replace dropouts, three volunteers 
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were recruited in addition to the anticipated 12 subjects. It was 
decided not to recruit more replacements, when blinded interim 
safety analyses suggested that the dropout rate approached 50%  
at the highest dose. The mean age of the 15 participants was 23.2 
years (range 19 – 29 years).
Subject disposition
Study dropouts occurred solely due to nausea and vomiting, at dif-
ferent stages of the study. Of 15 subjects who started, 1/15 dropped 
out after 100 mg (6,6%), 4/14 after 200 mg (28,6%), and 5/11 after 
300 mg (45,5%) 5-htp respectively. Two subjects opted to continue 
the study despite having vomited on the 100 mg and 200 mg occa-
sions respectively, and dropped out after the next higher dose. In 
total nine out of 15 subjects commenced all four occasions, six of 
whom completed all doses without vomiting. The subject disposi-
tion is represented in Figure 1. Different numbers of subjects per 
dosing group were evaluable for the different analyses. For analyses 
of safety and tolerability, all subjects who started with a dose were 
included. Vomiting may have had an impact on both the pharma-
cokinetics of study medication (since the absorption of 5-htp and 
cbd could have been influenced, also considering that in eight out 
of 10 cases of vomiting subjects did not receive their second dose  
of cbd), and on neuroendocrine responses (enhanced pharmaco-
kinetic variability, stress-related cortisol increase and nausea-
induced prolactin elevation). Therefore, subject occasions on which 
a subject vomited were excluded from the primary pharmacokinetic 
and pharmacodynamic endocrine analyses. A secondary analysis 
was performed to investigate whether subjects who vomited were 
more susceptible to the effects of 5-htp or had higher drug levels. 
For this, the neuroendocrine and pharmacokinetic results at 100 mg 
were compared between subjects who never vomited at all (Sub-
group A), and those who did not vomit at 100 mg but did at a higher 
dose (Subgroup B). This approach eliminated the direct influence  
of vomiting on the neuroendocrine reactions or plasma concentra-
tions, but allowed us to identify inherent differences in drug sensi-
tivity or pharmacokinetic characteristics between subjects who 
were prone to vomiting and those who were not.
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Adverse events 
No side effects were reported during the placebo occasion. During 
all 5-htp occasions, nausea occurred most frequently (6/15; 12/14; 
9/11 occasions for 100, 200 and 300 mg respectively). Vomiting 
occurred less frequently but in a dose-related manner (1/15; 4/14; 
5/11 occasions respectively). The main other reported side effects 
were epigastric discomfort (5/15; 5/14; 7/11 occasions respectively), 
dizziness/lightheadedness (1/15; 4/14; 4/11 occasions respectively) 
and drowsiness/sleepiness/tiredness (4/15; 2/14; 0/11 occasions 
respectively). On two occasions during an episode of nausea and 
vomiting at 300 mg, mild disorientation in place and euphoria with 
déja-vu’s occurred respectively.
Self report questionnaires
There were no significant effects on the STAI, poms and visual ana-
logue scales, except for a significant decrease on the poms vigor 
scale (p=0.008), in the 4-hour period after the 200 mg dose. The 
scl-90 subscale somatization showed a significant effect on the 
nausea score for 100 mg (p=0.045), 200 mg (p=0.002), and 300 mg 
(p=0.040) in the 4-hour period. There also was a significant effect 
on the warm/cold score for the 300 mg dose for the 4-hour period 
(p<0.001).
Pharmacokinetics 
The results from the nonmem model as described in the Methods 
section are shown in Table 1. The average concentration-time-
curves for the three different doses of 5-htp are displayed in Figure 
2. 5-htp has dose-proportional pharmacokinetics. The absorption 
and elimination half-lives, which are highly correlated, show a 
large variability. However, these parameters do not determine the 
level of exposure of 5-htp as much as mean oral clearance (Cl/F), 
which has a limited inter-individual variability of 31%. Subjects 
who vomited at higher doses of 5-htp may have had inherently dif-
ferent pharmacokinetic characteristics, leading to higher plasma 
levels at the 100 mg dose, although this dose did not yet lead to 
vomiting. To examine this possibility, we performed a secondary 
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comparison of the 5-htp concentrations at 100 mg between Sub-
group A (n=6) and Subgroup B (n=6), at 4 and 8 hours. No significant 
differences in concentrations could be found. 
Pharmacodynamic effects 
There was a significant dose effect on cortisol and prolactin. The 
auc of cortisol differed significantly from placebo on all three 
occasions for the 4-hour period, which covered the main part of the 
response (Table 2). Figure 3 shows the plasma cortisol responses 
(nmol/l) after the four dose regimens. The effect of acth was short 
lasting and only statistically significant after 200 mg in the 4-hour 
period (Figure 4). The prolactin response reached statistical signifi-
cance only for 100 mg and 200 mg in the 4-hour period, but not  
in the small number of subjects who completed the 300 mg dose 
(Figure 5). To examine the possibility that vomiting subjects were 
more sensitive to the effects of 5-htp, the pharmacodynamic 
responses at the 100 mg dose were compared between Subgroup  
A (n=6) and Subgroup B (n=6). Vomiting subjects showed a larger 
average increase in the auc of the scl Nausea score for the 8-hour 
period after the 100 mg dose, but there were no relationships with 
the cortisol or prolactin responses. 
Discussion
The lack of a standardized serotonergic challenge procedure ham-
pers the application of this potentially useful paradigm in biolo-
gical psychiatry and cns drug development (Gijsman et al., 2004). 
The variability of different serotonergic challenge tests also con-
tributes to the confusion that surrounds many aspects of the role 
of serotonergic systems in psychiatric disease. We have therefore 
set up a series of experiments, with the aim of identifying a repro-
ducible and practical serotonergic challenge procedure. Such a  
procedure would have to be well tolerated, show little pharma-
cokinetic variability, and cause clear reproducible dose-related 
responses of meaningful functions of the central nervous system 
(cns) (Gijsman et al., 2004). 
One of the main aims of this study was to determine the phar-
macokinetic (pk) properties of the 5-htp/cbd-challenge. The study 
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also allowed us to create an impression of the inter- and intra-sub-
ject variability of the challenge. Although the study did not sys-
tematically evaluate all aspects of reproducibility, it did allow an 
assessment of dose-proportionality, and inter- and intra-subject 
variability of different pharmacokinetic properties. The 5-htp/cbd 
-challenge displays clear dose proportional increases in plasma 
concentrations, and the variability of the main pharmacokinetic 
parameter that determines drug exposure, mean oral clearance 
(Cl/F), shows an acceptable inter-individual coefficient of variation 
(iicv) of 31%. Another aspect of the reliability of the challenge can 
be derived from a comparison with a previous study in which a 
lower dose range of 5-htp was examined, which also included 100 
mg 5-htp combined with cbd (Gijsman et al., 2002a). Both studies 
showed quite similar pharmacokinetic characteristics for this chal-
lenge: Mean oral clearance (Cl/F) was 36 L/hr with a 30% iicv in the 
first study, and 28 L/hr with 31% iicv in the current one. The aver-
age elimination tlkb was 3.0 hr in both studies. After oral adminis-
tration, absorption and elimination of 5-htp run in parallel and 
cannot be reliably separated by the pk models used in this study. 
Consequently, these two parameters were highly correlated, and 
their added intersubject variability was considerable. It could not 
be assessed whether variability was largest for absorption or for 
elimination. An inter-individual kinetic variability of about 30% 
seems acceptable for a challenge test, particularly since a non-
invasive challenge will be more acceptable for depressed patients 
than an intravenous infusion, which may also cause stress-related 
cortisol increases. 
It seems reasonable to assume that vomiting may have reduced 
drug absorption, also because this usually interfered with the 
ingestion of the second carbidopa-dose. Subjects who vomited 
were therefore excluded from the primary pharmacokinetic analy-
ses. It is possible that subjects who vomited after 5-htp had higher 
plasma levels or were more sensitive to the drug’s effects. To 
explore this possibility, we compared the effects of 5-htp 100 mg 
between subjects who never vomited at any dose of 5-htp (n=6), 
and those who did not vomit at 100 mg but only at a higher dose 
(n=6). Although both subgroups are too small for statistical com-
fort, they showed quite similar pharmacokinetic profiles of 5-htp 
at the 100 mg dose. Neuroendocrine responses were also very 
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comparable. However, subjects who vomited at a higher dose had 
statistically significant larger nausea scores at the 100 mg dose, 
which had not yet caused vomiting. This suggests that nausea and 
vomiting in these subjects are not due to higher plasma levels, but 
to a larger sensitivity of the pertaining gastrointestinal and/or 
medullar chemoreceptors. This does not seem to be accompanied 
by an increased sensitivity of the other (central) serotonergic sys-
tems that are involved in the release of cortisol or prolactin, since 
these neuroendocrine responses appeared very similar in these 
small subgroups. Before vomiting occurs, nausea does not seem  
to have an influence on the pharmacokinetics of 5-htp. This con-
tributes to the pharmacokinetic reproducibility of the different 
dose regimens of the 5-htp/cbd-challenge.
5-htp 100, 200 and 300 mg plus cbd caused dose-related 
increases in cortisol release, the most reliable response parameter 
for serotonergic challenges. A comparable estimated difference 
from placebo of 91 nmol/l was obtained with the 100 mg dose of 
5-htp plus cbd in the 4 hour period in a previous study (Gijsman et 
al., 2002a). Thus, it seems that the pharmacodynamic reproducibil-
ity of the 5-htp/cbd-challenge is adequate for 100 mg, but this 
remains to be proven for the higher dose range. 
The acth response for the 5-htp 200 mg treatment was statisti-
cally significant compared to placebo. However,at 300 mg the aver-
age response was lower and the increase not did reach statistical 
significance. This could signify a lack of statistical power, due to 
dropouts at the highest dose; an assay variability that was higher 
than for cortisol; and somewhat conservative estimates of treat-
ment effects (ie. overall aucs rather than individual timepoints, 
relatively few measurements etc.). It is unlikely that 5-htp 200 mg 
approached its ceiling effects on crh-acth activation, since this 
would have led to a congruent reduction in cortisol at the highest 
dose. Alternatively, a dose-related cortisol-increase despite a lack 
of a dose-propotional acth-increase could indicate that 5-htp-
induced cortisol-release is partly independent from crh-acth acti-
vation; ie. that at higher doses it occurs at the level of the adrenal 
cortex. This cannot be fully excluded from this study, but there are 
several arguments from previous studies pointing to the contrary. 
acth-release was shown to be induced by 5-htp alone or combined 
with cbd (Imura et al., 1973; Lee et al., 1991), although not all studies 
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confirmed this finding (Gijsman et al., 2002a). Several pharmaco-
logical studies in experimental animals and healthy humans sug-
gest that serotonergic stimulation of cortisol-release involves  
activation of hypothalamic 5-htb (5-htac) receptors (Gartside and 
Cowen, 1990; Jorgensen et al., 2002). In all these studies, the acth-
response preceded the cortisol-response, whereas a primary adre-
nal cortisol-release would have resulted in an acth-reduction. 
Nonetheless, our results cannot fully exclude that the slightly 
lower average acth-response at the highest dose of 5-htp-induced 
was due to negative feedback from an ensuing 5-htp-induced 
adrenal cortisol release. The data itself and most of the literature 
results are compatible with a mixed hypothalamic/pituitary and 
peripheral/adrenal effect for 5-htp, and more research is needed  
to separate these two potentially concomitant processes
The average maximum cortisol level caused by the highest 5-htp 
dose was 609.5 nmol/l. This approaches the effect of a (close to 
maximum tolerated) intravenous mcpp dose of 0.5 mg/kg, which 
leads to an average maximum concentration of around 630 nmol/l 
(Gijsman et al., 1998). Thus, it seems that the 5-htp/cbd-challenge 
with doses of 100-300 mg covers a major part of the maximum 
effect range for cortisol release that can be attained in healthy  
volunteers. The administration of higher doses of both mcpp and 
5-htp was unfortunately impeded by adverse events, including 
nausea and vomiting. These side effects prevent a wider use of  
the 5-htp dosing regimens employed in this study, although these 
otherwise satisfy many of the methodological criteria of an ade-
quate challenge test. Only the lowest dose of 100 mg 5-htp plus 
cbd seems to be tolerated well enough to be of practical use. Dose 
related nausea and vomiting are also the most frequently reported 
side effects in the literature (den Boer and Westenberg, 1990; Mag-
nussen and Nielsen-Kudsk, 1979; Westenberg et al., 1982). Gener-
ally, it seems that plasma concentrations above 1000 mg/l cause 
high rates of nausea and vomiting, which clearly limits the appli-
cability of the 5-htp/cbd-challenge at doses at or above 200 mg. 
In practice, the current 5-htp/cbd-challenge is limited to a  
maximum oral dose of 100 mg. Although this produces cortisol 
responses with an acceptable reproducibility, these are quite  
limited compared to the maximum response that is generated by 
other (less practical or less well tolerated) serotonergic challenge 
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tests. In principle, a challenge does not always have to produce a 
maximum response to show treatment effects or differences 
between patient groups. In fact, (supra)maximal challenges may 
even obscure changes or differences in serotonergic sensitivity 
between different groups by means of ceiling effects or unintended 
neuroendocrine activation through other (less specific or adverse 
effect related) mechanisms. On the other hand, it is also difficult to 
detect differences between patient groups or treatment effects, if 
the challenge test produces a suboptimal stimulation. Therefore, it 
would be preferable to have a challenge test with a larger therapeu-
tic window, covering the main part of the dose response curve 
without unacceptable side effects. One possibility to achieve this 
may be to combine a high-dose 5-htp/cbd-challenge with an anti-
emetic to suppress nausea and vomiting. The most appropriate 
anti-emetic agent needs to be established, because several differ-
ent neurotransmitter systems are involved in drug-induced nausea 
and vomiting, notably serotonin and dopamine, which are also 
involved in the neuroendocrine challenge-responses. Not every 
anti-emetic may be efficacious, and others may interfere with the 
desired serotonergic effects. It remains important to develop a 
serotonergic challenge with all the proper methodological charac-
teristics, to provide a reliable tool for the study of serotonergic 
functions in health and disease. So far, 5-htp 100 mg combined 
with carbidopa 100+50 mg seems to be the best tolerated and most 
reproducible oral serotonergic challenge test.
we would like to thank the staff of the biochemical laboratory of  
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Table 1 Population pharmacokinetic parameters of 5-htp
Parameter Mean sem iicv
Oral clearance (Cl/F, l/hr) 28.0 2.06 31%
Absorption half-life (hr) 0.358 0.0963 22%*
Elimination half-life (hr) 3.02 0.222 122%*
lag-time (hr) 0.407 0.0353 19%
Residual variability (sd) 142
*Correlation coefficient between absorption and elimination; half-life = -0.75; Mean = population average;  
SEM = standard error of the population average; IICV= interindividual coefficient of variation.
Table 2 Pharmacodynamic effects over 4 hours: Least square mean (sd) auc over 4 hours 
of cortisol (nmol/l), prolactin (μU/ml), acth (ng/l) and scl-90 Nausea score and 
estimated difference from placebo with 95% confidence interval for placebo, 100 
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Figure 1 Subject disposition for dropout rate, primary and secondary pharmacokinetic 
analysis, primary and secondary neuroendocrine analyses and safety analyses.5-htp/cbd dosering
100 mg 200 mg 300 mg
Non-vomiting completers available 
for primary analysis per occasion
Drop-out due to nausea and vomiting
Subjects evaluable for safety
Subgroup b (subjects who 
vomited at ) 200mg but 
not at 100mg)
Subgroup a (non-vomiting 
competers for entire study)
15 10  612
 2  42*
 2  1 1
14 1115
* PK failed for 100mg in one subject due to technical reasons, another subject vomited at 100mg; 
both subjects proceeded to the next occasion and subsequently dropped out.
Figure 2 Average graph of predicted and observed 100 mg (n=12), 200 mg (n=10) and  
300 mg (n=6) 5-htp (ng/ml) and cbd co-treatment with sd error bars
Time (min)


















5-htp 100mg + cbd (n=12)
5-htp 200mg + cbd (n=10)
5-htp 300mg + cbd (n=6)
predicted
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Figure 3 Average plasma cortisol (nmol/l) time-course profile after administration of pla-
cebo (n=10), 100 mg (n=12), 200 mg (n=10) and 300 mg (n=6) 5-htp and cbd co-
treatment with sd error bars, and least square mean auc’s over 4 hours. 



















































Figure 4 Average plasma acth (ng/l) time-course profile after administration of placebo 
(n=10), 100 mg (n=12), 200 mg (n=10) and 300 mg (n=6) 5-htp and cbd co-treat-
ment with sd error bars, and least square mean auc’s over 4 hours. 
Time (min)
 















5-htp 100mg + cbd (n=12)
5-htp 200mg + cbd (n=10)
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Figure 5 Average plasma prolactin (μU/l) time-course profile after administration of pla-
cebo (n=10), 100 mg (n=12), 200 mg (n=10) and 300 mg (n=6) 5-htp and cbd co-
treatment with sd error bars, and least square mean auc’s over 4 hours. 
Time (min)
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 * correlation coefficient between absorption and elimination half-life: -0.75 / Mean= Population Average / 
sem= Standard Error of the Population Average / iicv= Inter Individual Coefficient of Variation
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Abstract
background  A recently developed oral serotonergic challenge test consisting of 
5-Hydroxytryptophane (5-htp 200mg) combined with carbidopa 
(cbd 100mg + 50mg) exhibited dose-related neuroendocrine 
responsiveness and predictable pharmacokinetics. However, its 
applicability is limited by nausea and vomiting (Smarius et al.). 
objectives  A randomized, double blind, placebo-controlled, four-way cross-
over trial was performed in 12 healthy male volunteers. The 5-htp/
cbd-challenge was combined with two oral anti-emetics (granise-
tron 2mg or domperidone 10mg) to investigate its reliability when 
side-effects are suppressed. The neuroendocrine response (serum 
cortisol and prolactin), the side-effect profile (Visual Analogue 
Scale Nausea (vas)) and vomiting subjects per treatment were the 
main outcome measures. 
results  Compared to 5-htp/cbd/placebo, 5-htp/cbd/granisetron had no 
impact on cortisol [% change with 95% confidence interval: -7.1% 
(-19; 6.5)] or prolactin levels [-9.6% (-25.1; 9.1)]; 5-htp/cbd/domperi-
done increased cortisol [+13.0% (-4.2; 33.4)] and increased prolactin 
extensively [+336.8% (245.7; 451.9)]. Compared to placebo, vas Nau-
sea increased non-significantly with granisetron [+7.6mm(-1.3; 
16.5)], as opposed to domperidone [+16.2mm(7.2; 25.2)] and 5-htp/
cbd/placebo [+14.7mm(5.5; 23.8)]. No subjects vomited with granis-
etron, compared to two subjects treated with 5-htp/cbd/placebo 
and five subjects with domperidone. Compared to 5-htp/cbd/pla-
cebo, granisetron addition decreased cmax of 5-htp statistically sig-
nificantly (from 1483 ng/ml to 1272 ng/ml) without influencing 
aucjm∞.
conclusions Addition of granisetron to the combined 5-htp/cbd challenge sup-
presses nausea and vomiting without influencing the neuroendo-
crine response or pharmacokinetics, enhancing its clinical applica-
bility in future psychiatric research and drug development. 
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Introduction
Various pharmacological challenge tests have been utilized to 
quantify the integrity and function of serotonergic pathways in the 
human central nervous system (cns). These may be helpful in inno-
vative central nervous system drug development and in delineat-
ing potential biological markers associated with psychiatric disor-
ders. A commonly used serotonergic challenge test encompasses 
single oral administration of 5-Hydroxytryptophane (5-htp), the 
immediate precursor of serotonin (5-ht). 5-ht is formed centrally 
following carboxylation of 5-htp in various serotonergic neurons. 
Subsequently, serotonergic neurons with hypothalamic projec-
tions induce cortisol and prolactin release in peripheral blood, 
probably indirectly via increased corticotrophin-releasing hormone 
(crh) release. Based on this assumption, serum cortisol and prolac-
tin are frequently used neuroendocrine endpoints of serotonergic 
challenges. However, there is little standardisation of 5-htp-chal-
lenge tests, and their use has been hampered by unclear pharma-
cokinetics, and a narrow window between neuroendocrine 
responses and side effects (nausea and vomiting). Combined with 
carbidopa (cbd) to prevent peripheral carboxylation, Smarius et al. 
recently found a 5-htp (100mg, 200mg and 300mg) challenge test 
to have a dose-dependent neuroendocrine responsivity and pre-
dictable pharmacokinetics (Smarius et al.). However, a wider use  
of this challenge test in psychiatric drug development and research 
was thwarted by the frequent dose-dependent occurrence of nau-
sea and vomiting. 100mg 5-htp combined with cbd 100mg + 50mg 
seemed to be the best tolerated and most reproducible oral seroto-
nergic challenge test, but this causes a suboptimal stimulation of 
central serotonergic pathways that may be too small to show dif-
ferences between patient groups or treatment effects. It would 
therefore be preferable to have a challenge test with a larger win-
dow between neuroendocrine effects and side-effects. 
To investigate this objective, two pharmacologically distinct 
anti-emetics were combined with a challenge test consisting of 
200mg 5-htp administered together with cbd in the present study. 
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Methods 
Study design
This study is a randomized, double blind, placebo controlled, four-
way crossover study with the oral administration of 5-htp with  
carbidopa (cbd) co-treatment, combined with two different anti-
emetics with washout periods of at least 4 days. The study protocol 
was approved by the Medical Ethics Committee of Leiden Univer-
sity Medical Centre and performed according to Good Clinical Prac-
tice and International Conference on Harmonisation guidelines. 
Drug administration
The four treatments were: 
1. 5-htpbjj mg /cbdajjpej mg and placebo anti-emetic  
 (5-htp/cbd/placebo); 
2. 5-htpbjjmg /cbdajjpej mg and 10 mg domperidone orally  
 (5-htp/cbd/domperidone); 
3. 5-htp bjj mg /cbdajjpejmg and 2 mg granisetron orally  
 (5-htp/cbd/granisetron); 
4. matched double-dummy placebo. 
The neuroendocrine responses (serum cortisol and serum prolac-
tin) and the side-effect profile (Visual Analogue Scale Nausea, 
Somatic subscale of the Symptoms Check List and number of  
vomiting subjects per occasion) were the main outcome measures.
Subjects
Twelve healthy, male volunteers participated in the study. After 
providing their written informed consent subjects received a full 
medical examination during a pre-study screening. A Dutch trans-
lation of the Structured Clinical Interview for dsm-iv axis I (scid i), 
was used to exclude any subject with a past or present psychiatric 
disorder, including substance abuse (Groenestijn mac et al.). Sub-
jects with a current average use of alcohol of more than 3 units a 
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day or smoking more than 5 cigarettes a day were not allowed to 
participate in this study. No xanthine or tryptophan containing 
foods or beverages, tobacco or alcohol were allowed during the stay 
in the research unit. Concomitant medication other than paraceta-
mol was not permitted during the study period. 
5-htp and cbd
5-htp and cbd were obtained from bufa b.v. (Uitgeest, The Nether-
lands). Granisetron and domperidone were obtained from the 
Department of Clinical Pharmacy of the Leiden University Medical 
Centre. All medication was prepared by the Department of Clinical 
Pharmacy of the Leiden University Medical Centre, including cap-
sules containing 100 mg 5-htp and capsules containing 50 mg cbd 
were made with matching placebos. 
Study days
Volunteers arrived at the Centre for Human Drug Research (chdr) 
in the morning after an overnight fast. Subjects received the first 
oral dose of cbd (100 mg) or placebo (t=-3 hr), which was followed 
by a standardized breakfast. Subsequently, a cannula was inserted 
into the antecubital vein of one arm for blood sampling. Adminis-
tration of either granisetron or domperidone, or its placebo, took 
place at 10.00 hours (t=-1 hr). At 11.00 hours (t=0 hr), 5-htp or pla-
cebo was administered. The second dose of cbd (50 mg) was given 
at t=3 hr after which volunteers received a light lunch and dinner 
(t=7 hr). All challenges were performed under hospital conditions 
and a research physician attended all study occasions. 
Vital signs and biochemical measurements
Vital signs were monitored at 1 hour before and at 1, 2, 3, 4, 5 and  
6 hours after 5-htp administration. Blood pressure was measured 
using a non-invasive oscillometric system, the Nihon Kohden Lifes-
coop EC bsm-1101J/K (Nihon Kohden Co., Tokyo, Japan). For Electro-
cardiography (12 lead) a Nihon Kohden Cardiofax with ECaps 12 soft-
ware (Nihon Kohden Co., Tokyo, Japan) was used. Oral temperature 
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was measured with a digital thermometer (Terumo Corporation, 
Tokyo, Japan). On each study day at 1 hour, 30 minutes and 5 min-
utes before and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6 and 8 hours after 5-htp 
administration, 6 ml whole blood was drawn in a Greiner Vacuette 
edta-tube, tilted, and immediately stored on ice water (0°C). 
Within one hour the blood was centrifuged at 4°C for 10 minutes  
at 2000 g. Plasma was divided into three portions, with at least 
 0.5 ml for cortisol and prolactin and at least 1 ml for the 5-htp 
assay. Any remaining plasma is stored as reserve. Plasma was 
stored directly at -20°C. The determination of cortisol in serum  
was performed with a competitive electrochemiluminescence 
immunoassay (eclia) using a Roche Elecsys 1010 immunoassay 
analyzer (Mannheim, Germany). The sample volume was 20 µL.  
The detection limit was 0.5 nmol/l and the total precision in the 
measuring range was 2%. The prolactin assay was performed in 
serum by electrochemiluminescence immunoassay (eclia) on a 
Roche Elecsys 1010 immunoassay analyzer (Mannheim, Germany). 
The assay employed two monoclonal antibodies specifically 
directed against prolactin. One of the antibodies carried a ruthe-
nium complex label and the other was biotinylated. The 5-htp 
assay was performed at the Biochemical Laboratory of the Rijn-
geestgroep, Oegstgeest, the Netherlands according to methods 
described previously (Gijsman et al. 183-89). 
Side-effects
Adverse events were registered from spontaneous reports and 
hourly inquiries. Only side effects judged definitely, probably or 
possibly related to the treatment were considered in the analyses. 
Side effects did not necessarily lead to dropout from the study. If 
deemed safe by the research physician, subjects who experienced 
side effects were allowed to participate in the following study day. 
Self report questionnaires
The volunteers scored self report questionnaires at 1 hour before 
and 1, 2, 3, 4, 5, 6 and 8 hours after 5-htp administration. The soma-
tization-subscale of the Dutch Translation and adaptation of the 
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Symptom Check List (scl-90) (Arrindell WA) and Visual Analogue 
Scales as originally described by Norris, for the four factors corre-
sponding to alertness, mood, calmness and nausea (Bond A and 
Lader M 211-18) were used for follow-up of subjective effects. The 
volunteers practised all four visual Analogue Scales three times 
during the pre-study screening.
Pharmacodynamic analysis
All pharmacodynamic data were log transformed except vas-Nau-
sea and scl-90. Within the anova design, estimated means (Least 
squared means; lsm’s) of the neuroendocrine parameters (cortisol 
and prolactin) and the side-effect profile (vas-Nausea and scl-90) 
were calculated over eight hours using subject, subject by treat-
ment and subject by time as random factors and treatment, time, 
study day and treatment by time as fixed factors and average pre-
value as covariate. Estimated difference from placebo for all treat-
ments were estimated and presented with 95% confidence inter-
vals. Additionally, difference from 5-htp/cbd/placebo for 5-htp/
cbd/granisetron and 5-htp/cbd/domperidone was calculated. 
Since vomiting could have had an effect on the pd neuroendocrine 
effects, study days on which subjects had vomited were excluded 
from neuroendocrine analysis. vas-Nausea and scl-90 were ana-
lyzed including all study days on which subjects had experienced 
nausea and emesis. 
Pharmacokinetic analysis
cmax, tmax, aucjm∞ and the terminal half-life of 5-htp were cal- 
culated over 8 hours with non-compartmental analysis using 
sas9.1.2. (sas Institute Inc., Cary, usa) The hypothesis that anti-
emetics had no influence on pk parameters of 5-htp was tested  
on aucjm∞ and cmax with a mixed model analysis of variance, with 
treatment as fixed factor and subject as random factor and an 
unstructured covariance structure. Past experience suggests that 
aucjm∞ and cmax are distributed as log-normal, therefore parame-
ters were log transformed before analysis. Since vomiting could 
have influenced the pk, occasions on which subjects vomited were 
excluded from pharmacokinetic analysis.
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Results 
Demographic data and subject disposition
Twelve subjects initially provided informed consent and were 
included in the study (mean age 24 years; range 18 -38 years). One 
subject dropped out during the 5-htp/cbd/placebo treatment due 
to intolerable dizziness and was subsequently replaced. There were 
no drop-outs due to nausea or vomiting on any occasion. 
Adverse events 
The most common side-effect during placebo treatment was head-
ache (6/12 study days). Vomiting occurred in 0/13, 5/12 and 2/13 
study days for the 5-htp/cbd/granisetron, 5-htp/cbd/domperi-
done and 5-htp/cbd/placebo treatments, respectively. Nausea 
occurred more frequently than vomiting (3/13, 8/12 and 6/13 study 
days, respectively). The main other reported side effects during 
active treatment were headache (2/13, 5/12 and 5/13 study days, 
respectively) and dizziness (2/13, 2/12 and 5/13 study days, 
respectively). 
Self report questionnaires
Granisetron seemed effective in suppressing 5-htp induced nau-
sea. Compared to placebo vas-Nausea did not increase signifi-
cantly during the 5-htp/cbd/granisetron treatment, while this was 
the case for both 5-htp/cbd/placebo and 5-htp/cbd/domperidone 
treatments (Table 2). Moreover, scl-90 Nausea was significantly 
lower during the 5-htp/cbd/granisetron treatment compared to 
the 5-htp/cbd/placebo treatment (Table 2, Figure 4).
Pharmacodynamic effects 
Mean cortisol response differed significantly from placebo for all 
three active treatments. The 5-htp/cbd/granisetron induced a cor-
tisol response that differed significantly from placebo but did not 
differ significantly from that induced by 5-htp/cbd/placebo (Table 
2 and Figure 1). Compared with placebo, mean prolactin response 
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increased significantly for the 5-htp/cbd/domperidone and 5-htp/
cbd/placebo treatments, but not the 5-htp/cbd/granisetron treat-
ment. However, the difference between 5-htp/cbd/granisetron 
and 5-htp/cbd/placebo was not statistically significant (Table 2 
and Figure 2). Moreover, the mean increases in cortisol and prolac-
tin during the 5-htp/cbd/ placebo treatment were comparable to 
our previous findings on the same challenge test (Smarius et al.). 
Pharmacokinetics 
Pharmacokinetic parameters for 5-htp are presented in Table 1 and 
the average concentration-time-curves for 5-htp, 5-htp combined 
with domperidone and 5-htp combined with granisetron are dis-
played in Figure 1. 
Discussion
We have demonstrated enhanced tolerability of a serotonergic 
challenge test consisting of 5-htpbjjmg /cbdajj+ejmg with  
addition of the selective 5-htc receptor antagonist granisetron. 
Moreover, the addition of granisetron had no impact on the 5-htp 
induced serum cortisol response or pharmacokinetics of 5-htp. 
After its conversion from 5-htp, serotonin (5-ht) is available for 
non-specific post-synaptic neurotransmission via the 5-htac, 
5-htb, 5-htc and 5-htd receptors. As a result, nausea and vomiting 
ensue as the most intolerable untoward effects. 5-ht induced nau-
sea and vomiting are hypothesized to result from stimulation of 
both peripheral (vagal fibres and chemoreceptor trigger zone (ctz)) 
and central (medulla oblongata and solitary tract nucleus) 5-ht 
receptors (Endo et al. 189-201; Sanger and Andrews 3-16). Granise-
tron strongly and selectively binds to 5-htc receptors and since it 
readily crosses the blood-brain-barrier (bbb) it is believed to exert 
its anti-emetic action both centrally and peripherally (Tan 1563-71). 
Normally, domperidone does not effectively cross the bbb and pre-
dominantly antagonizes db receptors in the pontine vomiting cen-
tre in the area postrema, which lies outside the bbb. The dopamine 
(da) receptor antagonists are believed to exert their anti-emetic 
action by antagonism of the db-receptor (db) in the area postrema 
(Mitchelson 295-315) but the actual source of dopamine release 
109 chapter 5 • 5-htp/carbidopa combined with granisetron
modulating nausea and emesis is unknown. Therefore, although 
there is a clear rationale on how db antagonists prevent emesis 
evoked by dopamine agonists (eg. l-dopa in Parkinson’s disease), 
it is not clear how they inhibit emesis associated with other condi-
tions (eg. chemotherapy, post-operative nausea). Domperidone 
was not effective in curbing nausea and vomiting, indicating that 
these symptoms are not mediated by (indirect) serotonergic stimu-
lation of pontine dopamine systems.
Compared with previous investigations of our serotonergic  
challenge (Smarius et al.) the addition of granisetron in this trial  
to the combined 5-htp/cbd challenge test did not significantly 
influence 5-htp induced serum cortisol release. Also, the mean 
maximal serum cortisol concentration attained with5-htpbjjmg /
cbdajj+ejmg /granisetron (465.8 nmol/l) was very similar to that 
attained with5-htpbjjmg /cbdajj+ejmg without anti-emetic (455.9 
nmol/l) in our previous trial (Smarius et al.). This concentration 
approaches the maximal one attained with a previous (close to 
maximum tolerated) intravenous meta-chlorophenylpiperazine 
(mcpp) dose of 0.5 mg/kg, which lead to an average maximum 
serum cortisol concentration of around 630 nmol/l (Gijsman et al. 
289-95). Thus, it seems that the combined 5-htp/cbd/granisetron 
challenge covers a major part of the maximum range for serum  
cortisol release that can be attained in healthy volunteers, without 
being hampered by nausea and vomiting. Challenge tests are used 
to show changes in responsivity of a particular system, in this case 
the hpa-axis, during pathological conditions or treatments. There-
fore, it is essential that the level of stimulation of the hpa-axis with 
this newly developed challenge (5-htp/cbd/granisetron) is neither 
too small to show decreases, nor too large to show increases. 
The combined 5-htp/cbd/domperidone challenge was associ-
ated with significant hyperprolactinemia in comparison with the 
5-htp/cbd/placebo and 5-htp/cbd/granisetron treatments. Pro-
lactin release is believed to depend not only on the stimulation of 
the postsynaptic 5-htb receptors (Van de Kar et al. 203-08), but also 
on tonic inhibition by the neurotransmitter dopamine (da). Pre-
treatment with the Db antagonist domperidone caused a mean 
increase in prolactin of roughly 400% compared to 32% and 17% 
for the 5-htp-challenge with placebo and granisetron respectively. 
Prolactin release is a well-known effect of Db-antagonism, but the 
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limited (albeit statistically significant) prolactin increase by 5-htp 
with or without granisetron demonstrates that prolactin can also 
be stimulated directly by serotonergic mechanisms.
Compared to 5-htp/cbd/placebo, pretreatment with granisetron 
lead to a statistically significant decrease in cmax of 5-htp of 14 ng/
ml (from 1483 to 1272 ng/ml) without influencing its aucjm∞. It 
would perhaps have been expected that an anti-emetic would 
improve absorption, rather than reduce it. However, the difference 
was small and it could be spurious or due to a more erratic absorp-
tion of 5-htp without an anti-emetic, as a manifestation of gastro-
intestinal side-effects.
There is some controversy regarding the pharmacological mech-
anisms of serotonergic stimulation of the hpa axis. Our studies 
show that serotonin-induced hpa axis activation is not critically 
dependent on 5-htc-receptors. Furthermore, previous experiments 
found no effects of granisetron on 5-htp induced acth release 
(Gartside and Cowen 103-09). Studies in experimental animals and 
healthy humans suggest that activation of central post-synaptic 
5-hta or 5-htac) receptors is involved (Jorgensen et al. 788-95).
The current challenge is composed of three different medica-
tions, to improve the pharmacokinetic stability and tolerability  
of the test. Despite this complexity, we believe that the improved 
reproducibility and reduced side effect profile of the combined 
5-htp/cbd/granisetron-test renders it more acceptable as a prac-
tical serotonergic challenge test in clinical research. Such a test 
could be used to show biochemical/neuroendocrine differences 
between healthy individuals and individuals (at risk of) suffering 
from hpa-axis related psychiatric disease. It could also be useful  
in innovative drug development, to study the effects of neuro-
modulatory agents that may have few specific pharmacological 
cns-effects of their own in healthy subjects, but which are 
expected to indirectly affect serotonergic functionality. For exam-
ple, specific serotonin reuptake inhibitors (ssri’s) have few consis-
tent effects in healthy subjects (Dumont et al. 495-510), but cause 
clear changes in sensitivity to serotonergic challenges. ssri’s like 
paroxetine (Sargent, Williamson, and Cowen 49-52) or citalopram 
(Lowe et al. 473-84) cause an increase in 5-htp-induced cortisol 
release. Furthermore, this sensitivity changes over time. Initially, 
5-htp-induced cortisol release is augmented in combination with 
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paroxetine, but this diminishes during three weeks of continued 
ssri-treatment (Sargent, Williamson, and Cowen 49-52). These 
changes may indicate a decrease in serotonergic sensitivity during 
chronic ssri-dosing. This may be related to down-regulation of 
(post synaptic 5ht2) serotonin receptors, which has also been 
implicated in the delayed therapeutic action of ssris. 
An improved serotonergic challenge may be a very useful instru-
ment to investigate the physiology of serotonergic systems in 
health and disease, and its changes over time under different con-
ditions or treatments. Addition of granisetron to the oral 5-htp/
cbd challenge (Smarius et al.) has enlarged the window between 
the neuroendocrine pharmacodynamic effects and the adverse 
side-effects of this serotonergic challenge. 
we would like to thank mrs. jolanda verhagen, laboratory 
technician at the department of clinical chemistry of the 
leiden university medical centre who has invested much  
time and effort in developing the 5-htp assay and has been 
primarily responsible for its measurement during our series 
of 5-htp trials.
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Table 1 Pharmacokinetic parameters for 5-htp: Least square mean (SE) of cmax (ng/ml) 
and auc0-∞ (min*ng/ml) with estimated difference from 5-htp/cbd with 95% 
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Figure 1 Average time profile of serum 5-htp (ng/ml) over 8 hours for the treatments 
5-htp/cbd (n=13), 5-htp/cbd/domperidone (n=12) and 5-htp/cbd/granisetron 
(n=12) with sd error bars.



















5-htp  200mg + cbd (n=13)
5-htp  200mg + cbd + domperidone (n=12)
5-htp  200mg + cbd + granisetron (n=12)
Time (min)
Figure 2 Estimated means (nmol/l) with sd error bars and estimated change from placebo 
(%) for serum cortisol after administration of placebo (n=12), 5-htp/cbd (n=11), 
5-htp/cbd/domperidone (n=7), 5-htp/cbd/granisetron (n=13), excluding data of 
study days on which subjects vomited. 
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Figure 3 Estimated means (μg/l) with sd error bars and estimated change from placebo 
(%) for serum prolactin after administration of placebo (n=12), 5-htp/cbd (n=11), 
5-htp/cbd/domperidone (n=7), 5-htp/cbd/granisetron (n=13), excluding data of 
study days on which subjects vomited.
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Figure 4 Estimated mean change from baseline (5 point scale) and estimated change from 
placebo for scl-90 Nausea after administration of placebo (n=12), 5-htp/cbd 
(n=12), 5-htp/cbd/domperidone (n=12), 5-htp/cbd/granisetron (n=13) with sd 
error bars, including all data.
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Abstract
  The synthetic vasopressin (avp) analogue desmopressin (ddavp) 
has been used as pharmacological function test to quantify vaso-
pressinergic co-activation of the hypothalamus-pituitary-adrenal 
(hpa) axis in the past. Such exogenous vasopressinergic stimula-
tion may induce confounding cardiovascular, pro-coagulatory and 
anti-diuretic effects and low endogenous corticotrophin-releasing-
hormone (crh) levels may limit its potential to reliably assess co-
activation. Alternatively, the dopamine-2-(Db)-antagonist metoclo-
pramide is believed to induce co-activation indirectly by releasing 
endogenous avp. We investigated this indirect co-activation with 
metoclopramide under conditions of low and enhanced endoge-
nous crh-release in healthy volunteers. A randomized, double-
blind, placebo-controlled, four-way crossover study was performed 
in 12 healthy males. crh-release was induced by administering an 
oral 5-hydroxytryptophan (5-htp) 200mg function test. Co-activa-
tion was investigated by administering metoclopramide 10 mg 
intravenously around the expected maximal effect of 5-htp. The 
neuroendocrine effects were compared to those of metoclo-
pramide alone, the 5-htp test alone and matching placebo. Meto-
clopramide safely induced hpa-axis activation by itself, and 
potently synergized 5-htp-induced corticotrophinergic activation 
of the hpa-axis. These findings are indicative of vasopressinergic 
co-activation and suggest a role for metoclopramide as a practical 
function test for co-activation of the hpa-axis. However, its appli-
cation will be hampered pending clarification of the exact pharma-
cological mechanism by which metoclopramide induces co-activa-
tion of the hpa axis. 
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Introduction
Corticotrophin-releasing hormone (crh) and arginine-vasopressin 
(avp) are the major neuropeptide activators of the hypothalamus-
pituitary-adrenal (hpa) axis (Aguilera and Rabadan-Diehl, 2000; 
Ring, 2005; Scott and Dinan, 1998). Under physiological circum-
stances, crh acts as major neuroendocrine secretagogue that 
induces corticotrophinergic hpa activation via pituitary crha 
receptors (crha), while avp by itself has weak neuroendocrine 
properties and induces vasopressinergic co-activation of the hpa  
at pituitary vasopressin 3 receptors (vc, also referred to as Vab 
receptor) (Ring, 2005; Scott and Dinan, 1998; Scott and Dinan, 
2002). Following acute stress, avp releases adrenocorticotrophic 
hormone (acth) synergistically in the presence of increased levels 
of crh (DeBold et al., 1984; Favrod-Coune et al., 1993; Lamberts et 
al., 1984). During chronic stress, either increased avp synthesis 
and/or release, increased vc responsivity and/or expression 
(Goekoop and Wiegant, 2009), genetic polymorphisms of the vc-
receptor (Dempster et al., 2007) or a combination of these factors  
is hypothesized to lead to chronic hpa hyperactivity (Aguilera and 
Rabadan-Diehl, 2000; Volpi et al., 2004). In this context, sustained 
vasopressinergic co-activation has been implicated in stress-
related psychopathology (Dinan et al., 2004; Dinan and Scott, 
2005; Holsboer, 1983; Holsboer et al., 1984b; Volpi et al., 2004).  
A pharmacological function test that quantifies vasopressinergic 
co-activation would therefore be a useful tool to study this func-
tional component of the hpa-axis in health and disease, and during 
treatments directed at the vasopressinergic system.
 The synthetic analogue of avp, desmopressin (ddavp) is fre-
quently applied as pharmacological function test for vasopressin-
ergic co-activation (Dinan et al., 1999; Dinan et al., 2004). It stimu-
lates the vc receptor directly in the presence of (endogenous) crh, 
inducing pituitary acth and subsequent adrenal cortisol release. 
Most experiments with ddavp in healthy volunteers occur in the 
mid-morning when hpa-axis activity and endogenous crh levels 
are relatively low. Since avp acts in synergy with crh, 10 µg ddavp 
induces small and (frequently) variable co-activation under low 
crh activity (Dinan et al., 1999; Dinan et al., 2004; Jacobs et al., 
2009). Too small or too variable responses limit the test’s 
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informative value and would not allow for an accurate assessment 
of conditions or treatments that modulate vasopressinergic co-
activation. Recent studies have shown that doses higher than 10µg 
ddavp alone may not produce much more acth- or cortisol release 
during baseline conditions (Jacobs et al., 2009). Moreover, higher 
ddavp doses may cause (confounding) cardiovascular, pro-coagu-
latory and anti-diuretic effects which would limit its tolerability 
and applicability (Jacobs et al., 2009). Alternative ways of inducing 
informative vasopressinergic co-activation therefore need to be 
explored.
 One approach would be to stimulate endogenous release of avp 
instead of exogenous stimulation of vc receptors. The Db-receptor 
antagonist anti-emetic metoclopramide has been shown to acti-
vate the hpa-axis (Chiodera et al., 1986; Seki et al., 1997; Walsh et al., 
2005). It is hypothesized to produce vasopressinergic co-activation 
by endogenously releasing avp from the pituitary and/or hypotha-
lamus, through a hitherto unclear pharmacological mechanism 
(Chiodera et al., 1986; Nomura et al., 1984). If this were the case, 
metoclopramide would not affect crh levels and would induce 
small neuroendocrine responses that are comparable to those 
achieved by ddavp under low crh activity. Stimulation of the  
crh system by exogenous administration of human corticotrophic 
release hormone (hcrh) induces considerably greater hpa-axis acti-
vation (Dinan et al., 1999; Holsboer, 1983; Holsboer et al., 1984a; von 
Bardeleben and Holsboer, 1988). Alternatively, serotonergic (precur-
sor) agents can be used as endogenous corticotrophinergic stimu-
lants of the hpa-axis (Dinan et al., 1999; Gijsman et al., 1998; Gijs-
man et al., 2002; Smarius et al., 2008). A serotonergic function test 
consisting of 5-hydroxytryptophan (5-htp) has been developed for 
this purpose (Jacobs et al., 2008a). 5-htp is the direct precursor of 
serotonin (5-ht) and is centrally converted into 5-ht. Enhanced 
5-ht release stimulates crh release via postsynaptic 5-htba or 
5-htbc receptors in the paraventricular nucleus (pvn) of the hypoth-
alamus (Gartside and Cowen, 1990; Jorgensen et al., 2002). The neu-
roendocrine response associated with the endogenous release of 
crh (by administering 5-htp) is therefore expected to be syner-
gized by endogenously released avp (with metoclopramide). More-
over, such an effect would be an (indirect) indication of vasopress-
inergic co-activation of the hpa-axis with metoclopramide. 
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We examined metoclopramide’s effect on neuroendocrine hpa-axis 
activation under physiological circumstances (by administering 
metoclopramide alone) and under enhanced crh-mediated activa-
tion of the hpa-axis (by administering the 5-htp function test fol-
lowed by metoclopramide) in healthy male volunteers. 
Experimental Procedures 
Study design
The study protocol was approved by the Medical Ethics Committee 
of Leiden University Medical Centre (lumc) and performed accord-
ing to Good Clinical Practice and International Conference on Har-
monisation (GCP-ICH) guidelines. A randomized, double-blind, 
double-dummy placebo-controlled, four-way crossover trial was 
performed in 12 healthy volunteers. 
Main outcome measures
The main pharmacodynamic (pd) outcome measures were the neu-
roendocrine effects (serum acth, cortisol, prolactin and avp) of 
10mg metoclopramide, the 200mg 5-htp function test, and 10mg 
metoclopramide combined with the 200mg 5-htp function test. 
Also, adverse events (ae’s) were recorded to assess the safety and 
tolerability of concomitantly administered metoclopramide and 
the 5-htp function test.
Drug administration
The 5-htp function test was administered according to the proce-
dure described previously (Jacobs et al., 2008a; Smarius et al., 
2008). It consisted of the administration of carbidopa 100 mg (at 
t=-180 minutes to reduce peripheral metabolism of 5-htp) and 
granisetron 2 mg (at t=-60 minutes to prevent nausea and vomit-
ing), followed by a single oral dose of 5-htp 200 mg (at t=0 min-
utes) and a repeat dose of carbidopa 50 mg (at t=180 minutes). 
Metoclopramide 10 mg was administered intravenously (i.v.) one 
hour following the administration of 5-htp, which was expected  
to coincide with the maximal effect (emax) of 5-htp according to 
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previous experiments. For all three active drugs, matching double-
dummies were administered as placebo. A schematic overview of 
the four different treatments is provided in table 1. 
Volunteers
Twelve healthy, male volunteers participated in the study. After 
obtaining written informed consent, the volunteers underwent  
a full medical screening to assess eligibility. Volunteers with a  
current average use of alcohol of more than four units a day or 
smoking more than five cigarettes a day were not allowed to par-
ticipate in this study. Volunteers with a significant personal or 
family history of psychiatric disorder according to dsm-iv, a his-
tory of movement disorder (including movement disorder due to 
D-antagonists) and with past or present recreational use of meth-
amphetamines, mdma or ‘ecstasy’, were excluded from study 
participation. Xanthine or tryptophan containing foods or bever-
ages, tobacco or alcohol were not allowed during the stay in the 
research unit. Concomitant medication other than paracetamol 
was not permitted from two weeks preceding and during the 
study period. 
Study drugs
5-htp and carbidopa were obtained from bufa b.v. (Uitgeest,  
The Netherlands). Granisetron and metoclopramide were obtained 
from the Department of Clinical Pharmacy of the lumc. All medi-
cations and their respective placebos were prepared by the Depart-
ment of Clinical Pharmacy of the lumc, including 100 mg 5-htp,  
50 mg carbidopa and 2mg granisetron in capsules, and syringes 
containing 10mg metoclopramide.
Study days
Volunteers arrived at the Centre for Human Drug Research (chdr) 
on the evening prior to each study day. On admission urinary 
screening was performed for drug of abuse using the OnCall Test, 
ACON laboratories, Inc. Rapid Assays for Drug Abuse (Instruchemie 
Hilversum B.V. the Netherlands). Volunteers went to bed at 23.00h 
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and were woken up around 8.00h the next morning. Subjects 
received the first oral dose of carbidopa (100 mg) or placebo (t=-180 
minutes), which was followed by a standardized breakfast. An 
intravenous cannula was inserted into the antecubital vein of each 
arm for blood sampling and intravenous administration of study 
medication. This occurred at least 1 hour preceding the first pd 
blood sampling to allow potential procedure-related hpa-axis acti-
vation to return to baseline. Administration of granisetron or its 
placebo took place at t=-60 minutes. At t=0 minutes 5-htp or pla-
cebo was administered and followed by metoclopramide or placebo 
at t=60 minutes and the second dose of carbidopa (50 mg) at t=120 
minutes. A standard light lunch was served at t=130 minutes and 
dinner followed at t=420 minutes. 
Neuroendocrine assays
Venous blood (1.2ml; prechilled edta tubes) was collected for the 
determination of plasma acth on -120, -60 before and 1, 30, 55, 70, 
80, 90, 105, 120, 150, 180, 240, 300 and 540 minutes after the admin-
istration of 5-htp. Samples were immediately placed on ice, proc-
essed within 30 minutes and stored at -80°C. acth was determined 
with a solid-phase, two-site sequential chemiluminescent immu-
nometric assay using an Immulite 2500 immunoassay analyzer 
from DPC (Los Angeles, usa) at the laboratory for clinical chemistry 
of lumc. The detection limit for acth was 1.1 pmol/l and the total 
precision in the measuring range was about 5%. Venous blood 
(1.2ml; serum tubes) for the assay of serum cortisol and prolactin 
was taken at -120, -60 before and 1, 30, 55, 90, 120, 150, 180, 210, 240, 
300, 360, 420 and 540 minutes after the administration of 5-htp. 
Samples were stored for 30 – 45 minutes at ambient temperature to 
allow coagulation, subsequently centrifuged for 15 minutes at 
2000 x g and stored at -20 °C. Serum cortisol and prolactin were 
determined using an in-house AutoDELFIA (Perkin Elmer Lifesci-
ences) assay at Organon Development GmbH, Department of Bio-
analytics, Waltrop, Germany. Cortisol was measured with a solid 
phase time-resolved fluoroimmunoassay based on the competitive 
reaction between Europium-labelled cortisol and sample cortisol. 
The fluorescence was inversely proportional to the concentrations 
of cortisol in the samples. Prolactin was measured using a solid 
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phase, two-site fluoroimmunometric assay based on the direct 
sandwich technique. The fluorescence was proportional to the  
concentration of prolactin in the sample.
avp assay
Venous blood (5ml, prechilled K3 edta Aprotonin tubes) was col-
lected for the determination plasma avp on 1, 30, 55, 70, 80, 90, 105, 
120, 150 and 200 minutes after the administration of 5-htp. Sam-
ples were centrifuged directly after homogenisation for 15 minutes 
at 2000 x g at 4 °C and stored immediately at -20 °C. avp was iso-
lated from the edta plasma by solid phase extraction. The final 
plasma extract was analyzed by a Radio Immuno Assay (RIA) (Bühl-
mann Laboratories AG, Schönenbuch, Switzerland) based on the 
competition between radioactive [IABE]-labelled and non-radioac-
tive vasopressin for a fixed number of antibody binding site by 
Xendo Drug Development BV, Groningen, the Netherlands
5-htp assay
Venous blood (2.6ml; serum tubes) for the determination plasma 
5-htp was taken at 1, 30, 55, 90, 120, 150, 180, 210, 240, 270, 300, 340, 
420 and 540 minutes after the administration of 5-htp. Samples 
were immediately placed on ice, centrifuged for 15 minutes at 2000 
x g and stored directly at -20 °C. After addition of buffer and inter-
nal standard, a solution with 1.55 mol/l trichloroacetic acid, 13.4 
mmol/l edta and 50 mmol/l sodium bisulphite (Na2S2O5) was 
added to remove proteins. After centrifuging at 3000g for 32 min-
utes, the supernatant was assayed by highpressure liquid chroma-
tography (HPLC) with electrochemical detection using 650mV. The 
HPLC contained a Merck LiChrospher 60 RP-Select B, 5_m, 125 _ 4 
mm internal diameter plus 1cm guard column. For the mobile 
phase, we used a solution (pH 3.60) with 50 mmol/l sodium acetate 
(NaAc), 50 mmol/l citric acid, 0.27 mmol/l edta, 1.17 mmol/l 
1-octanesulfonic acid sodium salt and 1.5% volume-to-volume 
ratio acetonitrile. The lower limits of detection and quantification 
were 0.5 and 1.7 ng/ml, respectively. The coefficients of variability 
for precision and reliability were 2.6 and 7.9%, respectively. Sam-
ples were analyzed at the laboratory for clinical chemistry of lumc.
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Metoclopramide assay
Venous blood (1.8ml; 1.109M citrated tubes) for the determination 
of plasma metoclopramide was taken at 235, 270, 300, 420 and 600 
minutes for subjects 1-6 and 250, 285, 361, 480 and 720 minutes for 
subjects 7-12 after the administration of 5-htp. Samples were cen-
trifuged for 10 minutes at 2000 x g at 4°C and 0.5ml plasma was 
transferred and stored at -20°C. A sensitive and specific hplc-ms/
ms (Waters 2790, Applied Biosystems API-4000) method was devel-
oped for the quantitative determination of metoclopramide in 
human plasma. Plasma samples were prepared by liquid-liquid 
extraction using ethylether and separated on an Alltima C18 col-
umn with 5mM ammonium acetate (pH=5.0): acetonitrile: metha-
nol = 50: 40: 10 (v/v) as the mobile phase. Detection was performed 
on a triple-quadruple tandem mass spectrometer using positive 
electro spray ionization (ESI), and multiple reaction monitoring 
(mrm) was applied. The lowest limit of quantification of metoclo-
pramide was 0.5ng/ml, and the linear range was 0.5 -200 ng/ml. 
Accuracies and precisions of all were within ±15%. Samples were 
analyzed at the Clinical Pharmacology Research Centre of Peking 
Union Medical College Hospital (pumc), Beijing, China.
Vital signs
Blood pressure and pulse rate were measured using the Nihon-Koh-
den (bsm-1100) or Colin (Pressmate bp-8800) blood pressure appa-
ratus. Electrocardiogram (ecg) recordings were made at t=-15 min-
utes and t=175, 230, 300 and 600 minutes. 
Pharmacodynamic (pd) analysis
acth, serum cortisol and prolactin were log-transformed prior to 
analysis to correct for the expected log-normal distribution of the 
data. Repeatedly measured pharmacodynamic data were analyzed 
with a mixed model analysis of variance with fixed factors treat-
ment, period, time and treatment by time, random factor subject, 
subject by treatment and subject by time and the average pre-
value as covariate, using SAS for windows V9.1.2 (SAS Institute, Inc., 
Cary, NC, usa). Initially, the treatments 5-htp and 5-htp/meto-
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clopramide were planned to be analyzed over the period 0 to 180 
minutes. Since metoclopramide was administered at t=60 minutes, 
metoclopramide was to be contrasted for the period 60 to 180 min-
utes. However, a blinded data review showed that lunch at t=130 
induced unexpectedly large and highly variable surges in both 
acth and cortisol. It was therefore decided prior to statistical anal-
yses to change the planned analyses for the periods 0 to 180 min-
utes and 60 to 180 minutes, to 0 to 130 minutes and 60 to 130 min-
utes. Some volunteers vomited probably due to the serotonergic 
effects of 5-htp. Since vomiting could influence the neuroendo-
crine response, five of the 60 study occasions were excluded a  
priori from the neuroendocrine analyses: three for 5-htp and two 
for 5-htp combined with metoclopramide. Testing for co-activation 
was complicated by the fact that metoclopramide was adminis-
tered 60 minutes after 5-htp or its placebo. At that time, the neu-
roendocrine values were higher when metoclopramide was admin-
istered during the 5-htp test than after the placebo challenge. 
Log-transformation of these data would have produced percentual 
changes from dissimilar pretreatment values. Instead, it was 
decided to perform an analysis for co-activation based on the 
untransformed acth and cortisol values rather than on Log-trans-
formed data, with the following arguments. If there was no syner-
gism or other form of interaction between metoclopramide and 
the 5-htp challenge, each pharmacological intervention would 
cause an independent absolute increase of acth and cortisol. In 
this case, the null hypothesis is that the absolute effects of meto-
clopramide added to those of the 5-htp challenge do not differ 
from the absolute responses after the combination, even if pre-
treatment values are not the same. In case of co-activation, the 
effects of the combination would be larger than the summed 
effects of the individual tests. Based on this reasoning, the null 
hypothesis was tested by contrasting the absolute untransformed 
effects of 5-htp combined with metoclopramide minus 5-htp 
alone, with those of metoclopramide alone minus placebo.
Pharmacokinetic analysis (pk)
The mean cmax, tmax, terminal half life, clearance and aucjm∞  
for metoclopramide and 5-htp were calculated with noncom- 
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partmental analysis using WinNonLin Professional for windows 
V5.0 (Pharsight Corporation, 800 West El Camino Real, Suite 200, 
Mountain View, CA 94040).
Side-effects
Adverse events were registered from spontaneous reports and 
hourly inquiries. 
Results 
Subject disposition and demographic data
Thirteen volunteers were screened after having provided informed 
consent. One subject did not comply with the inclusion criteria and 
was excluded from participation. Twelve volunteers received study 
medication, of which one discontinued due to personal circum-
stances after having completed the third study period. This subject 
was not replaced. Participants had a mean age of 25 years (range  
19 - 42 years) and a mean BMI of 23.4 kg/mB (range 20 - 27 kg/mB).
Adverse events 
All ae’s were of mild to moderate intensity, transitory in nature  
and had mostly dissipated within 12 hours after drug administra-
tion. ae’s were in line with the side-effect profile described in the 
Summary of Product Characteristics of 5-htp and metoclopramide. 
No subjects discontinued participation directly related to adverse 
effects. The most commonly occurring ae’s were headache (1/12 
subjects) for placebo; headache (4/12 subjects), dizziness (4/12 sub-
jects), nausea (8/12 subjects), abdominal discomfort (5/12 subjects) 
and vomiting (2/12 subjects) for 5-htp; dizziness (2/12 subjects), 
drowsiness (2/12 subjects), nausea (5/12 subjects) and vomiting 
(2/12 subjects) for 5-htp/metoclopramide; and drowsiness (4/12 
subjects) for metoclopramide respectively. One subject experi-
enced a reversible QTc prolongation during the 5-htp/metoclo-
pramide treatment.
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Neuroendocrine effects 
The least square means (lsm’s) for acth and cortisol are presented 
respectively in figure 1 and figure 2. These changes are expressed as 
estimates of percentual difference from placebo, with 95% confi-
dence intervals (table 2) and maximal mean concentrations (cmax). 
acth increased by +43.9(23.4, 67.8)% (cmax 30.2ng/l) with 10mg 
metoclopramide, by +55.4(31.9, 83.1)% (cmax 26.2ng/l) after 200mg 
5-htp and by +167(127, 214)% (cmax 60.6ng/l) following 200mg 5-htp 
combined with 10mg metoclopramide. Metoclopramide combined 
with 5-htp induced larger acth responses than either 5-htp or  
metoclopramide alone (table 2). The additive effect of metoclopra-
mide combined with 5-htp was statistically significant [+52.6(27.1, 
83.2)%] compared to the effect of 5-htp alone. The combination of 
5-htp and metoclopramide lead to an increase in acth that was  
significantly greater than the sum of the increases induced by 5 
-htp alone and metoclopramide alone [+9.3 (2.8, 15.8)ng/l].
 Cortisol increased similarly by +64.0(40.4, 91.6)%, (cmax 145µg/l) 
after 10mg metoclopramide, by +48.1(29.2, 69.8)%, (cmax 191.4 µg/l) 
with 200mg 5-htp and by +141(104, 184)%, (cmax 209µg/l) following 
200mg 5-htp combined with 10mg metoclopramide (table 2). Meto-
clopramide combined with 5-htp also had a statistically significant 
effect on cortisol release [+21.8(1.0, 46.9)%] compared to 5-htp alone. 
 Prolactin was increased by +995(824, 1197)% after 10mg metoclo-
pramide, +19.0(0.8, 40.5)% with 200mg 5-htp and by +926(753, 
1134)% following 200mg 5-htp combined with 10mg metoclo- 
pramide (table 2). Plasma avp levels remained unaffected by either 
treatment combination (table 2). 
Pharmacokinetics (pk) 
The oral administration of 5-htp lead to a mean cmax of 1319 µg/l 
while the oral administration of 5-htp followed by i.v. metoclopra-
mide had a mean cmax of 1302 µg/l. These mean maximal concen-
tration occurred around 170 minutes after the oral administration  
of 5-htp in both instances and did not differ significantly from  
one another. The mean maximal metoclopramide concentrations 
(cmax) were comparable with i.v. administration leading to a mean 
cmax of 58.1 µg/l in the absence of 5-htp and a mean cmax of 61.1 µg/l 
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in the presence of oral 5-htp. Since 5-htp was not sampled suffi-
ciently until the end of its concentration curve, the terminal half-
life was not accurately determinable (Table 3). 
Discussion
Metoclopramide activated the hpa-axis under physiological cir-
cumstances/crh concentrations: 10 mg administered i.v. induced 
higher maximum mean acth levels (cmax 30.2 ng/l) than those 
induced previously with the avp-analogue ddavp (cmax 15.9 ng/l - 
19.3 ng/l) (Jacobs et al., 2009), but decisively lower maximum mean 
acth levels than those induced by the crh-mediated agents 5-htp 
(cmax 55.2 ng/l) in this trial and hcrh (cmax 80 ng/l - 115 ng/l) in pre-
vious trials (Scott and Dinan, 1998; von Bardeleben and Holsboer, 
1988). Contrary to previous findings, metoclopramide did not 
increase (peripheral) avp levels in this study. Metoclopramide has 
predominant Db receptor antagonist properties and is hypothe-
sized to induce vasopressinergic hpa-axis activation by releasing 
avp into the portal system, which results in pituitary vc receptor 
stimulation and acth-release. Previously, metoclopramide 10mg 
administered i.v. induced significant avp release and subsequent 
hpa-axis activation in healthy volunteers and a group of schizo-
phrenic patients (Chiodera et al., 1986; Nomura et al., 1984; Seki et 
al., 1997; Walsh et al., 2005). On the other hand, metoclopramide 
failed to increase avp in isolated neuropituitary tissue, indicating 
that it might also exert its effect in the hypothalamus (Pitzel and 
Konig, 1984). Although these observations formed the basis of our 
study, it should be realized that hpa-axis activation with metoclo-
pramide has not unequivocally been shown to be mediated by (por-
tal) avp-release. Furthermore, variable maximum increases in avp 
(varying between 0.2 and 1.9 pg/ml) have been reported previously 
(Chiodera et al., 1986; Nomura et al., 1984). Such variability in avp 
release may be explained by methodological issues, since most 
previous experiments were not properly placebo controlled. Also, 
the measurement of peripheral avp plasma concentrations is tech-
nically complicated, and peripheral changes might not necessarily 
reflect central avp production because avp can also be released 
from other sources. Finally, avp release in rats following stress is 
short-lived and avp returns to basal levels within a question of 
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minutes (Engelmann et al., 2004). This would imply that our sam-
pling scheme was probably not optimal to detect such changes, 
at least if avp release were to be comparable in humans. Notwith-
standing these difficulties, we demonstrated that metoclopramide 
by itself can activate the hpa-axis and is associated with mean 
acth levels that are indicative of vasopressinergic co-activation.
 The oral administration of 200 mg 5-htp alone potently acti-
vated the hpa-axis. The maximal average acth concentrations of 
46.6 ng/l and cortisol levels of up to 181.4 µg/l were comparable to 
those induced with other corticotrophinergic function tests in pre-
vious studies. For instance, 100µg hcrh i.v. caused maximal acth 
concentration of 59.2 ng/l and maximal cortisol levels of 196.4 µg/l 
(Accepted – J Psychopharmacol). Also, the present cortisol levels 
approached those attained previously with (near-maximally toler-
ated) serotonergic (170 to 230 µg/l) (Jacobs et al., 2008; Smarius et 
al., 2008) and corticotrophinergic (210 to 230 µg/l) (Dinan and 
Scott, 2005; Scott et al., 1999) function tests. Taken together, acth 
and cortisol release induced by 200 mg 5-htp is reconcilable with 
corticotrophinergic activation of the hpa-axis. 
 The i.v. administration of 10mg metoclopramide around the  
emax of orally administered 200 mg 5-htp induced mean acth  
concentrations (167% relative to placebo) roughly four times those 
induced by metoclopramide alone (44% relative to placebo) and 
three times those induced by 5-htp alone (55% relative to placebo). 
Moreover, the acth release induced by metoclopramide in the 
presence of enhanced crh levels induced by 5-htp was synergistic 
and therefore indicative of vasopressinergic co-activation (9.3 ng/l 
more than the sum of the individual treatments). Since the admin-
istration of metoclopramide was not associated with endogenous 
avp release in our experiment, alternative mechanisms by which 
metoclopramide induces co-activation should be considered. 
Besides metoclopramide’s Dbreceptor antagonist properties, it  
also acts as 5-htc receptor antagonist and 5-htdreceptor agonist. 
Previously, 10 mg metoclopramide i.v. induced acth release which 
was not suppressed by the serotonergic 5-hta and 5-htb receptor 
antagonists metergoline and ketanserine (Coiro et al., 1989). Also,  
a recent study has shown that the 5-htc-antagonist granisetron 
does not influence the effects of 5-htp on hpa-axis activation 
(Jacobs et al., 2008). In this context, it is not unthinkable that 
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metoclopramide’s co-activatory neuroendocrine effects are  
mediated, at least in part, by 5-htd-agonism rather than mere 
endogenous avp release. In summary, metoclopramide is able to 
co-activate the hpa-axis in the presence of supraphysiological crh 
concentrations. Although such an effect is strongly indicative of 
vasopressinergic co-activation, it still remains unclear whether 
these effects have endogenous avp release in common, or (indi-
rect) acth release by means of either Db antagonism, 5-htd ago-
nism or a combination of both mechanisms. 
 Our study was complicated by a striking variability of the post-
prandial acth and cortisol surge following lunch. A post hoc analy-
sis showed that this effect was largely suppressed by metoclo-
pramide. hpa activation of this size and variability was unexpected 
since it had not been observed previously with other antiemetics 
(like granisetron and domperidone). The diurnal cortisol rhythm 
has repeatedly been shown to demonstrate a minor surge during 
midday, which is also present but attenuated during a period of 
food deprivation. This midday cortisol release is augmented by 
food-intake only during the afternoon but not during the evening 
meal (Follenius et al., 1982; Quigley and Yen, 1979). Although the 
underlying mechanism remains uncertain, food intake is supposed 
to play a synchronizing role in the circadian periodicity of the hpa 
(Follenius et al., 1982). Apparently, this food-effect is reduced by 
metoclopramide, which may be related to the gastrointestinal 
effects of this compound, which is registered not only as an 
antiemetic but also for its prokinetic properties. The potential 
mechanisms for the observed effect of metoclopramide on activa-
tion of the hpa-axis by food are unclear. It is not caused by a 
reduced absorption of 5-htp, since its plasma kinetics were not 
affected by the addition of metoclopramide (cmax 1319 µg/l and 
1302 µg/l for 5-htp alone and 5-htp combined with metoclopra-
mide, respectively). Whatever the cause, we had to restrict our 
analysis of metoclopramide’s neuroendocrine effects to the period 
before lunch, after the blinded observation of considerable fluctua-
tions in acth- and cortisol levels following the afternoon meal. 
Since the bulk of the effects of metoclopramide occurred before 
lunch, we could still detect strong singular and additive hpa-
effects over the 70-minute time period between the injection and 
the meal, as shown in Figure 1. However, in future studies food-
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induced fluctuations of acth and cortisol should be avoided alto-
gether by not serving food for at least four hours after the adminis-
tration of 5-htp.
 5-htp by itself and 5-htp combined with metoclopramide were 
associated with bothersome and potentially confounding adverse 
effects such as dizziness, nausea and vomiting. On the other hand, 
metoclopramide alone was only associated with moderate drowsi-
ness. In the present study 5-htp was administered to enhance 
endogenous crh release in healthy volunteers, with the purpose  
of examining metoclopramide’s potential to induce co-activation. 
Since the hpa-axis is expected to be hyperactive in patients suffer-
ing from stress-related psychopathology, the exogenous enhance-
ment of endogenous crh release with 5-htp is not a necessary  
consideration. Therefore, metoclopramide administered by itself  
is expected to sufficiently quantify vasopressinergic co-activation 
in stress-related psychopathology and is not expected to cause 
troublesome side-effects since it will not be combined with 5-htp.
 In conclusion, 10 mg metoclopramide causes acth release that 
is larger than exogenous vasopressinergic co-activation with 
ddavp, but convincingly smaller than that found with corticotro-
phinergic function tests like hcrh and 5-htp. Also, metoclopra-
mide synergizes acth release in the presence of supraphysiological 
crh concentrations induced by the serotonergic precursor 5-htp. 
These results are compatible with the hypothesis that metoclopra-
mide causes vasopressinergic co-activation of the hpa-axis. How-
ever, the exact mechanism underlying such co-activation remains 
elusive since metoclopramide has both Db antagonist and 5-htdag-
onist properties and increased (peripheral) avp release with meto-
clopramide could not be replicated. At any rate, this study shows 
that metoclopramide may be a useful function test for (vasopress-
inergic) co-activation of the hpa-axis since it is easy to administer 
and it has little potentially confounding or bothersome effects 
when administered alone. Potential future applications may 
include the detection of depressed individuals with (vasopressiner-
gic) hyperactivity of the hpa axis or to monitor the pharmacody-
namic effects of novel antidepressants directed at the vc receptor.
the work was supported by the schering-plough research 
institute.
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Table 1  A schematic overview of the four different treatments, each consisting of oral 
(p.o.) and intravenous (i.v.) administration of placebo, carbidopa, granisetron and 
5-hydroxytryptophan (5-htp) on the specified time points (t=). 
Treatment t=-180 min t=-60 min t=0 min t=60 min t=180 min




200mg 5-htp p.o. placebo i.v. 50mg carbidopa 
p.o.
2 placebo p.o. placebo p.o. placebo p.o. 10mg metoclo-
pramide i.v.
placebo p.o.








4 placebo p.o. placebo p.o. placebo p.o. placebo i.v. placebo p.o.
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Table 3  Pharmacokinetic (pk) parameters for metoclopramide (mcp) administered as  
10 mg i.v. bolus alone and in the presence of 200 mg 5-htp administered p.o.  
60 min earlier; and for 5-htp administered 200 mg p.o. alone and followed 60 min 
later by 10 mg metoclopramide as i.v. bolus: Mean (sd) of terminal half life (tlkb), 











Terminal half life (tlkb) 270.0 (55.1) 256.7 (81.6) 205.6 (95.3) 212.5 (141.3)
tmax (min) 46.2 (64.4) 63.7 (105.2) 169.8 (54.4) 171.1 (41.6)
cmax (µg/l) 58.1 (16.6) 63.7 (25.2) 1318.6 (141.0) 1301.7 (155.3)
aucjm∞ (min*µg/l) 15479.0 (5699.8) 20825.4 (11258.9) 566797.7 (113461.7) 530032.0 (73757.5)
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Figure 1  Least square mean (lsm) of plasma adrenocorticotrophic hormone (acth) with 
95% confidence interval bars (ng/L) for the period 0–360 min (closed circle: placebo; 
open circle: 10 mg metoclopramide administered i.v. at t = 60 min; closed triangle: 
200 mg 5-htp administered p.o. at t = 0 min; open square: 200 mg 5-htp adminis-
tered at t = 0 min followed by 10 mg metoclopramide administered i.v. at t = 60 min; 
grey dotted arrow at t = 0 min: administration of 5-htp; grey arrow at t = 60 min: 
administration of metoclopramide; grey dotted line at t = 120 min: lunch) 
Time (min)
 



















200mg 5-htp p.o. +  10mg 
metoclopramide i.v.
10mg metoclopramide i.v.
Figure 2  Least square mean (lsm) of serum cortisol with 95% confidence interval bars (μg/l) 
for the period 0–360 min (closed circle: placebo; open circle: 10 mg metoclopramide 
administered i.v. at t = 60 min; closed triangle: 200 mg 5-htp administered p.o.  
at t = 0 min; open square: 200 mg 5-htp administered at t = 0 min followed by 10 mg 
metoclopramide administered i.v. at t = 60 min; grey dotted arrow at t = 0 min: 
administration of 5-htp; grey arrow at t = 60 min: administration of metoclopra- 
mide; grey dotted line at t = 120 min: lunch). 
Time (min)
 



















200mg 5-htp p.o. +  
10mg metoclopramide i.v.
10mg metoclopramide i.v.
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Abstract
introduction and purpose Functional proton magnetic resonance spectros-
copy (mrs) can be applied to measure pharmacodynamic effects of 
central nervous system (cns)-active drugs. The serotonin precursor 
5-hydroxytryptophan (5-htp), administered together with carbi-
dopa and granisetron to improve kinetics and reduce adverse 
effects, acutely enhances central serotonergic neurotransmission 
and induces hypothalamus-pituitary-adrenal-(hpa) axis activation. 
We studied the hypothalamic levels of glutamate/glutamine (Glx), 
choline (Chol), n-acetyl-aspartate (naa) and creatine using 7-Tesla 
(7T) mrs, and adrenocorticotrophic hormone (acth) and cortisol in 
peripheral blood, after the administration of the 5-htp function 
test in healthy volunteers. 
methods  A randomized, double blind, placebo-controlled, two-way cross-
over study was performed in 12 healthy males with a 7 day wash-
out period. After administration of the oral 5-htp function test, 
acth and cortisol were measured over four hours and mrs scans  
at 7T were performed every 30 minutes over three hours measuring 
Glx: Creatine, Chol: Creatine and naa: Creatine ratios. 
results  In the hypothalamus, the administration of 5-htp had no effect on 
the average Glx, Chol or naa levels over 180 minutes but induced a 
significant decrease of Glx at 60 minutes on post-hoc analysis. 
5-htp induced significant acth release reaching an emax of 60.2 
ng/l at 80 minutes followed by cortisol with an emax of 246.4 ng/ml 
at 110 minutes. 
conclusions The reduction in hypothalamic Glx-levels after serotonergic stimu-
lation is compatible with activation of excitatory neurons in this 
region, which is expected to cause depletion of local glutamate 
stores. The hypothalamic mrs-response reached its maximum 
prior to subsequent increases of acth and cortisol, which supports 
the functional relevance of hypothalamic Glx-depletion for activa-
tion of the hpa-axis. This exploratory study shows that mrs is 
capable of detecting neuronal activation following functional 
stimulation of a targeted brain area. 
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Introduction
Pharmacological function tests are used to quantify the function-
ality of central neurotransmitter and neuropeptide systems in 
health and disease, and following treatment. The serotonergic sys-
tem can be pharmacologically stimulated with serotonin precur-
sors, selective agonists or re-uptake inhibitors. A test consisting of 
orally administered (p.o.) L-5-hydroxytryptophan (5-htp), carbidopa 
and granisetron acutely increases synaptic availability of serotonin 
(or 5-hydroxytrytamine, 5-ht) (Gijsman et al., 2002; Smarius et al., 
2008). Carbidopa prevents peripheral conversion of 5-htp to 5-ht 
(which would preclude brain penetration), while granisetron limits 
serotonergic side-effects (such as gastro-intestinal stimulation 
and vomiting) without influencing the neuroendocrine response or 
5-htp pharmacokinetics (pk) (Jacobs et al., 2008). Thus, in the pres-
ence of carbidopa and granisetron peripherally, the direct serotonin 
precursor 5-htp is decarboxylized centrally into 5-ht. The conver-
sion of 5-htp to 5-ht is believed to occur in the dorsal raphé nuclei 
of the brainstem and its associated cortical, subcortical and limbic 
projections (Dinan, 1996; Leonard, 2005; Sotty et al., 2009). We have 
previously demonstrated reproducible, concentration-dependent 
pharmacodynamic effects with acceptable variability associated 
with this serotonergic function test in healthy volunteers. Also, 
5-htp plasma concentrations demonstrated dose-dependence 
with a limited pk variability (Smarius et al., 2008). Taken together, 
these features argue for a reliable pharmacological research tool in 
examining the central 5-ht system. 
 Enhanced serotonergic neurotransmission ensuing from the 
decarboxylation of 5-htp into 5-ht potently activates the hypo-
thalamus-pituitary-adrenal axis (hpa). The stimulation of 5htba or 
5htbc receptors in the paraventricular nucleus (pvn) of the hypo-
thalamus is believed to release corticotrophin releasing hormone 
(crh) (Gartside and Cowen, 1990). Subsequently, crh stimulates 
adrenocorticotrophic hormone (acth) release from the anterior 
pituitary which in turn induces cortisol release from the adrenal 
cortices. Ultimately, cortisol exerts negative feedback on crh and 
acth release via the mineralocorticoid (mr) and glucocorticoid 
(gr) receptors (de Kloet et al., 2005), leading to a suppression and 
ultimate cessation of the 5-htp induced neuroendocrine response. 
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acth and cortisol therefore are the peripheral neuroendocrine 
reflections of increased central 5-ht neurotransmission. 
 Neuroendocrine hormone responses in plasma are merely indi-
rect measures of increased neurotransmission, influenced by both 
central and peripheral amplification, the negative feedback mecha-
nism and the peripheral clearance of the hormones. More direct 
measurements of drug-induced neuronal activity in the brain 
could lead to a better understanding of the cns processes induced 
by the stimulation of neurotransmitter systems. Neuroimaging 
techniques of pharmacological cns-processes such as functional 
magnetic resonance imaging (fmri) is often used to demonstrate 
regional shifts in blood oxygen level dependent (bold) signals. For 
instance, the specific 5-htbc agonist meta-chlorophenylpiperazine 
(mcpp) increased the bold signal in human brain areas that are 
particularly rich in 5-htbc receptors, such as the pvn, hippocampus, 
caudate, pallidum, amygdala and anterior cingulate (Anderson et 
al., 2002) which was prevented by the 5-htbc receptor antagonist 
SB242084 in rats (Stark et al., 2008). However, bold-mri is not 
quantitative and the signal tends to drift with time. Consequently, 
the bold-effects of a drug can only be reliably pursued for no more 
than 30 or 60 minutes, which for most oral drugs is unsuitable. 
Also, the bold-mri signal is sensitive to nonspecific confounding 
factors such as (drug-induced) vascular reactivity and shows sub-
stantial intersession variance in cross-over designs (Anderson et 
al., 2008; Stark et al., 2006). These factors limit the application  
of fmri in the quantification of drug-induced neuronal activity. 
Alternatively, in vivo proton magnetic resonance spectroscopy 
(mrs) could be a candidate neuroimaging technique to directly 
quantify drug-induced neurotransmission. mrs of the brain deter-
mines concentrations of protons from tissue chemicals other 
than water, such as glutamate-glutamine (which cannot be dis-
tinguished reliably, hence combined as (Glx)), n-acetyl-aspartate 
(naa), myo-inositol, lactate, choline (Chol) and creatine (Creat). In 
this context, naa and GLx are generally regarded as surrogate mrs 
markers for neuronal activity, whereas Chol is rather considered a 
metabolic marker of membrane density and integrity (Soares and 
Law, 2009; Wise and Tracey, 2006). To semiquantify changes in the 
levels of these metabolites, creatine is frequently used as an inter-
nal reference, since this is related to neuronal membrane turnover 
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and is also expected to remain stable after acute administration 
of (non-proapoptotic) cns active drugs (Mason and Krystal, 2006). 
mrs is typically applied in neurodegenerative disease and malig-
nant brain tumours, exhibiting relatively specific abnormalities 
in naa (Soares and Law, 2009; De Stefano et al., 2007). Recently, a 
study using mrs found Glx-increases in the occipital lobe after 7 to 
10 days of treatment with the specific serotonin reuptake inhibitor 
(ssri) citalopram, while this was not the case for the noradrenaline 
reuptake inhibitor (nri) (Taylor et al., 2008). These findings indicate 
that mrs is not only able to demonstrate and quantify changes in 
neuronal biochemistry in structural brain disorders but potentially 
also during (prolonged) pharmacological treatment. 
 We studied whether neuronal changes can also be measured 
after acute pharmacological stimulation with a cns-active drug 
using mrs. For this, a 5-htp function test was used that causes a 
robust serotonergic stimulation of the hypothalamus of healthy 
male volunteers. This was an exploratory study, since neither the 
extent and variability nor the time course of hypothalamic mrs-
changes could be predicted in advance.
Methods 
Study design
A randomized, double blind, placebo controlled, two-way crossover 
trial with administration of 5-htp combined with carbidopa and 
granisetron was performed as described previously. The treatments 
were administered with a wash-out period of at least 7 days. The 
study protocol was approved by the Medical Ethics Committee of 
Leiden University Medical Centre (lumc) and performed according 
to legal and regulatory requirements. 
Drug administration
The function test consisted of, the administration of carbidopa 100 
mg (at t=-180 minutes) and granisetron 2 mg (at t=-60 minutes), 
followed by a single oral dose of 5-htp 200mg (at t=0 minutes) 
and carbidopa 50mg (at t=180 minutes). For all three active drugs, 
matching double-dummies were administered as placebo (Jacobs 
et al., 2008; Gijsman et al., 2002; Smarius et al., 2008). 
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Subjects
Twelve healthy, male volunteers participated in the study.  
Volunteers without a personal or a first-degree family history of  
a significant psychiatric disorder according to dsm-iv and who 
have never used mdMA, methamphetamines or ecstasy were 
included in the study. Volunteers who used more than 4 units al- 
cohol and/or xanthines on average per day; smoked more than  
5 cigarettes per day; used any drugs of abuse or substance within 
two weeks before the first dosing; had a cardiac pacemaker, pierc-
ings or other metal objects attached to the body and suffering 
from claustrophobia were excluded from study participation.  
No xanthine or tryptophan containing foods or beverages, tobacco 
or alcohol were allowed during study days. Concomitant medica-
tion other than paracetamol was not permitted during the study 
period. 
5-htp and carbidopa
5-htp and carbidopa were obtained from bufa b.v. (Uitgeest, The 
Netherlands). Granisetron was obtained from the Department of 
Clinical Pharmacy of the lumc. All medication and matching pla-
cebo were prepared by the Department of Clinical Pharmacy of the 
lumc. 
Study days
Volunteers arrived at the Centre for Human Drug Research (chdr) 
at 22h00 on the evening preceding each study day. After waking 
up the next morning, a low tryptophane breakfast was supplied. 
One intravenous cannula for blood sampling was inserted into the 
antecubital vein of one arm for blood sampling. At t=-180 minutes 
volunteers received carbidopa 100 mg or placebo at chdr after 
which volunteers were transported to the 7t-mri-unit by taxi, 
accompanied by a research physician. Granisetron or placebo was 
administered at t=-60 minutes and 5-htp or placebo subsequently 
at t=0 minutes. Six mrs scans were performed at 30 min before 
and 30, 60, 90, 120 and 180 minutes following 5-htp administra-
tion. A research physician was present throughout the entire study 
day. Carbidopa 50 mg was given at t=180 minutes. Volunteers were 
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supplied with a standard meal at t=420 minutes. Volunteers were 
transported back to chdr after all scanning sessions were per-
formed, and subsequently went home after dinner. 
Biochemical measurements
1.2 ml venous blood was collected in prechilled edta collection 
tubes for the determination of plasma acth on -10 and 1, 10, 25, 
45, 55, 75, 80, 85, 105, 110, 150, 170, 240 and 300 minutes relative 
to 5-htp administration. Samples were immediately placed on 
ice, processed within 30 minutes and stored at -80°C. acth was 
analyzed within six weeks using the Immulite 2500 Analyzer 
Assay (euro/dcp, United Kingdom) at the Laboratory for Clinical 
Chemistry, lumc, Leiden, the Netherlands. 3 ml venous blood was 
collected in non-additive tubes for the determination of serum cor-
tisol on -10 and 1, 10, 25, 45, 75, 110, 170, 240 and 300 minutes rela-
tive to 5-htp administration. Samples were allowed to coagulate 
for 30 minutes at room temperature, centrifuged within 1 hour of 
collection and serum stored at -20°C until analysis. Serum cortisol 
was analyzed using the eclia assay method on Modular Analytics 
e170 (Roche, Switzerland) at the Laboratory for Clinical Chemistry, 
lumc, Leiden, the Netherlands. The 5-htp assay was performed at 
Laboratory for Clinical Chemistry, lumc, Leiden, the Netherlands 
according to methods described previously (Gijsman et al., 2002). 
mrs acquisition
mrs scans were performed in a Philips Achieva 7.0 Tesla whole body 
mri scanner (Philips Healthcare, Best, The Netherlands) installed  
at the lumc based C.J. Gorter Center for High-Field mri. Each indi-
vidual scanning session had a duration of approximately 10 min-
utes: first, a T1-weighted mri scan was performed (with a duration 
of approximately 3 minutes) followed by mrs (with a duration  
of approximately 7 minutes). mrs of the hypothalamus was  
performed using single voxel stimulated echo acquisition mode 
(steam) with the following parameters; repetition time (tr): 
2000ms, echo time (te): 19ms, mixing time (tm): 20ms, 128 aver-
ages, 2048 time domain points, and 4000Hz bandwith. Typical 
voxel size dimensions were 13 x 12 x 10 mm, in left-right (LR),  
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anterior-posterior (ap) and feet-head (fh) direction respectively.  
A typical example of mrs voxel positioning is shown in figure 1.  
For optimization of B0 field homogeneity, 2nd order pencil beam 
shimming was applied and 6 saturation slabs were positioned on 
either side of the voxel to suppress signal from surrounding tissue. 
After zero-filling to 4,096 data points, exponential multiplication 
of 2 Hz, Fourier transformation, and linear baseline correction was 
performed. The integrated area under the curve of n-acetylaspar-
tate (naa) (referenced at 2.0 parts per million), Glx, Chol and Creat 
were determined using integration software routines, which were 
provided by the manufacturer. Creat was used as internal reference 
for Chol, Glx and naa. A typical example of the mrs spectra is 
shown in figure 2. 
Side-effects
Adverse events were registered from spontaneous reports and 
hourly inquiries. 
Statistical analysis
Since the responses and variability of the mrs measurements were 
unknown, power estimates could not be based on the expected 
mrs responses. Based on previous experiments with the 5-htp-
function test (Gijsman et al., 2002; Jacobs et al., 2008; Smarius 
et al., 2008), a sample size of six was considered large enough to 
show statistically significant acth responses. To confirm that the 
power calculation was adequate, a blinded interim analysis was 
executed after dosing of the first six subjects. For the final analysis 
pharmacodynamic data were logarithmically (log) transformed 
except for the mrs parameters. Within the repeated measures 
mixed model ancova design, estimated means (least squared 
means; lsms) of the neuroendocrine parameters (acth, cortisol) 
were calculated over four hours and lsms of the mrs ratios (Chol: 
Creat, Glx: Creat, naa: Creat) were calculated over 180 minutes 
using treatment, time, study day and treatment by time as fixed 
factors, subject, subject by treatment and subject by time as ran-
dom factors and average prevalue as covariate. The difference from 
placebo was estimated percentually for acth and cortisol (due to 
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log-transformation) and that for the mrs ratios in terms of abso-
lute changes. All estimated differences were presented with 95% 
confidence intervals. 
Pharmacokinetic (pk) analysis 
The mean cmax, tmax, terminal half life and aucjm∞ for 5-htp were 
calculated with noncompartmental analysis using WinNonLin  
Professional for windows V5.0 (Pharsight Corporation, 800 West  
El Camino Real, Suite 200, Mountain View, CA 94040).
Results 
Demographic data and subject disposition
The study recruited 12 volunteers who were included after having 
provided informed consent (mean age 27 years; range 20 - 38 years). 
Incomplete data sets had occurred during 5-htp study days due to 
vomiting (2 study occasions), flawed mrs baseline scans (2 study 
occasions), technical mri failure (1 study occasion) and withdrawal 
of informed consent (1 study occasion). Consequently, neuroendo-
crine data for 10 subjects and mrs data for 8 subjects were available 
for 5-htp analysis, while the data of 12 subjects were available for 
placebo analysis.
Adverse events 
The most common side-effect during placebo treatment was head-
ache (2/12 occasions). Side-effects associated with 5-htp treat-
ment were 5-ht related and included mild nausea (10/11 occasions), 
vomiting (5/11 occasions), abdominal discomfort (3/11 occasions) 
dizziness (3/11 occasions) and headache (3/11 occasions).
Neuroendocrine effects 
The mean acth and cortisol responses differed significantly from 
placebo for 5-htp (Table 1). acth reached a maximum mean con-
centration (emax) of 60.2 ng/l at 80 minutes (Figure 4) and cortisol 
an emax of 246.4 ng/ml at 110 minutes (Figure 5) after administering 
5-htp. 
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mrs effects
Overall, the mean naa: creat, Chol: creat and Glx: creat ratios did 
not differ significantly from placebo over the period of 0 to 180 
minutes (Table 2). Based on the time profiles, a post hoc statistical 
analysis was performed of the effects at the average peak time. 
This secondary analysis showed a significant decline of Glx: creat, 
one hour after administration of 5-htp (Table 2 and Figure 3). This 
Glx: creat trough at 60 minutes preceded the emax of acth at 80 
minutes and emax of cortisol at 110 minutes (Figure 6). The other 
mrs ratios either did not show a clear peak, or this did not differ 
significantly from the placebo effect at the same time. 
5-htp pk
pk results are presented as means with standard deviations 
between brackets: oral 200 mg 5-htp led to a cmax of 1867 (392)  
ng/ml, at 176 (82) minutes after its administration (Figure 6). Termi-
nal half life (takb) was 265.2 (91.1) minutes and aucjm∞ was 848135 
(313093) min*ng/ml. Since 5-htp was not sampled sufficiently until 
the end of its concentration-time profile curve, the terminal half-
life was not accurately determinable. 
Discussion
5-htp induced a significant hypothalamic glutamate-glutamine 
(Glx) trough 60 minutes after its administration, while its effects 
on Glx, Chol and n-acetyl-aspartate (naa) levels over the entire  
180 minutes observation period were probably too short lasted 
or too small or variable to be detectable in a group of 12 subjects. 
acth reached its emax of 60.2 ng/l at 80 minutes followed by 
cortisol, with its emax of 246.4 ng/ml, at 110 minutes after the 
administration of 5-htp. The mrs Glx spectrum is constituted by 
the combined extracellular peaks of glutamate and glutamine 
since these spectra are inseparable. Glutamate is the most abun-
dant excitatory neurotransmitter in the brain and one of the most 
important components of cellular energy metabolism (Mason 
and Krystal, 2006). This would arguably make it the most informa-
tive mrs-measurable metabolite associated with (drug-induced 
excitatory) neurotransmission (Soares and Law, 2009). However, 
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little research has been done on the effects of serotonergic agents 
on cerebral Glx levels and it is unclear how 5-ht and Glx are linked 
mechanistically. In this context, other areas not directly involved in 
the hpa-axis may be stimulated by the 5-htp function test, influ-
encing the hypothalamus indirectly. Spectroscopy of a (limbic) con-
trol region with lower serotonergic receptor density than the hypo-
thalamus would also have strengthened the evidence for a specific 
5-ht mediated hypothalamic effect. However, the time course of 
the different effects following oral 5-htp-administration provides 
support for a functional connection between Glx and the neuroen-
docrine responses. The timing of the Glx trough, which preceded 
the emax of acth by 20 minutes and that of cortisol by 50 minutes, 
can be reconciled with a serotonin–induced (and probably 5htba or 
5htbc mediated) release of crh from the hypothalamic pvn.
Glx showed a significant trough at 60 minutes, acth peaked at 80 
minutes followed by cortisol at 110 minutes and 5-htp reached its 
maximal concentration around 170 minutes (figure 7). At the same 
time, acth and cortisol had started to decline from their peaks at 
80 minutes and 110 minutes onwards (figure 7). Therefore, we can 
assume that the major part of the 5-htp-induced hypothalamic 
activation must have taken place during the 50 to 70 minute 
period after 5-htp-administration. From the moment of its release 
cortisol exerts negative feedback via the mineralocorticoid recep-
tor (mr) and at higher concentrations also via the glucocorticoid 
receptor (gr) (de Kloet et al., 2005). The decline of acth and corti-
sol in blood is thus a net consequence of both its clearance from 
the body and negative feedback on the production. In this study, 
negative feedback would have inhibited hypothalamic 5-ht neu-
rotransmission and consequently also the release of Glx. Thus, the 
short-lasting effects on Glx levels in the hypothalamus were, at 
least in part, most probably due to the inhibiting effects of cortisol 
feedback. 
 Taylor also looked at the effects of serotonergic treatment on 
mrs parameters in the brain (Taylor et al., 2008). In this trial, Glx 
increased in the occipital lobes of healthy subjects treated for 7 
to 10 days with 20mg citalopram. These findings are difficult to 
compare to ours, since there are obvious functional and metabolic 
differences between the occipital lobe and the hypothalamus. 
However, there is also a pharmacological difference between acute 
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administration of a precursor and prolonged treatment with a 
reuptake inhibitor of serotonin. Serotonergic systems are activated 
by acute administration of 5-htp, whereas they are desensitized 
during chronic treatment with a selective serotonin reuptake 
inhibitor (ssri). In this respect, a divergent Glx-response is perhaps 
not surprising. It is not easy to explain elevations of occipital Glx-
levels following medium-term ssri administration. However, acute 
Glx-depletion following synaptic stimulation is perhaps more in 
line with predictions and is also supported by a reduction in Glx 
after acute cortical excitation with transcranial magnetic stimula-
tion (tms) (Singh et al., 2009). Following neuronal excitation (in this 
case by serotonergic stimulation of the hypothalamus), glutamate 
is released into the synaptic cleft by exocytosis. To interrupt post-
synaptic activation and prevent accumulation of toxic glutamate 
levels, the neurotransmitter is rapidly cleared from the synapse by 
neuronal and astrocytic reuptake via excitatory amino acid NaP-
coupled glutamate transporters (eaats). Astrocytes convert glu-
tamate back into glutamine and release it via the system-n-trans-
porter (sn) into the synaptic cleft for reuptake by neurons (Danbolt, 
2001; Iversen et al., 2009). The net effect of this process on local Glx-
levels is therefore expected amount to zero, because mrs cannot 
distinguish glutamate from glutamine, nor intracellular (astrocytic 
or neuronal) from extracellular (synaptic or interstitial) sources 
of these metabolites. However, secondary to increased release 
of extracellular glutamate and glutamine, these compounds are 
also cleared from the synaptic cleft by diffusion and blood flow 
(Danbolt, 2001), which could lead to the Glx-reductions that were 
observed with acute administration of the 5-htp function test. 
 It is uncertain whether mrs would be feasible as a neuroimag-
ing technique in the detection of other functional drug-induced 
changes. 7-Tesla mrs is reliable for volumes of at least 1 to 1.5cmC. 
Measurements in a structure with a smaller volume of interest 
(voi) can be disturbed by a low signal to noise ratio. Also, imaging 
multiple brain regions at the same time is associated with its own 
complexities. We performed spectroscopy of a hypothalamic voi 
of ca. 1.5cmC surrounding the pvn, while the pvn itself typically 
comprises a volume of only 15 to 30 mmC. This is only a very small 
fraction of the scanned voi, which has undoubtedly limited the 
sensitivity of the technique to detect pvn-activation. Furthermore, 
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since we exclusively performed spectroscopy on the hypothala-
mus, non-specific effects (such as nausea or vomiting) or a more 
generalized serotonergic effect of 5-htp on the observed reduction 
in Glx cannot be excluded. The fact that changes were found none-
theless may indicate that the mrs-changes in the pvn must have 
been substantial. Detection of this small activation area was also 
due to the relatively low intersession variability of the much larger 
surrounding ‘dead’ volume. The variability of the predose (baseline) 
Glx: creat ratios was around 20% and the intrasubject variability 
was 15%. The low baseline variability and the high sensitivity of 
7-Tesla mrs despite a fairly large voi suggest that this technique 
can be particularly useful for drugs that can be predicted to act on 
a specific brain region. Such functional anatomical predictions can 
be made using preclinical in vivo techniques like brain tissue micro-
dialysis and registration of local neurophysiological activity. 
 Creat was used as internal reference for naa, Chol and Glx. It 
is possible that the Creat concentrations may have changed dur-
ing the course of each experimental session. The Glx: creat trough 
might therefore reflect an increase in Creat concentrations rather 
than a decrease in Glx concentrations. However, it is impossible to 
reliably estimate changes in absolute quantitative Creat concen-
trations because hypothalamic 7T metabolite and water T1 and T2 
relaxation values are unknown. Moreover, absolute Creat concen-
trations are usually calculated based on the unsuppressed water 
signal as internal reference which may change during the course of 
each experiment. Metabolite referencing to Creat is therefore not 
optimal and limits the interpretation of our results. This is however 
a general problem when using mrs and is not specific for the pres-
ent trial.
 A weakness of this study is that the power for the detection of 
changes by mrs may be relatively low. Measuring 5-htp-induced 
activation of the hypothalamus using mrs at 7T is a novel tech-
nique. We based our initial power calculation on 5-htp’s effects on 
acth, and performed a blinded interim assessment to determine 
if mrs would be just as robust. As expected, the 5-htp neuroendo-
crine responses were reliable and comparable to our previous expe-
riences with 5-htp (Danbolt, 2001; Gijsman et al., 2002; Jacobs et al., 
2008; Smarius et al., 2008). However, the mrs-analyses were com-
plicated by technical issues and unforeseen dropouts. Statistical 
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power was also limited by the short duration of the hypothalamic 
activation as detected by mrs, which was may have been due to 
the inhibitory effects of cortisol feedback on the hypothalamus. 
 The potential applications of mrs as novel technique in cns 
pharmacology need to be investigated further in well-designed 
experiments. In this context, careful consideration should be given 
to the expected cns effects of the drug under investigation, includ-
ing the size of the activated area relative to the sampling volume, 
and the timing and duration of the physiological responses.
the authors declare no conflict of interest.
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Table 1 Neuroendocrine parameters for the period 0 minutes to 240 minutes for the 
200mg 5-htp function test: Estimated means (back transformed Least Square 
Means) for plasma acth (ng/l) and serum cortisol (ng/ml) and estimated differ-
ence (%) with 95% confidence interval from placebo for the 200 mg 5-htp func-
tion test. 
Neuroendocrine parameter




 n=10 5-htp vs placebo p-value
acth (ng/L) 16.9 33.4 +97.8 (56.7, 149.6) p<0.0001
Serum cortisol (ng/mL) 95.6 159.8 +67.2 (44.2;93.9) P<0.0001
Table 2 mrs ratios for the period 0 minutes to 180 minutes and peak effects at 60 min-
utes for the 200mg 5-htp function test: Estimated means (untransformed Least 
Square Means) from placebo for Chol: Creat , Glx: Creat and naa: Creat and esti-
mated difference with 95% confidence interval from placebo for the 200mg 
5-htp function test. 
MRS ratio Least Square Means Estimated difference p-value
Placebo 5-htp 5-htp vs placebo
n=12 n=8
Chol:Creat ratio 0 to 180 minutes 1.071 1.117 0.046 (-0.017,0.109) 0.128
Peak effect at 60 minutes 1.159 1.064 0.096 (0.004, 0.195) 0.059
Glx:Creat ratio 0 to 180 minutes 0.229 0.259 -0.030 (-0.066, 0.006) 0.090
Peak effect at 60 minutes 0.196 0.252 -0.055 (-0.110, -0.001) 0.045
NAA:Creat ratio 0 to 180 minutes 1.041 1.057 0.016 (-0.049, 0.080) 0.597
Peak effect at 60 minutes 1.036 1.057 0.021 (-0.076, 0.118) 0.670
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Figure 1 Typical example of the mrs planning. The white rectangles represent the borders 
of the mrs voxel that contains the hypothalamus.
Figure 2  Example of the typical mrs spectra for choline (chol); creatine (creat); glutamate-
glutamine (Glx) and n-acetylaspartate (naa) derived from a volunteer in the 
present study.
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Figure 3 Estimated means with 95% CI error bars for mrs Glx: Creat over the period 0  
to 180 minutes, after administration of placebo (n=12) and the 200mg 5-htp  
function test (n=8).
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Figure 4 Estimated means (ng/l) with 95% CI error bars for plasma adrenocorticotrophic 
hormone (acth) over the period 0 to 240 minutes, after administration of  
placebo (n=12) and the 200mg 5-htp function test (n=8).
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Figure 5 Estimated means (ng/ml) with 95% CI error bars for serum cortisol over the 
period 0 to 240 minutes, after administration of placebo (n=12) and the 200mg 
5-htp function test (n=8).
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Figure 6 Average time profile with sd error bars of serum 5-htp (ng/ml) over 300 minutes 
for the 200mg 5-htp function test (n=10).



























































200mg 5-htp function test (n=11)
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Figure 7 Combined graphical representation of the estimated mean percentual change 
from placebo (%) with 95% CI error bars for adrenocorticotrophic hormone 
(acth) and cortisol (left Y-axis) and the mean change relative to placebo with 
error bars for mrs Glx: Creat (right Y-axis), after administration of the 200mg 
5-htp function test. The grey circles and dotted lines represent the respective 
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This thesis focused on the quantification of hpa axis activation  
in healthy volunteers by applying pharmacological function tests 
with distinct pharmacodynamic (pd) mechanisms. Its main objec-
tive was to contribute to the validation of different function tests 
for the two most well-characterized hpa axis activation routes.  
To realize this objective, different experiments were executed in 
which specific principles that have been proposed to optimize the 
reliability of pharmacological function tests were observed. hcrh 
and 5-htp were applied for the corticotrophinergic (crh-mediated) 
route while ddavp and metoclopramide were used for the vaso-
pressinergic (avp-mediated) pathway. Additionally, the application 
of these function tests was expected to contribute to a better 
understanding of the respective contributions of the corticotro-
phinergic and vasopressinergic pathways to hpa axis activation  
in health. Finally, an extra dimension was added to the validation 
process by applying a neuroimaging technique to measure changes 
in hypothalamic metabolites during pharmacological stimulation.
What are the major findings of this thesis?
ddavp is a synthetic analogue of vasopressin which, together with 
endogenous crh, functions as a co-activator of pituitary acth-
release (DeBold et al., 1983; Favrod-Coune et al., 1993; Lamberts et 
al., 1984). However, it also has cardiovascular, pro-coagulatory and 
anti-diuretic effects that may cause safety concerns in some 
patients and could have secondary confounding effects via (sym-
patho-adrenal-medullary - sam) stress activation. In chapter 2 the 
effects of vasopressinergic activation on the hpa-axis were investi-
gated, relative to the potentially confounding autonomic and sys-
temic effects of ddavp. The neuroendocrine effects of a 10µg ddavp 
bolus administered over one minute were similar to those of a 30µg 
incremental infusion administered over one hour, despite higher 
ddavp concentrations after the infusion. In contrast, the cardio-
vascular- and coagulatory effects of ddavp were dose-related. This 
differential effect is probably related to low endogenous crh levels 
under physiological conditions and/or maximal vc receptor occu-
pancy at doses above 10 µg. These findings indicate that ddavp 
administered over one minute at a dose of not more than 10µg  
is safe and does not cause confounding sam (stress) effects. 
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However, the neuroendocrine effects associated with the systemic 
administration of 10µg ddavp by itself are so small and variable 
that its role in future research focusing on (physiological) avp-
mediated hpa axis activation is expected to be limited. Since avp 
functions as co-activator of the hpa axis in the presence of crh, 
chapter 3 examined whether the concomitant administration of 
ddavp and low doses of synthetic crh - corticorelin or hcrh - could 
provide a more robust stimulation of the hpa axis in healthy volun-
teers than with ddavp alone, and whether such a combination 
could provide information on the extent of vasopressinergic co-
activation relative to major corticotrophinergic activation with 
hcrh alone. The administration of 100µg hcrh induces robust hpa 
axis activation while combining 10µg ddavp with either 10µg or 
30µg hcrh boosts vasopressinergic co-activation and causes dose-
related acth- and cort release that is larger than with 10µg ddavp 
alone, and roughly similar to the neuroendocrine effects of 100µg 
hcrh alone. Finally, in chapter 3 it was explored whether distinct 
corticotrophinergic activation and vasopressinergic co-activation 
of the hpa axis could be examined on a single short laboratory visit 
by sequentially administering ddavp and hcrh: the interaction 
effect of prior 10µg ddavp administration on corticotrophinergic 
activation by administering 100µg hcrh two hours later was inves-
tigated and was found not to interact in a significant way. 
The function tests described in chapters 2 and 3 are associated 
with problems that may hamper their continued application in hpa 
axis research. These encompass confounding pd effects (ddavp 
and hcrh), safety concerns in some patient population (ddavp) 
and the lack of information that (peripheral) pituitary stimulation 
by ddavp and hcrh provides about essential more proximal struc-
tures such as the hypothalamus, medial prefrontal cortex (mpfc) 
and limbic system in stress related disorders. For the purpose of 
stimulating these central systems, two other function tests were 
examined in Chapters 4, 5 and 6. 5-htp combined with carbidopa 
has previously been shown to induce robust activation of the hpa 
axis by inducing acth- and cort release (Gijsman et al., 2002).  
The neuroendocrine activation associated with 5-htp is attributed 
to actions at hypothalamic 5-ht receptors with subsequent endog-
enous crh-release that results in corticotrophinergic hpa axis acti-
vation (Gartside and Cowen, 1990). In chapter 4, the dose- and 
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plasma concentration-effect relationship for orally administered 
5-htp combined with carbidopa was investigated. The combined 
5-htp test was found to be an effective corticotrophinergic func-
tion test via the serotonergic route, which exhibits dose-related 
plasma concentrations and neuroendocrine responsiveness. How-
ever, the frequent occurrence of serotonin-associated side-effects 
such as nausea and vomiting limits its applicability in clinical 
research. Subsequently, in chapter 5 it was aimed to suppress the 
serotonergic side-effects associated with the combined 5-htp/ 
carbidopa function test by the addition of an anti-emetic. The 
addition of the subtype selective 5-htc receptor antagonist granis-
etron to the combined 5-htp/carbidopa function test suppresses 
nausea and vomiting without influencing the neuroendocrine 
response or the pharmacokinetic (pk) characteristics of 5-htp, 
making it a potentially useful tool to assess centrally-mediated 
corticotrophinergic hpa axis activation. On the other hand, meto-
clopramide has been reported to induce vasopressinergic co-acti-
vation by stimulating endogenous avp release (Chiodera et al., 
1986; Nomura et al., 1984; Seki et al., 1997; Walsh et al., 2005). The 
previously reported experiments that have investigated the neuro-
endocrine effects of metoclopramide were associated with impor-
tant methodological drawbacks. Additionally, the mechanism by 
which metoclopramide induces avp-release remains speculative 
and the relation of its pd effects to its pk has never been investi-
gated. In the penultimate chapter 6, intravenous administration  
of the Db receptor antagonist metoclopramide was investigated as 
a centrally acting vasopressinergic function test. Metoclopramide 
effectively releases acth by itself and induces co-activation in the 
presence of enhanced (5-htp induced) corticotrophinergic activa-
tion: metoclopramide’s neuroendocrine effects under physiologi-
cal and supraphysiological crh concentrations are compatible 
with, but not indicative of, endogenous avp release and subse-
quent vasopressinergic co-activation of the hpa axis. 
The (peripheral) systemic neuroendocrine responses that are 
induced by function tests of the hpa-axis reflect fluctuations 
within the (central) pituitary portal system following stimulation. 
Changes in the concentrations of plasma acth and cort are a net 
effect of different dynamic processes including central and periph-
eral amplification, hpa axis negative feedback and the clearance of 
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neuroendocrine hormones. So far, it has not been possible to quan-
tify each of these different processes sufficiently reliably. More 
direct measurements of drug-induced neuronal activity in the 
brain using neuroimaging techniques could lead to a better under-
standing of the central (pharmacological) cns processes induced 
by the stimulation of neurotransmitter systems with function 
tests, and add one piece to the complex puzzle of hpa-axis regula-
tion. In chapter 7 the effects of the combined 5-htp/carbidopa/
granisetron function test on hypothalamic glutamate/glutamine 
(Glx), choline, n-acetyl-aspartate (naa) and creatine levels were 
studied in healthy volunteers using 7-Tesla (7T) mrs. These 
responses were subsequently related to the (well-characterized) 
peripheral acth and cort responses. Following serotonin-medi-
ated corticotrophinergic hpa axis activation with 5-htp, hypotha-
lamic Glx-levels are reduced and are followed by the release of acth 
from the pituitary and cort from the adrenal glands. Taken 
together, this pilot study supports the involvement of hypotha-
lamic Glx-depletion in hpa axis activation and demonstrates that  
it is possible to quantify serotonin-mediated changes in hypotha-
lamic metabolism using a well-known neuroimaging technique.
What has this thesis provided?
This thesis has shown that the major hpa axis activation routes  
can be quantified by the application of specific pharmacological 
stimulation tests. Stimulation can be achieved either directly  
with peripherally acting agents (hcrh and ddavp) or indirectly  
with drugs that have central effects (5-htp and metoclopramide) 
(Figure 4). Activation of the corticotrophinergic route is achieved 
by administering either the crh analogue hcrh or the direct pre-
cursor of serotonin 5-htp. 100 µg hcrh induces robust acth and 
cort release by a direct and relatively specific stimulation of the 
pituitary crha receptor system. 200mg 5-htp, combined with car-
bidopa and granisetron to stabilize the pk and to reduce systemic 
side-effects of 5-htp, potently releases acth and cort in a dose- 
and concentration dependent manner that is reconcilable with 
(indirect) 5-ht-induced release of endogenous crh via the 5-htba  
or 5-htbc receptors situated in the hypothalamic pvn. Also, 5-htp-
induced hpa axis activation is related to a decrease in 
168 pharmacological aspects of corticotrophinergic and vasopressinergic function
  tests for hpa axis activation
hypothalamic glutamate-glutamine levels in the anatomical 
region of the pvn. These hypothalamic changes precede the release 
of acth and subsequent cort and are therefore reconcilable with  
a depletion of hypothalamic glutamate stores following 5-ht 
induced crh release. 100 µg hcrh and 200 mg 5-htp induce corti-
cotrophinergic hpa axis activation that is associated with similar 
maximal cort levels. Importantly, these cort levels are compara-
ble with the previously maximally attainable cort levels with 100 
µg hcrh (210 ng/ml) (Dinan et al., 1999; Scott et al., 1999) and 
0.5mg/kg mcpp (230 ng/ml) (Gijsman et al., 1998) in healthy volun-
teers. Thus, pharmacological stimulation of the hpa axis in healthy 
individuals via the corticotrophinergic route seems to be associ-
ated with an average cort ceiling effect in the vicinity of 220 ng/
ml. On the other hand, vasopressinergic co-activation can be quan-
tified by applying ddavp and metoclopramide as function tests.  
10 µg ddavp directly stimulates pituitary vc receptors and induces 
demonstrable neuroendocrine effects that are too small and vari-
able to reliably quantify vasopressinergic co-activation. In fact, the 
neuroendocrine response induced by 10 µg ddavp alone is roughly 
half that of the corticotrophinergic cort ceiling effect. Previously, 
ddavp has been shown to induce dose-dependent vasopressinergic 
co-activation at 5 µg and 10 µg but not at 15µg. Also, 30 µg ddavp 
induces activation that is comparable to that of 10 µg, despite 
reaching a 1.8 fold higher plasma concentration. This apparently 
low maximal effect of ddavp alone is attributed to low endogenous 
crh levels under physiological conditions and/or maximal vc 
receptor occupancy at doses above 10µg. The administration of 
doses of more than 10µg ddavp will thus not lead to more sizeable 
vasopressinergic co-activation but is expected to cause non-spe-
cific confounding effects that will thwart its validity and applica-
bility even further. Instead, vasopressinergic co-activation can be 
boosted by exogenously administering (low) doses of hcrh. This 
thesis showed that combining 10 µg ddavp with 10 hcrh or 30 µg 
hcrh both induce a cort response that is greater than that of 10 
µg ddavp alone, and only marginally smaller than that of the cort 
ceiling effect attained with for instance 100 µg hcrh: 10 µg hcrh 
combined with 10 µg ddavp induces a cort response that is 40% 
greater than 10 µg ddavp alone, reaching 80% of the cort ceiling 
effect, while combining 10 µg ddavp with 30 µg hcrh induces a 
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response that is 60% greater than 10 µg ddavp alone which 
approaches 90% of the ceiling effect. These findings indicate that 
vasopressinergic co-activation of the hpa axis is a dose-dependent 
function of ambient crh or crha-receptor activation that can be 
mimicked pharmacologically in healthy volunteers by the concom-
itant administration of ddavp and low doses hcrh. The boosted 
response induced by 30 µg hcrh combined with 10 µg ddavp 
approaches the cort ceiling to such an extent that it makes differ-
entiating vasopressinergic co-activation from corticotrophinergic 
activation virtually impossible, while 10 µg hcrh combined with  
10 µg ddavp induces a response that distinguishes itself from both 
vasopressinergic co-activation with 10 µg ddavp alone and cortico-
trophinergic activation with 100 µg hcrh alone. The optimal hcrh 
dose that needs to be combined with 10 µg ddavp for optimal vaso-
pressinergic co-activation, without obscuring the difference 
between vasopressinergic co-activation and corticotrophinergic 
activation, is therefore expected to lie around 10 µg since it is not 
restricted by flooring- or ceiling effects as in the case of 10 µg 
ddavp alone and 100 µg hcrh. However, such a prediction is pre-
carious since we have not examined the full dose-response curve  
of hcrh (including the effects of 10 µg or 30 µg hcrh alone). pk-pd 
modeling will have to confirm the optimal combination in future. 
Alternatively, metoclopramide is believed to induce vasopressiner-
gic co-activation (indirectly) by releasing endogenous avp from the 
hypothalamus and/or the pituitary following Db receptor stimula-
tion. However, metoclopramide’s precise pharmacological mecha-
nism remains unclear and the release of endogenous avp still 
needs to be confirmed. At any rate, metoclopramide is a potentially 
useful tool in vasopressinergic hpa axis research since it has the 
advantage that it does not need to be combined with hcrh and 
that it is not associated with potentially confounding (autonomic) 
effects. Finally, 10 µg ddavp followed by 100 µg hcrh two hours 
later do not interact significantly, which allows for a practical func-
tion test examining both hpa-activation routes on a single short 
test occasion. 
It is important to realize that the function tests described in this 
thesis are easily executable under research conditions. They consist 
of the oral or intravenous administration of registered drugs that  
is followed by a complete neuroendocrine assessment within 4 
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hours. Furthermore, the addition of granisetron to 5-htp suppres-
ses the bothersome 5-ht associated side-effects of 5-htp, and the 
adverse effects associated with hcrh and low doses of ddavp are 
self-limiting and of little clinical significance. Also, full character-
ization of the hpa-response provides a dynamic quantification  
of hpa axis activation: instead of utilizing a few sparse sampling 
points (as in the case of the car), acth and cort are sampled 
intensively, allowing for a reliable quantitative analysis of neuroen-
docrine changes as a function of both time and function test drug 
concentrations. Additionally, the application of 7T spectroscopy 
provided indications that it is possible to demonstrate changes in 
neuronal metabolites after the administration of a precursor drug 
such as of 5-htp. Taken together, the present function tests are 
associated with a minimal burden for research subjects, while pro-
viding an optimally informative data yield, making them ethically 
acceptable and practical to administer. 
In summary, this thesis has provided a number of pharmacolo-
gically well-characterized clinical research tools for the assessment 
of the major hpa axis activation routes (Table 3). 200 mg 5-htp com-
bined with carbidopa and granisetron induces safe dose- and con-
centration dependent activation via the central corticotrophinergic 
route. Also, this test is well-tolerated and has minimal confounding 
pd effects and predictable and reproducible pk. 10 µg ddavp com-
bined with a dose of 10 µg or 30 µg hcrh induces dose-dependent 
(pituitary) vasopressinergic activation, without the potentially  
dangerous and confounding effects of higher doses ddavp. Meto-
clopramide could be considered as an alternative vasopressinergic 
function test that probably operates centrally, but replication of its 
(vasopressinergic) effects and further clarification of its pharmaco-
logical mechanism will determine its role as function test in future. 
hcrh allows for the assessment of direct pituitary corticotrophic 
stimulation, although the optimal hcrh dose to characterize the 
full response curve still needs to be established. The sequential 
administration of ddavp followed by hcrh presents the possibility 
to independently assess vasopressinergic as well as the corticotro-
phinergic aspects of hpa axis activation on a single short study day, 
without falling prey to interaction effects. Thus, the present tests 
can be considered suitable for application in clinical hpa axis 
research in both healthy volunteers and patient groups.
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How can these function tests be applied?
The development of novel drugs for the treatment of major depres-
sive disorder (mdd) has stagnated in recent years (Conn and Roth, 
2008). Target identification and -validation in the development of 
novel cns drugs are generally problematic and undoubtedly con-
tribute to the current impasse (Agid et al., 2007; Pangalos et al., 
2007). More importantly, the validity of preclinical (animal) models 
that are used to predict the efficacy of novel antidepressant drugs 
(ad’s) is limited. These models have been developed and validated 
after discovery of the antidepressant properties of the tricyclic 
antidepressant drugs (tca’s), and therefore all rely heavily on the 
modulation of 5-ht, noradrenaline (na) and dopamine (da) circuits 
(Cryan and Slattery, 2007; Conn and Roth, 2008). Hyperactivity of 
the hpa axis is one of the most consistent (neuroendocrine) abnor-
malities associated with (certain subgroups of) mdd and other so-
called stress-related psychiatric disorders (Pariante and Lightman, 
2008; Schule et al., 2009). Whether such hyperactivity represents a 
vulnerability trait/risk factor or a pathogenetic factor in the devel-
opment of stress-related psychopathology, or whether it consti-
tutes a mere epiphenomenon of such pathology remains obscure 
(Schule et al., 2009). At any rate, the neuropeptides crh and avp (in 
particular) have been implicated in hpa axis hyperactivity in both 
humans and animals (Dinan et al., 2004; Pariante and Lightman, 
2008; Schule et al., 2009). The precise pathophysiological mecha-
nism and the share of depressed patients that display hpa axis 
hyperactivity still needs to be established (Pariante and Miller, 
2001; Pariante and Lightman, 2008). Taken together, the contribu-
tion of hpa axis hyperactivity to the pathophysiology of mdd 
remains elusive and the traditional mono-amine based preclinical 
animal models are associated with the obvious weakness that they 
deny the role of neuropeptides in hpa axis hyperactivation. Despite 
these problems, new compounds that target corticotrophinergic 
and/or vasopressinergic hpa axis disturbances for the treatment of 
mdd are currently under development. The hitherto unclear contri-
butions of crh and avp in hpa axis hyperfunction and inadequate 
preclinical models pose a concrete risk for failure of such com-
pounds in future clinical trials. However, the application of phar-
macological function tests may guide the development of these 
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potentially clinically relevant compounds along a rational path, 
and contribute to further elucidation of the pathophysiology of 
stress-systems in psychiatric disease. 
Pharmacological function tests can be applied as pathophysio-
logical research tools to characterize disturbed hpa axis activation 
associated with mdd. The nature of aberrant hpa axis activation 
can be assessed in patient groups by quantifying corticotrophiner-
gic activation (using hcrh alone or 5-htp combined with carbidopa 
and granisetron) on the one hand and (enhanced) vasopressinergic 
co-activation (using ddavp with or without a low dose hcrh or 
metoclopramide) on the other hand. Subsequently, the findings  
in patients can be validated by comparing the hpa axis responses 
to those of healthy volunteer groups who have received the respec-
tive (identical) function tests. Also, part of such validation process 
can be performed in experimental animals. Such characterization 
of corticotrophinergic activation and vasopressinergic co-activa-
tion in animals, healthy individuals and patients might aid in the 
future development of a diagnostic and classification system that 
is based on (endo)pathophysiological characteristics, rather than 
the currently widely used phenomenological ones. More provoca-
tively, the quantification of hpa axis activation in asymptomatic 
probands of individuals with mdd or carriers of known genetic pre-
disposing factors such as polymorphisms of 5-ht, crh and/or vc 
receptors might help identify individuals at risk for developing full-
blown mdd timely. Such detailed analyses of complex multifaceted 
regulatory systems are only possible with well-validated function 
tests and function parameters. 
The development of preclinical models that are able to predict 
the effect of novel drugs that target the hpa axis deserves priority. 
The role of pharmacological function tests in this process is still 
undefined and needs further exploration. For instance, function 
tests can be applied in animals as pharmacological models for hpa 
axis hyperactivation instead of the traditional chronic stress mod-
els that rely on mechanically induced hyperactivation such as 
mechanical restraint or repeated electrical stimulation. Once vali-
dated, the findings in animals can be integrated with clinical data 
derived from healthy volunteers and patients. In this sense, phar-
macological function tests are natural - but largely underutilized - 
(bidirectional) translational tools between animals and humans 
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that can enable researchers to develop (additional) preclinical mod-
els that acknowledge the role of disturbed neuropeptide function 
in depressive disorders, instead of solely relying on the current 
(reductionist) ones.
Pharmacological function tests can prove informative in “proof-
of-pharmacological principle” experiments with novel drugs. For 
instance, the effects of a vc antagonist could be demonstrated 
using a function test that quantifies vasopressinergic co-activa-
tion in both animals and humans. By doing this, the intended 
mechanism of action can be confirmed, and the dosage regimens 
can be pharmacologically optimized in animals, healthy volunteers 
and selected patient groups, before costly clinical trials are 
launched. Also, instead of examining the effects of drugs under 
basal conditions, it would be instructive to evaluate their actions  
in models of pathological states in both humans and animals.  
In this context mdd-associated hpa axis hyperactivation can be 
mimicked pharmacologically in healthy individuals using pharma-
cological function tests. Such an artificially hyperactivated hpa 
axis is expected to lend itself to pharmacological modulation with 
compounds that target the crha and/or vc receptors. Artificially 
induced hyperactivation can also be used to mimic certain (neuro-
endocrine) aspects of stress-related disorders in healthy volunteers 
or subjects at risk, and in turn such use as disease models can con-
tribute to the validation of the function test as a predictive tool in 
drug development. Finally, antidepressant drugs such as the selec-
tive serotonin re-uptake inhibitors (ssri’s), the mono-amine oxi-
dase inhibitors (maoi’s) and the tca’s have been shown to modu-
late hpa axis function. In mice, treatment with different ad’s 
(ssri’s, maoi’s) induces a marked increase in hippocampal mr  
and gr and decreases crh mrna in the pvn (Schule, 2007). Also,  
a gradual attenuation of hpa axis hyperactivity has been demon-
strated with serial application of the dex/crh test when treating 
depressed patients with tca’s and ssri’s (Schule, 2007). Taken 
together, these findings are indicative of more efficient negative 
feedback secondary to the upregulation over time of the mr and  
gr in when treating patients suffering from depression with ad’s. 
Moreover, enhanced negative feedback via the mr/gr is expected 
to affect the corticotrophinergic and/or vasopressinergic activa-
tion routes of the hpa axis. However, changes in the sensitivity of 
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the crha and/or vc receptor system after treatment with ad’s have 
not been investigated as such.  
In this context, function tests can be applied to investigate the 
effects of widely used, clinically well-validated antidepressant 
drugs on hpa axis activation. Such information can aid in further 
clarifying the relationship between the central mono-amine  
circuits and the hypothalamic neuropeptides in both health  
and disease. 
What still needs to be clarified?
hpa axis function is determined by dynamic interactions between 
production and clearance, modulation and co-activation, and acti-
vation and inhibition, involving different complex regulation sys-
tems and negative feedback processes. The studies described in 
this thesis have focused on the quantification of hpa axis activa-
tion and the exploration and partial optimization of pharmacoki-
netic- and pharmacodynamic properties of pharmacological 
agents that target different central and peripheral components  
of the stress system. These studies have not taken the influence  
of negative feedback on pharmacologically induced hpa axis acti-
vation into account. It should be realized that the neuroendocrine 
responses described in this thesis do not purely reflect activation, 
but are always the product of concomitant pharmacological stimu-
lation and physiological feedback. A complete physiological model 
that takes both activation and feedback into account is needed  
for a more accurate understanding of hpa axis function. However, 
complete characterization of the major activation centers and 
feedback loops in both healthy volunteers and different patient 
groups will be time-consuming, and requires more detailed infor-
mation about processes that are currently difficult to study in  
isolation. In this context, physiological pk-pd modeling can be  
of important value in further characterizing the hitherto incom-
pletely characterized aspects of hpa axis physiology. Moreover, 
such a model can be useful in predicting the responses of patient 
populations to the different function tests and the effects of novel 
drugs targeting hpa neuropeptide systems. In the case of the hpa 
axis, pk-pd modeling remains a complex and relatively unexplored 
field. An important reason for this is because hpa axis physiology  
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is dynamic and that the feedback loops exist on different func-
tional-anatomical levels. Before it would be possible to proceed  
to model such an intricate system, the different aspects of hpa  
axis physiology will have to be functionally disentangled. It is not 
unthinkable that the function tests described in this thesis can be 
combined with other function tests that temporarily shut off the 
negative feedback system. For instance, dex can be administered 
and followed by 5-htp to investigate whether the same blunted 
response as with hcrh can be observed in patients with mdd. With 
regards to the avp system, dex administration can be followed by 
ddavp to examine vasopressinergic co-activation in the absence of 
an intact gr/mr feedback mechanism. For the time being, quanti-
fication of the differential activatory and inhibitory aspects of hpa 
axis physiology should be pursued by applying the different phar-
macological function, in an attempt to fill the gaps in the current 
understanding of hpa axis physiology.
The diurnal rhythm of cort is an important aspect that has also 
not specifically deserved attention in this thesis. Healthy humans 
demonstrate an ultradian pattern of cort release that forms the 
basis of the typical diurnal cort rhythm (Lightman et al., 2008). 
Additionally, there are robust dynamic interactions between basal 
cort pulsatility and normal hpa axis function that determines an 
individual’s ability to respond to (psychological) stress. Whether 
the same holds true for the neuroendocrine responses following 
pharmacological stimulation is essentially unclear. In the 
described experiments, it was attempted to minimize additional 
variability due to differences in basal cort levels by administering 
all function tests between 9 and 11h in the morning and by per-
forming all invasive study procedures (such as insertion of intrave-
nous cannulas) at least 120 minutes before function test adminis-
tration. Additionally, the basal cort (and acth) levels before 
administration were included as covariate in the ancova analysis 
models for the neuroendocrine responses. However, patients suf-
fering from mdd display a disturbed cort pulsatility and diurnal 
rhythm. It can therefore not be excluded with certainty that such 
disturbances will confound the effects of these function tests in 
patient groups. Abnormal diurnal rhythms will certainly affect the 
sensitivity and functionality of the different processes involved  
in the production, release, activation and inhibition 
176 pharmacological aspects of corticotrophinergic and vasopressinergic function
  tests for hpa axis activation
of neuroen docrine hormones. At present however, such data are 
lacking and this issue will have to be explored in future experi-
ments with patients, using high-frequency sampling methods and 
decon volution analyses of hormonal rhythms.
In conclusion, this thesis has shown that the major hpa axis 
activation routes can be quantified either directly (with peripher-
ally acting hcrh and ddavp) or indirectly (using centrally acting 
5-htp and metoclopramide) by directed pharmacological stimula-
tion with pharmacological function tests. 5-htp, hcrh and ddavp 
combined with low doses of hcrh are pharmacologically best  
characterized, making them apt for application in clinical hpa  
axis research settings in both healthy volunteers and patient 
groups. On the other hand, metoclopramide’s role as vasopressin-
ergic pharmacological function test needs to be explored further. 
Importantly, 10 µg ddavp followed by 100 µg hcrh two hours later 
do not interact significantly, which allows for a practical function 
test examining both hpa-activation routes on a single short clinical 
laboratory visit. Over the past decades, a wealth of information on 
hpa axis function in both health and disease has been gathered. 
The precise physiological mechanisms that underlie both hpa axis 
activation and negative feedback have been studied extensively, 
enabling hpa axis researches and pharmacologists alike to further 
pursue the origins and potential treatment of disturbed hpa axis 
activation in stress-related psychiatric disorders. In this context, 
well-characterized pharmacological function tests can be applied 
as pathophysiological research tools to characterize disturbed hpa 
axis activation, as translational tools between animal and humans 
in developing more adequate preclinical models, and in “proof-of-
pharmacological principle” experiments with novel drugs that tar-
get the different hpa axis activation centers.
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Figure 4  Graphic representation of the pharmacological function tests that have been 
investigated in this thesis: hcrh (direct) and 5-htp (indirect) for quantification 
of corticotrophinergic and ddavp (direct) and metoclopramide (indirect) for the 
quantification of vasopressinergic activation of the hpa axis (5-ht: 5-hydroxy-
tryptamine/serotonin; 5-htp: 5-hydroxytryptophane; hcrh: corticorelin; ddavp: 
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Samenvatting / Summary in Dutch 
De hypothalamus-hypofyse-bijnier-as (ook hypothalamus-
pituitary-adrenal axis of hpa-as) bestaat uit verschillende en- 
docriene klieren, die elkaar via hormonen stimuleren en ook weer 
remmen via feedbackmechanismen. Op die manier blijft de activi-
teit van dit belangrijke stress-systeem binnen de fysiologische  
perken. De hpa-as is bij een aantal aandoeningen verstoord, onder 
andere bij bepaalde (ernstige) vormen van depressieve stoornissen 
en angststoornissen. Om meer inzicht te krijgen in de afwijkingen 
van het stress-systeem en in de invloed van bestaande en nieuwe 
medicamenten daarop, zijn goed gevalideerde functietesten nodig, 
die gedetailleerde informatie geven over elk aspect van de hpa-as. 
Tot nu toe waren er alleen testen die inzicht gaven in de hpa-as als 
geheel of in onderdelen daarvan, meestal zonder veel aandacht 
voor de dynamiek van de verschillende hormonen en hun onder-
linge feedforward- en feedbackmechanismen. Dit proefschrift 
heeft als doel om een aantal far macologische functietesten van de 
hpa-as verder te verfijnen. Bij gezonde vrijwilligers werden diverse 
functietesten met ver schillende farmacologische eigenschappen 
toegepast, die op verschillende manieren de hpa-as beïnvloeden.  
In elk experiment werd een aantal basisprincipes in acht genomen 
waarmee de betrouwbaarheid van functietesten kan worden geop-
timaliseerd. In hoofdstuk 2 tot 6 werden 5-htp (dat wordt omgezet 
in de neurotransmitter serotonine; 5-ht) en hcrh toegepast voor 
hpa-as activatie via de corticotrofinerge route. ddavp (een analo-
gon van de neuropeptide vasopressine; avp) en metoclopramide 
(dat endogene avp afgifte zou bevorderen) werden gebruikt voor 
vasopressinerge co-activatie. We verwachtten dat het toepassen 
van dit model meer inzicht zou geven in de rol van zowel het corti-
cotrofinerge- als vasopressinerge systeem bij hpa-as activatie.  
Tenslotte werd een beeldvormende techniek, magnetic resonance 
spectroscopy (mrs), in hoofdstuk 7 toegepast om veranderingen in 
hypothalame metabolieten gedurende farmacologische stimulatie 
te meten.
hoofdstuk 1: introduction 
De hpa-as is een functioneel-anatomisch geheel dat bestaat uit 
verschillende centrale neurotransmitter- en neuropeptide circuits 
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in de mediaal-prefrontale cortex (mpfc), het limbische systeem en 
de hypothalamus; en de perifeer geproduceerde stresshormonen 
afkomstig uit de hypofyse en bijnieren. hpa-as activatie kan wor-
den beschouwd als het neuro-endocriene eindresultaat van de 
affectregulatie. De hypothalame productie van corticotrophin 
releasing hormoon (crh) leidt tot de afgifte van adrenocorticotro-
fisch hormoon (acth) uit de adenohypofyse en vervolgens tot cor-
tisol (cort) uit de bijnierschors. De afgifte van acth kan via zowel 
corticotrofinerge activatie als vasopressinerge co-activatie van de 
hpa-as verlopen. cort zet een divers spectrum aan gedragsma-
tige-, cognitieve-, immunologische- en metabole veranderingen in 
gang en remt tegelijkertijd de neuro-endocriene respons via een 
complex feedbackmechanisme. In hoofdstuk 1 wordt geconclu-
deerd dat een overexpressie van de vc receptor, verhoogde centrale 
avp productie, of een combinatie van deze factoren leidt tot een 
voortdurend overmatige vasopressinerge co-activatie. Dit me- 
chanisme speelt mogelijk een rol bij een overactieve hpa-as bij  
verschillende vormen van stress-gerelateerde psychopathologie, 
waaronder sommige (ernstige) depressieve stoornissen. Hoe ver-
stoorde vasopressinerge co-activatie in relatie staat tot cortico-
trofinerge activatie of tot het negatieve feedbackmechanisme  
bij hpa-as pathologie is echter onduidelijk. Het toepassen van 
betrouwbare klinische instrumenten om de corticotrofiner ge- en 
vasopressinerge aspecten van hpa-as activatie en/of feedback te 
ontrafelen, zou kunnen bijdragen aan verdere opheldering van deze 
complexe kluwen. Hiervoor kunnen farmacologische functietesten 
worden toegepast. Dergelijke functietesten worden vaker gebruikt 
om inzicht te krijgen in systemen die zich moeilijk lenen voor 
onderzoek in rust, zoals bijvoorbeeld de orale glucose-tolerantie 
test en de intracutane allergietesten. Verschillende functietesten 
die specifiek toegepast worden bij hpa-as onderzoek, worden over-
zichtelijk besproken. Dit overzicht omvat testen voor hpa-as feed-
back (de orale dex test en de dex/hcrh test) en hpa-as activatie 
via zowel de corticotrofinerge route (hcrh en 5-htp) als de vaso-
pressinerge route (ddavp en metoclopramide). De tekortkomingen 
van deze testen worden besproken en worden er aan de hand van 
een aantal basisprincipes voorstellen gedaan om de betrouwbaar-
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heid van de betrokken functietesten te vergroten. De verwachting 
hierbij is enerzijds dat de (eenmaal geoptimaliseerde) functietes-
ten in de toekomst gebruikt kunnen worden om afwijkende hpa-as 
functie bij verschillende patiëntengroepen te onderzoeken, en dat 
zij anderzijds toegepast kunnen worden bij het ontwikkelen van 
nieuwe geneesmiddelen die ingrijpen op de hpa-as. 
hoofdstuk 2: “desmopressin as a pharmacological tool in 
vasopressinergic hypothalamus–pituitary–adrenal axis modulation: 
neuroendocrine, cardiovascular and coagulatory effects” 
De vasopressinerge hpa-as activatieroute kan worden gestimu-
leerd door het i.v. geven van het synthetische analogon van avp, 
desmopressine (ddavp). ddavp is een partiëel specifieke avp 
receptoragonist, die farmacologisch actief is op zowel de vaso-
pressine 2 – (vb) als de vasopressine 3 receptor (vc of vab). Stimula-
tie van vc in de adenohypofyse leidt tot activatie van de hpa-as 
door verhoogde acth-synthese. Hierbij induceerden 5µg en 10µg 
ddavp i.v. in eerder onderzoek een dosisgerelateerd acth- en cort 
respons bij gezonde vrijwilligers maar 15µg niet. In dit hoofdstuk 
worden de effecten van vasopressinerge activatie van de hpa-as 
met ddavp onderzocht en gerelateerd aan de potentieel versto-
rende autonome en systemische effecten van ddavp. De neuroen-
docrine effecten van een 10µg ddavp zijn vergelijkbaar met die van 
30µg, ondanks hogere ddavp plasmaspiegels bij de hogere dose-
ring. Daarentegen zijn de effecten van ddavp op het cardiovascu-
lair systeem en op de stolling dosisafhankelijk. Dit verschil in 
effect is mogelijk te verklaren vanuit lage endogene crh spiegels 
onder basale condities en/of maximale vc receptor bezetting bij 
doseringen hoger dan 10 µg. Deze bevindingen geven aan dat het 
toedienen van 10µg ddavp veilig is en geen verstorende autonome 
effecten veroorzaakt. De neuroendocrine effecten van 10µg ddavp 
zijn echter zo klein en variabel dat de toepasbaarheid daarvan bij 
avp-gemedieerd hpa-as onderzoek beperkt zal zijn. Dit probleem 
kan echter niet worden verholpen door het geven van een hogere 
dosering, omdat de neuroendocrine effecten van ddavp boven de 
10 µg maar weinig toenemen.
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hoofdstuk 3: “a pharmacological tool to assess vasopressinergic 
co-activation of the hypothalamus–pituitary–adrenal axis more 
integrally in healthy volunteers” 
crh en avp zijn fysiologisch aan elkaar verbonden doordat avp 
fungeert als co-activator van de hpa-as in de aanwezigheid van 
crh. In hoofdstuk 3 wordt onderzocht of het tegelijk toedienen van 
ddavp en lage doseringen synthetisch crh - corticoreline oftewel 
hcrh – de hpa-as bij gezonde proefpersonen sterker stimuleert dan 
ddavp op zichelf. Hierbij is de verwachting dat een dergelijke com-
binatie meer inzicht zou geven in de omvang van vasopressinerge 
co-activatie (met alleen ddavp) vergeleken met corticotrofinerge 
activatie (met alleen hcrh). Het toedienen van 100µg hcrh veroor-
zaakt robuuste hpa-as activatie, terwijl het combineren van 10µg 
ddavp met 10µg of 30µg hcrh tot dosisafhankelijke vasopressi-
nerge co-activatie leidt. De neuro-endocriene respons van beide 
combinaties is dan ook groter dan met 10µg ddavp alleen en onge-
veer gelijk aan de neuro-endocriene effecten van alleen 100µg 
hcrh. Tenslotte wordt gekeken of het mogelijk is om corticotrofi-
nerge activatie en vasopressinerge co- activatie onafhankelijk van 
elkaar te onderzoeken tijdens een kort bezoek aan de kliniek door 
ddavp en hcrh achter elkaar toe te dienen. Het blijkt dat dit moge-
lijk is, omdat er geen sprake is van een interactie-effect op cortico-
trofinerge activatie met 100µg hcrh wanneer 10µg ddavp twee uur 
eerder wordt gegeven. 
hoofdstuk 4: “pharmacology of rising oral doses of 
5-hydroxytryptophan with carbidopa” 
Een potentieel bezwaar bij zowel ddavp als hcrh is dat zij de hpa-
as alleen op het niveau van de hypofyse stimuleren en daardoor de 
rol van de mpfc en het limbische systeem nauwelijks in acht 
nemen. Het zou daarom wenselijk zijn om de hpa-as met een 
“proximalere” of “centralere” farmacologische functietest te sti-
muleren. Er bestaat inmiddels consensus dat de neurotransmitter 
serotonine (5-ht) een belangrijke betekenis heeft in de affectregu-
lerende circuits, tenminste in het kader van de monoaminerge 
hypothese van depressie. 5-ht wordt geproduceerd door seroto-
nerge neuronen in de (dorsale) raphé nuclei van de hersenstam en 
wordt daarvandaan afgegeven in diverse (neurotransmitter)circuits 
in de hersenen, waaronder het limbische 
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systeem en hypothalamus. Een functietest die serotonine (5-ht) 
acuut verhoogt stimuleert daarmee de centrale serotonerge cir-
cuits en indirect ook de hpa-as. Orale toediening van 5- hydroxy-
tryptofaan (5-htp, een stof die direct in serotonine wordt omgezet) 
in combinatie met carbidopa activeert de hpa-as met krachtige 
afgifte van acth- en cort tot gevolg. Ofschoon dit model aantrek-
kelijk is, brengt deze serotonerge test verschillende problemen met 
zich mee, zoals gebrek aan standaardisering, een variabele kinetiek 
en een nauw venster tussen neuro-endocriene effecten en bijwer-
kingen. In hoofdstuk 4 wordt de relatie tussen de dosering/plas-
maspiegel en de neuroendocriene effecten bij oraal toegediende 
5-htp gecombineerd met carbidopa onderzocht. Deze gecombi-
neerde 5-htp test is een effectieve corticotrofinerge functietest via 
de serotonerge route en laat dosis-afhankelijke plasmaspiegels en 
neuro-endocriene effecten zien. Het vaak voorkomen van misse-
lijkheid en braken bij hogere doses 5-htp is echter beperkend in het 
toepassen van deze test in klinisch hpa-as onderzoek. 
hoofdstuk 5: “enhanced tolerability of the 5-hydroxytryptophane 
challenge test combined with granisetron” 
In hoofdstuk 5 wordt een anti-emeticum toegevoegd aan de 
gecombineerde 5-htp/carbidopa functietest. Hiermee wordt 
gepoogd het venster tussen de gewenste neuro-endocriene effec-
ten en de bijwerkingen te vergroten door het tegengaan van misse-
lijkheid en braken. Het toevoegen van de subtype-specifieke 5-htc 
receptor antagonist granisetron aan de gecombineerde 5-htp/car-
bidopa functietest onderdukt deze hinderlijke bijwerkingen zonder 
beïnvloeding van de neuro-endocriene respons of de farmacokine-
tiek (pk) van 5-htp. Dit verbetert de bruikbaarheid van 5-htp bij het 
onderzoeken van centraal-gemedieerde, corticotrofinerge hpa-as 
activatie bij zowel gezonde vrijwilligers als patiënten; tenminste in 
combinatie met carbidopa en granisetron. 
hoofdstuk 6: “metoclopramide as pharmacological tool to assess 
vasopressinergic activation of the hypothalamus-pituitary-adrenal 
(hpa) axis: a study in healthy volunteers” 
Eerder onderzoek rapporteerde dat de db receptor antagonist meto-
clopramide vasopressinerge co-activatie van de hpa-as induceert 
door de afgifte van endogene avp te stimuleren. De studies waarin 
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dit werd onderzocht kennen echter belangrijke (methodologische) 
bezwaren. Bovendien is het farmacologische mechanisme dat 
zorgt voor afgifte van avp speculatief en is de relatie tussen de 
neuroendocriene effecten en de pk van metoclopramide nooit eer-
der onderzocht. In hoofdstuk 6 wordt i.v. toegediende metoclopra-
mide onderzocht als een functietest voor centraal- gemedieerde 
vasopressinerge co-activatie. Metoclopramide (op zichzelf) leidt 
tot de afgifte van acth en cort en induceert co-activatie tijdens 
corticotrofinerge activatie door de gecombineerde 5-htp/carbi-
dopa/granisetron functietest. Deze neuro-endocriene effecten  
tijdens corticotrofinerge stimulatie suggereren dat metoclopra-
mide de afgifte van endogene avp versterkt, met vasopressinerge 
co-activatie van de hpa-as tot gevolg. De afgifte van avp zelf kon 
echter niet direct gemeten worden. 
hoofdstuk 7: “hypothalamic glutamate levels following serotonergic 
stimulation: a pilot study using 7-tesla magnetic resonance 
spectroscopy in healthy volunteers” 
De (perifere) neuro-endocriene effecten van de beschreven hpa-as 
functietesten weerspiegelen veranderingen in centrale neurotrans-
mittercircuits en de hypofyse na farmacologische stimulatie. Het 
toepassen van beeldvormende technieken om veranderingen op 
neuronaal niveau te meten, kan daarom inzicht geven in de cen-
trale farmacologische effecten van functietesten. Bovendien kan 
een dergelijk inzicht additionele informatie over de complexe 
regelmechanismen van de hpa-as verschaffen. In hoofdstuk 7 wor-
den de effecten van de gecombineerde 5-htp/carbidopa/graniset-
ron functietestest op hypothalame glutamaat/glutamine (Glx)-, 
choline-, N-acetyl-aspartaat (naa)- en creatine (Creat) concentra-
ties bij gezonde vrijwilligers met behulp van 7-Tesla (7T) magnetic 
resonance spectroscopy (mrs) onderzocht. Vervolgens worden de 
hypothalame veranderingen gerelateerd aan de perifere neuro-
endocriene effecten (acth- en cort afgifte) van de gecombineerde 
functietest. Corticotrofinerge activatie van de hpa-as via de seroto-
nerge route (met de gecombineerde 5-htp functietest) leidt tot een 
verlaging van de hypothalame Glx, en wordt gevolgd door afgifte 
van acth uit de hypofyse en cort uit de bijnieren. Samenvattend 
ondersteunt deze pilotstudie hypothalame Glx-depletie bij (seroto - 
nerge) hpa-as activatie en toont verder aan dat een beeldvormend 
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techniek in staat is om 5-ht gemedieerde veranderingen in het 
hypothalame metabolisme te meten. 
 Samenvattend toont dit proefschrift aan dat de corticotrofi-
nerge- en de vasopressinerge activatieroutes van de hpa-as zowel 
direct (met de perifeer werkende hcrh and ddavp) als indirect (met 
de centraal-actieve 5-htp en metoclopramide) door gerichte farma-
cologische stimulatie gekwantificeerd kunnen worden. Hierbij ken-
nen 5-htp, hcrh en ddavp gecombineerd met een lage dosering 
hcrh een goede farmacologische karakterisering en een goede ver-
draagbaarheid. Zij zijn daarom geschikt voor klinisch hpa-as 
onderzoek bij zowel gezonde vrijwilliers als patiënten. Daarente-
gen is de rol van metoclopramide als vasopressinerge functietest 
(vooralsnog) twijfelachtig. Belangrijk is dat 10 µg ddavp gevolgd 
door 100 µg hcrh 2 uur later, althans bij gezonde mensen, geen 
interactie-effect laat zien, wat deze test geschikt maakt voor het 
onderzoeken van de beide hpa-as activatieroutes tijdens eenzelfde 
(poli)klinisch bezoek. 
 Concluderend wordt gesteld dat een systematisch gebruik van 
goed gevalideerde farmacologische functietesten belangrijke 
informatie kan verschaffen over de (patho)fysiologie van de hpa-
as. Hierbij is er een rol voor dergelijke testen weggelegd als patho-
fysiologische onderzoeksinstrumenten bij (stress-gerelateerde) 
psychiatrische aandoeningen, als translationele instrumenten  
tussen proefdieren en mensen en bij “proof-of-pharmacological 
principle” experimenten met nieuwe geneesmiddelen die op ver-
schillende plaatsen in de hpa-as ingrijpen. 
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